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Abstract 
Diabetic retinopathy is a microvascular complication of type 1 and type 2 diabetes, 
affecting the retinal vasculature of the eye. In the Scottish diabetic retinopathy grading 
scheme (version 1.1), the severity of diabetic retinopathy is classified as no retinopathy, 
mild background, observable background, severe non-proliferative and proliferative 
retinopathy. In the GoDARTS (Genetics of Diabetes Audit and Research Tayside) cohort, 
we have longitudinal data of retinopathy in diabetic patients since 1990. 3,734 and 3,673 
GoDARTS patients were genotyped in the Affymetrix Genome-wide Human SNP Array 
6.0 and Illumina HumanOmniExpress BeadChip, respectively. As the pathophysiology of 
diabetic retinopathy remains elusive, the aim of this thesis is to use the GoDARTS 
phenotype and genotype data to study clinical and genetic determinants for diabetic 
retinopathy.  
 
The first part detailed the longitudinal analysis of diabetic retinopathy data, using the multi-
state Markov model. This methodology permitted us to infer the rates of transitions across 
retinopathy states under the influence of common population risk factors. We observed a 
consistent risk effect of HbA1c on the progression (no-retinopathy to mild background 
diabetic retinopathy, BDR, hazard ratio per standard deviation of HbA1c (HR): 1.42, 95% 
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confidence interval (CI): 1.32, 1.52; mild BDR to observable BDR HR: 1.32, 95% CI: 1.08, 
1.60; observable BDR to severe non-proliferative/proliferative DR (non-PDR/PDR) HR: 
2.23, 95% CI: 1.16, 4.29). Similarly, systolic blood pressure (SBP) and diastolic blood 
pressure (DBP) increased the risk for the transition from the asymptomatic phase to mild 
BDR (HR: 1.20; 95% CI: 1.11, 1.30) and the mild BDR to observable BDR (HR: 1.87; 95% 
CI: 1.46, 2.40), respectively. Regression from mild BDR to no DR was associated with 
lower SBP (HR: 0.79; 95% CI: 0.64, 0.97) and lower HbA1c (HR: 0.76; 95% CI: 0.64, 
0.89). Our results provided the evidence that glycaemic exposure and blood pressure are 
strongly associated with progression and remission of diabetic retinopathy. 
 
The second part studied narrow-sense heritability and genetic correlations of retinopathy 
and related risk factors in type 1 and type 2 diabetic patients explained by common 
genome-wide SNPs using a novel variance components methodology. We found that up to 
34% of phenotypic variation of diabetic retinopathy was attributable to total additive 
genetic effects in the GoDARTS 1000 Genomes imputed genetic data. The narrow-sense 
heritability explained by the study data was 49% for BMI (body mass index), 20% for 
cholesterol, 23% for serum creatinine, 21% for HbA1c (glycaemic exposure), 40% for 
HDL (high-density liproprotien), 18% for SBP (systolic blood pressure), 31% for 
triglycerides. Due to the wide credible intervals, the inference of genetic and residual 
correlations between retinopathy and the clinical risk factors was limited.  
 
The last part of the thesis described genome-wide meta-analysis of retinopathy in type 1 
and type 2 diabetic patients in the SUMMIT collaborative cohorts. This study analysed 
9,508,089 genetic variants in 5,422 diabetic retinopathy cases and 4,302 controls. We 
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identified the most significant signal SNP rs10746970 (P value of 2.22×10
-7
). In this study, 
we found diabetic retinopathy risk loci 1q43, 2q32.1, 6q16.1 13q32 identified in this study 
are in close proximity to regions of 1q13-42, 2q31-47, 6q22-27 and 13q14-32 previously 
reported in smaller scaled genome-wide association studies. We discovered previously 
unreported retinopathy risk loci of 1p34-p32, 2p12-p11.1, 2q11.2, 3p24.3, 3q24, 4q28-q32, 
5p14, 5q31.3, 6p21, q13-q21.2, 11q21, 12p11.22, 17q25.1 and 19q13.11. The identification 
of extensive susceptibility loci is suggestive of polygeneic effects contributing to the 
development of diabetic retinopathy. The closest genes to these loci have been implicated 
in multiple physiological processes including carbohydrate/lipid metabolism, functional 
activity in the neuronal and glial cells, and transcription regulation.  
 
This series of studies reported novel insights into the clinical and genetic susceptibility of 
diabetic retinopathy, and provided the scientific basis of informed clinical decisions on 
diabetic retinopathy prognosis and treatment. The findings are valuable to further studies of 
diabetic retinopathy.  
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Chapter 1  
Introduction 
 
1.1 Diabetic retinopathy 
1.1.1 Clinical features and classification 
The development of type 1 and 2 diabetes mellitus increase patients’ risk for developing a 
wide range of chronic complications. Macrovascular complications are identified by severe 
atherosclerosis in large blood vessels, and diabetic macroangiopathy affects the heart 
(coronary artery disease), the brain (cerebrovascular disease) and the lower extremities 
(peripheral vascular disease). In contrast, microvascular complications are characterised by 
weakening of capillary walls, leading to bleeding and a reduced blood flow. Diabetic 
microangiopathy affects the kidney (nephropathy), peripheral nerves (neuropathy) and the 
retina (retinopathy).  
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Diabetic retinopathy (DR) is a range of microangiopathies that can affect the retina of both 
eyes (Figure 1-1 and Figure 1-2), influenced by prolonged hyperglycaemia. Progression of 
diabetic retinopathy is sight threatening. Diabetic retinopathy is diagnosed by the methods 
of digital imaging photography or ophthalmoscopy (Figure 1-3), and in Scotland, clinical 
classification is based on the latest Scottish grading schemes for diabetic retinopathy and 
maculopathy (Table 1-2 and Table 1-3). The initial phase of diabetic retinopathy can be 
asymptomatic. The development of diabetic retinopathy is broadly classified into non-
proliferative and proliferative stages [1]. The non-proliferative or background stage is 
characterised by damages to retinal endothelium and the resultant capillary occlusion 
leading to retinal ischaemia, and related clinical features include microaneurysms, 
haemorrhages and cotton wool spots in the retinal periphery (Table 1-1,  Table 1-2 and 
Figure 1-4) [2]. The advanced proliferative stage develops with the proliferation of new 
blood vessels (neovascularisation) on the interface between the retina and the vitreous 
cavity [1,2]. Rupture of fragile blood vessels causes a large retinal haemorrahage [2]. 
Patients with a vitreous haemorrhage may experience obscured vision, and patients 
suffering from a preretinal haemorrhage may notice a moving visual blockage influenced 
by gravity [3]. When retinopathy affects the macula at the posterior pole of the retina, 
diabetic maculopathy develops (Table 1-3), and the loss of central vision becomes 
imminent [4]. Diabetic maculopathy is prevalent in type 2 diabetic patients [5]. Macular 
oedema and macular ischaemia are two sub-classes of diabetic maculopathy, and these two 
conditions can be concurrent [4]. Macular oedema is characterised by intraretinal fluid 
accumulation and swelling at the macular area [4], and the hallmark of macular ischaemia 
is macular vascular occlusion leading to cell death [4].   
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Figure 1-1 Human eye anatomy adapted from [6]. The wall of eyeball consists of three 
layers: the outermost connective tissue layer formed by cornea and sclera, the 
vascular tissue layer, the uvea composed of the iris, ciliary body and choroid; and the 
innermost neuronal tissue, the retina. The retina receives 65% to 85% of the blood 
supply from the choroid for nourishing photoreceptor cells [7].  
 
 
  
20 
 
 
 
Figure 1-2 The microstructure of human retina adapted from [8]. Light is transmitted 
through several transparent cellular layers before reaching photoreceptor cells (rods 
and cones) at the posterior of the retina. 
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Figure 1-3 A fundus photograph showing central retinal blood vessels radiating from  
the optical nerve in a healthy eye adapted from [4].  The fovea is seen as a red spot at 
the centre of the macular area free of blood vessels. 
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Table 1-1 Ophthalmic features associated with diabetic retinopathy summarised from 
[3].  
 
Microaneurysms: 
 Red dots, caused by protrusion of retinal capillaries. 
Haemorrhages: 
 Extravasation of retinal blood vessels.  
 Flame-shaped haemorrhages: haemorrhages in the nerve fiber layer of the retina.  
 Dot or Blot-shaped haemorrhages: haemorrhages deep in the connecting neuron 
layers of the retina.  
Exudates: 
 Yellow-white lesions, caused by deposits of plasma leaked from retinal capillaries.  
Cotton-wool spots: 
 Pale spots, caused by swellings of ischaemic nerve fibers.  
Intraretinal microvascular abnormalities (IRMA): 
 Burgundy-colored area, caused by dilatation of retinal capillaries.  
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Figure 1-4 Ophthalmic features of background diabetic retinopathy adapted from [9]. 
FH: flame-shaped haemorrhages; CWS: cotton wool spots; HE: hard exudates. 
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Table 1-2 Clinical diagnosis of diabetic retinopathy according to the Scottish diabetic 
retinopathy grading scheme 2007 v1.1. IRMA: intraretinal microvascular 
abnormalities.  
 
Retinopathy Description 
No visible 
retinopathy 
No diabetic retinopathy anywhere 
Mild background The presence of at least one of any of the following features 
anywhere 
 dot haemorrages 
 microaneurysms 
 hard exudates 
 cotton wool spots 
 blot haemorrages 
 superficial/flame shaped haemorrhages 
Observable 
background 
Four or more blot haemorrhages in one hemi-field only (Inferior and 
superior hemi-fields delineated by a line passing through the centre 
of the fovea and optic disc) 
Severe non-
proliferative 
retinopathy 
Any of the following features: 
 Four or more blot hameorrages in both inferior and superior 
hemi-fields 
 Venous beading 
 IRMA 
Proliferative 
retinopathy 
Any of the following features: 
 Active new vessels 
 Vitreous haemorrhage 
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Table 1-3 Clinical diagnosis of diabetic maculopathy based on the centre of the fovea 
in macula according to the Scottish diabetic maculopathy grading scheme 2007 v1.1. 
 
Maculopathy Description 
No maculopathy No features ≤disc diameters from the centre of the fovea sufficient to 
qualify for observable or referable maculopathy as defined below. 
Observable 
maculopathy 
Lesions as specified below within a radius of > 1 but ≤ 2 disc 
diameters the centre of the fovea. 
 Any hard exudates 
Referable 
maculopathy 
Lesions as specified below within a radius of ≤ 1 disc diameter of the 
centre of the fovea. 
 Any blot haemorrhages 
 Any hard exudates 
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1.1.2 Treatment 
Patients with early-stage diabetic retinopathy are regularly monitored for signs of severe 
non-proliferative/proliferative retinopathy or maculopathy, but effective therapeutic 
interventions for early-stage diabetic retinopathy remain limited [4]. Patients with 
proliferative retinopathy and diabetic macular oedema are referred for laser 
photocoagulation [4].  In the course of the treatment, an ophthalmologist administers 
flashes of laser beams to peripheral retina or fovea, aiming to reduce the size of ischaemic 
retina or to impair macular thickening respectively for proliferative retinopathy or macular 
oedema [3]. Multiple sessions of laser treatment are required for patients with proliferative 
retinopathy [3]. A study of laser photocoagulation in patients with proliferative retinopathy 
showed a 95% success rate in preventing further neovascularisation and improving visual 
acuity [3]. In contrary, a 60% visual improvement was reported for laser treatment in 
patients with diabetic macular oedema [3].  
 
If an extensive haemorrhage occurs in or behind the vitreous cavity or a fibrous mass 
threatens to detach from the retina, patients with proliferative retinopathy may undergo 
vitrectomy surgery [4]. This technique removes abnormal tissues and replaces the vitreous 
by clear fluid [4]. Despite of this surgical intervention, vitreous haemorrhages are likely to 
recur [4]. 
 
New treatment including intravitreal administration of anti-VEGF (vascular endothelial 
growth factor) is recommended for patients with proliferative retinopathy [3]. However, 
effectiveness of this intervention remains unclear. 
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1.1.3 Diabetic retinopathy screening 
Long-term follow-up studies showed that retinal screening is crucial for detecting onset or 
progression of diabetic retinopathy [4]. In Tayside, patients with diabetes were screened in 
a retinal exam using ophthalmoscopy or slit lamps, in a hospital by ophthalmologists and 
diabetologists or by hospital and community based optometrists [10,11]. Since 1986, non-
mydriatic (without dilation of the pupil) Polaroid photography has been shown as an 
effective method for identifying retinopathy in the diabetic population [12–14].  In 1992, a 
mobile unit mounted with a retinal camera was set up for systematic diabetic retinopathy 
screening in the Tayside diabetic population [15]. From 2003, digital retinal photography 
has been integrated into diabetic retinopathy screening, replacing Polaroid photography for 
a higher image quality and the ease of data storage [16]. In the same year, a Scotland-wide 
diabetic retinopathy screening program was established with an independent retinal grading 
scheme recommended by the Health Technology Board Scotland (HTBS) [17]. Currently, 
all type 1 and type 2 diabetic patients aged 12 years or older in Scotland are offered an 
annual retinal examination through the National Health Service (NHS) diabetic retinopathy 
screening program, or more frequently if required [4].  
 
1.1.4 Epidemiology 
Diabetic retinopathy is a prevalent microvascular complication in patients with diabetes. 
Nearly all type 1 diabetic patients develop diabetic retinopathy within 20 years of diagnosis 
[1]. Other previous studies have reported the prevalence of retinopathy in type 1 diabetic 
patients varies from 10% to 50%, stratified by the diagnostic procedure, ethnicity, 
population, the patient age, and the duration of diabetes [18].  
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At the diagnosis of diabetes, up to 21% of type 2 diabetes sufferers have clinical features 
for retinopathy [19], and exceeding 60% of type 2 diabetic patients develop retinopathy 
within 15-20 years [1]. The prevalence of diabetic retinopathy in European ancestry 
patients with type 2 diabetes ranges from 5% to 52% [18]. Leese et al [20] found in Tayside, 
Scotland, the prevalence of diabetic retinopathy in type 2 diabetic patients of an urban area 
is 7%, whereas in a rural area, the prevalence rises to 13%. 
 
Population risk factors for diabetic retinopathy includes diabetes duration [19], glycaemic 
exposure [21], blood pressure [22], serum total cholesterol [23], triglyceride [23], body 
mass index (BMI) [23], pregnancy [24] and cigarette smoking [25]. Management of 
diabetes by achieving glycaemic, blood pressure and lipid targets (glycated haemoglobin, 
HbA1c, 6.5% or 48.0 mmol/mol [26]; diastolic/systolic blood pressure, DBP/SBP, 140/80 
mm Hg; total cholesterol, 4.0 mmol/l, or low density lipoprotein cholesterol, LDL, 2.0 
mmol/l [27]) is the recommended primary prevention for retinopathy.  
 
Despite the optimal control of diabetic risk factors, patients with over 20 years’ diabetes are 
at risk for developing retinopathy. These population risk factors explain limited variations 
in the risk of diabetic retinopathy. The Diabetes Control and Complications Trial (DCCT) 
discovered 11% of variation in diabetic retinopathy susceptibility was accounted for by 
glycaemic exposure and diabetes duration [28–30]. Similarly, in the Wisconsin 
Epidemiologic Study of Diabetic Retinopathy (WESDR) study, the effect of glycaemic 
exposure, blood pressure and serum total cholesterol contributed 9-11% of variance 
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towards diabetic retinopathy risk [31]. These findings suggest a role for non-environmental 
risk factors for diabetic retinopathy. 
 
Increasing evidence suggests genetic variation can influence the susceptibility to diabetic 
retinopathy. For example, diabetic retinopathy shows patterns of familial aggregation, and 
higher prevalence of diabetic retinopathy was observed in siblings than in genetically 
unrelated individuals [32].  
1.1.5 Pathogenesis 
Although the pathogenic mechanism of diabetic retinopathy has not been fully elucidated, 
diabetic retinopathy studies have identified retinal microvascular abnormalities [33]. 
Sustained hyperglycaemia increases vascular permeability, accompanied by decreased 
synthesis of vasodilators (nitric oxide), elevated production of vasoconstrictors (angiotensin 
II, endothelin-1), with the release of vasopermeability-inducing cytokines (vascular 
endothelial growth factor, VEGF), resulting in programmed cell death (apoptosis) of retinal 
endothelial cells [33]. These retinal vascular abnormalities are linked to biochemical 
changes underlying multiple metabolic pathways (Figure 1-5 and Figure 1-6), and 
hormonal alterations in the endocrine system (Figure 1-7).  
30 
 
 
 
Figure 1-5 Multiple interconnecting pathways in glucose metabolism, leading to 
vascular tissue damage adapted from [33]. P: phosphate; NAD+/NADH: nicotinamide 
adenine dinucleotide; NADP+/NADPH: nicotinamide adenine dinucleotide phosphate; 
GAPDH: glyceraldehyde 3-phosphate dehydrogenase; DHAP: dihydroxyacetone 
phosphate; DAG: diacylglycerol; PKC: protein kinase C; AGE: advanced glycation 
end product; GFAT: glutamine fructose-6-phosphate amidotransferase; Gln: 
glutamine; Glu: glucose; UPP-GlcNAc: uridine diphosphate N-acetylglucosamine. 
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1.1.5.1 Polyol pathway 
The sorbitol-aldose reductase or the polyol pathway has been implicated in several diabetic 
complications including retinopathy, nephropathy (microangiopathy in kidney) and 
neuropathy (microangiopathy in neuronal tissues). The energy source molecule glucose 
enters cells through glucose transporter proteins (GLUT) by diffusion [34], and five 
subtypes differ in enzyme kinetics and insulin dependency, enabling a differential use of 
glucose in a diverse range of tissues [34]. GLUT1 primarily expressed in retinal, neuronal 
and renal tissues is insulin independent [34]. In diabetes, excessive intracellular glucose 
saturates glycolysis, the ubiquitous glucose metabolic pathway, and the build-up of glucose 
is metabolised in the polyol pathway (Figure 1-5) by the enzyme aldose reductase reducing 
glucose into sorbitol and oxidising the co-factor nicotinamide adenine dinucleotide 
phosphate (NADPH) [35]. In hyperglycaemia, the burden for aldose reductase for glucose 
is increased, leading to the accumulation of sorbitol and deprivation of NADPH for other 
cellular processes including nitric oxide and glutathione synthesis [33]. Acquired 
glutathione deficiency promotes oxidative stress. Imbalance of these metabolites causes 
cellular damages [33].  
 
1.1.5.2 Advanced glycation end product (AGE) pathway 
In the normal metabolic state, nonenzymatic protein glycation occurs at a low and constant 
rate [35], and in the diabetic state, high availability of intracellular glucose markedly 
accelerates the formation of AGEs from sugars reacting with free amino groups of proteins, 
lipids, and nucleic acids (Figure 1-5) [35]. A feature of AGEs is the formation of 
inappropriate protein cross links, leading to impaired protein structure and functions [35]. 
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The main influence of AGEs on diabetic retinopathy susceptibility is mediated by AGE-
binding receptors including the receptor for advanced glycation endproducts (RAGE) [36], 
activating proinflammatory signals [35]. AGEs were detected in retinal tissues, and 
blockade of AGE pathway retarded the development of retinopathy in diabetic patients [33]. 
 
1.1.5.3 Protein kinase C (PKC) pathway 
Hyperglycaemia triggers a profusion of glucose reflux through glycolysis, and in turn an 
increased synthesis of an intermediate metabolite diacylglycerol (DAG), a second 
messenger for activating nine of eleven identified isoforms of PKC (Figure 1-5) [35]. 
Hyperglycaemia also stimulates the PKC pathway via AGE [37] and polyol [38] mediated 
pathways. PKC-β isoforms are expressed in retinal and renal vasculature, and the PKC-β 
activity inducesactivation of endothelin-1 and inhibition of nitric oxide synthesis, causing 
blood circulation aberration [39]. PKC also activates expression of VEGF in vascular 
smooth muscle cells [40], inciting angiogenesis and endothelial permeability. 
 
PKC-β inhibitor (ruboxistaurin mesylate) was reported as an effective therapeutic drug in 
prevention of progressive vision loss amongst diabetic retinopathy patients [35]. 
Nevertheless, owing to versatile regulatory roles of PKC-β in cell signalling, inhibition of 
PKC-β has adverse effects [35], and hence, PKC-β has not been recommended as a 
therapeutic target for diabetic retinopathy.  
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1.1.5.4 Hexosamine pathway 
In diabetes, the build-up of intracellular glucose causes overproduction of fructose-6-
phosphate, a glycolytic metabolite, which is also a substrate for synthesis of N-
acetylglucosamine (GlcNAc) in the hexosamine pathway (Figure 1-5). GlcNAc 
glycosylation of the intracellular transcription factor Specificity Protein 1 (Sp1) reduces 
competitive phosphorylation at the same regulatory domain [33]. Dephosphorylation of Sp1 
is associated with increased transcription of the plasminogen activator inhibitor-1 gene 
(PAI-1), leading to vascular endothelial dysfunction and related alterations, consistent with 
retinal vascular damage observed in patients with diabetic retinopathy[33].  
 
1.1.5.5 Oxidative stress 
In hyperglycaemia, when glucose is oxidised, superfluous electron donors (NADH and 
FADH2) generated in the tricarboxylic acid or citric acid (TCA) cycle oversupply the 
downstream electron transport chain (Figure 1-6). Consequently, an overactive electron 
transport chain generates excess free radical by-products, exhausting cellular antioxidants 
and subsequently, causing oxidative stress [41]. Reactive oxygen radicals are known to 
destroy cellular functions, and have been implicated in diabetes [42]. Studies demonstrated 
the link between oxidative stress and diabetic retinopathy severity [43]. Attenuation of 
reactive oxygen species production suppresses polyol, AGE, PKC and hexosamine 
pathways, providing strong evidence for a unifying theory of oxidative stress-mediated 
pathological pathways in hyperglycaemia [44].   
34 
 
 
 
Figure 1-6 Biochemical pathways underlying glucose metabolism in humans adapted 
from [45], highlighting intra-mitochondrial reactions in the citric acid cycle and 
electron transport chain. NAD+/NADH: nicotinamide adenine dinucleotide; ATP: 
adenosine-5'-triphosphate; ADP: adenosine diphosphate; AMP: adenosine 
monophosphate ; HSCoA/CoA: coenzyme A; PPi: pyrophosphate; Pi: orthophosphate; 
CO2: carbon dioxide; FAD+/FADH2: flavin adenine dinucleotide; GTP: guanosine-5'-
triphosphate; e-: electron; H+: proton; O2: oxygen; H2O: water, OH-: hydroxide. 
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1.1.5.6 Renin-angiotensin system 
The renin-angiotensin system (RAS, Figure 1-7) is an endocrine system regulating blood 
pressure and volume of body fluid (blood plasma, lymph and tissue fluid), and has an 
implication for proliferative diabetic retinopathy. In the classical pathway, granular cells in 
the kidney, a group of specialised smooth muscle cells located in glomerular arterioles, 
synthesize and release the enzyme renin into blood circulation, in response to a drop in 
blood pressure. Plasma renin catalyses the cleavage of the oligopeptide angiotensinogen 
synthesized in liver, forming angiotensin I. Angiotensin-converting enzyme (ACE) are 
glycoproteins present in the lung, endothelial and renal cells, where both the membrane 
bound and secretory forms of ACE were found [46]. ACE mediates cleavage of angiotensin 
I. The resulting active hormone angiotensin II influences vasoconstriction and electrolyte 
homeostasis, restoring blood pressure balance.  
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Figure 1-7 The renin-angiotensin system influences an array of physiological functions 
in the human body adapted from [47]. 
 
 
 
However, further studies extended RAS to include additional focal angiotensin II-releasing 
circuits in neuronal [48], cardiovascular [49], renal [50,51] and adrenal [52] tissues. The 
precise mechanism for exacerbation of diabetic retinopathy by angiotensin II under a 
hyperglycaemic state is still enigmatic. Compelling evidence suggests that angiotensin II 
receptors in retina mediate the release of VEGF, inciting angiogenesis [53], and the 
inhibition of ACE suppresses neovascularisation [54].  
 
1.1.5.7 Hypertension-induced mechanical stress 
Hypertension is a known modifiable risk factor for diabetic retinopathy, and frequently 
concomitant with hyperglycaemia [55]. A series of studies applied mechanical stress to an 
in vitro cellular environment to investigate retinal responses to hypertension in vivo. The 
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results indicated that mechanic stretch up-regulated the expression of VEGF, a biomarker 
for proliferative retinopathy, in retinal pigment epithelial [56], endothelial and pericyte 
cells [57] through singling pathways involving phosphatidylinositol 3-kinase and protein 
kinase C [58]. Additionally, there was proof that mechanical stretch increased oxidative 
stress and apoptosis in porcine [59] and bovine [60] retinal pericytes, which was further 
exacerbated by hyperglycaemia [60]. The loss of retinal pericytes undermines the blood–
brain barrier in the retina, characteristic of diabetic retinopathy [55].        
 
1.1.6 Heritability 
1.1.6.1 Estimation methods 
The premise that many complex traits are heritable is crucial to many genetic epidemiology 
studies. Determining the degree to which a trait is heritable is a critical first stride towards 
deciphering the underlying genetic architecture and pertinent to designing appropriate gene-
mapping strategies. Heritability is a measure that quantifies the fraction of phenotypic 
variations due to genetic effects. Phenotypic variations (
pV  ) in a population are attributable 
to the variability in environment effects ( eV  ) and genetic components ( gV  ) including 
allelic interactions within a locus (dominance, dV  ), across loci (epistasis, epV  ) and additive 
allelic effects within and/or across loci ( aV  ). Heritability in the broad sense (
2
H ) is the 
ratio of the total genetic variance to the phenotypic variance, i.e. 
2
g pH V V . Although 
phenotypic variations are directly measureable from a population sample, the total genetic 
variations are frequently unobserved and challenging to gauge. In the past, animal and plant 
breeders discovered that close resemblance between relatives was due to the additive 
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genetic effects [61], and by considering phenotypic values within genetic related samples, it 
became feasible to attain approximations for the variance of the total additive genetic 
effects and the narrow-sense heritability ( 2h ), which is the ratio of the total additive genetic 
variance to the phenotypic variance, i.e. 
2
a ph V V . Owing to its vital role in breeding 
programs and quantitative genetics, hereinafter, the discussion is dedicated to narrow-sense 
heritability, unless otherwise stated.  
 
A number of heritability estimation techniques are commonly utilised, and the adoption of 
such an approach is on the basis of practical limitations such as the genetic relationship of 
samples, the sample size and/or the nature of genetic data. Historically, parent-offspring 
regression outcompeted the rivals by multiple counts. First, the parent-offspring 
relationship can be identified with ease. For example, in farm fields, the origination of 
seeds from the corresponding maternal crops can be established with certainty, whereas 
other types of relations such as full-sibship, half-sibship or paternity may not be accurately 
identified in a natural population. Second, the regression was statistically simple to perform. 
Third, the covariance of phenotypic values across a familial generation is considered as 
influenced by additive genetic effects at the absence of dominance or epistasis effects [62], 
and thus, the  narrow-sense heritability can be estimated from the coefficient of the 
regression [62]. However, the parent-offspring information may not always be available. 
For instance, generations may not overlap for some species, and therefore the lineage 
becomes impossible to establish. Sibship-based estimation methods were considered as a 
compelling alternative. In this analysis, analysis of variance (ANOVA) is applied to attain 
phenotypic covariations within- and between-family, which heritability can be estimated 
from the intraclass correlation [62]. In addition, the familial relationship of twins is 
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common in human populations [62], and as in Falconer's formula [63], the broad-sense 
heritability is estimated by  2 2 mz dzH r r   , where mzr  is the concordance of monozygotic 
twins (derived from the same embryo); dzr   is the concordance of dizygotic twins (derived 
from two embryos). Finally, large-scaled human population cohorts frequently consist of 
largely genetically unrelated individuals and a small number of relatives that may be within 
a generation or across-generations. With the availability of genome-wide variant data, 
genetic similarities between samples can be estimated to facilitate the estimation of narrow-
sense heritability using a linear mixed model [64]. 
 
Owing to the paucity of densely genotyped data for quantitative genetics studies, 
conventional methods for estimating heritability in relatives were based on inherent 
assumptions in respect to the expected genetic and environmental resemblance of relatives. 
For example, the phenotypic resemblance across monozygotic and dizygotic twins was 
assumed to be attributable to common environmental effects [64], which from the current 
perspective is questionable. Furthermore, heritability estimates for a trait are likely to be 
variable, reflective of temporal and spatial fluctuations in the underlying genetic and 
environmental effects. For instance, heritability for first lactation milk yield in dairy cattle 
was 25% in the 1970s, and 40% at the present time [64]. Environmental variance may 
differ between non-identical study populations or in an identical study population but 
sampled at different times [64]. Genetic variance can be altered by allele frequencies, the 
emergence or the extinction of variants [64]. Thus, heritability of a trait is specific to a 
population at a study time.  
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1.1.6.2 Heritability of diabetes and diabetic retinopathy 
The clinical phenotypes of diabetes and diabetic retinopathy are both categorical in nature, 
and to estimate heritability, these categorical phenotypes are transformed to underlying 
unobserved liability on a continuous scale [65]. The heritability estimate was 88% for type 
1 diabetes, in the Finnish Twin Cohort, which included 44 monozygotic and 183 dizygotic 
twin pairs with type 1 diabetes in a 22,650 population-based twin pairs [66]. In the Danish 
Twin Register where 62 twin pairs out of 606 were type 2 diabetic, the heritability estimate 
was 26% for type 2 diabetes [67]. It was suggested that the heritability estimate of type 2 
diabetes was reflective of heritable components of obesity, a major risk factor for type 2 
diabetes [68]. The broad-sense heritability was 27% for background and proliferative 
diabetic retinopathy in the FIND-Eye study, where most patients were diagnosed with type 
2 diabetes [69]. Heritability estimates were 25% and 52% for proliferative retinopathy 
respectively in the FIND-Eye cohort [69] and the FinnDiane study (a type 1 diabetes cohort) 
[70]. 
 
1.1.7 Genetics of diabetes 
Type 1 diabetes is characterised by autoimmune-mediated chronic destruction of insulin-
secreting beta cells in the pancreas. Through studies of candidate genes and a limited set of 
genome-wide nonsynonymous variants, 6 susceptibility genes for type 1 diabetes were 
successfully identified between 1974 and 2006, including HLA (major histocompatibility 
complex, class I), INS (insulin), CTLA4 (cytotoxic T-lymphocyte-associated protein 4), 
PTPN22 (protein tyrosine phosphatase, non-receptor type 22), IL2RA (interleukin 2 
receptor, alpha), and IFIH1 (interferon induced with helicase C domain 1) [71]. Since 2007, 
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several genome-wide association studies (GWAS) [72–74] reported a number of 
association genes for type 1 diabetes, including ERBB3 (v-erb-b2 avian erythroblastic 
leukemia viral oncogene homolog 3), RAB5B (RAB5B, member RAS oncogene family), 
SUOX (sulfite oxidase), RPS26 (ribosomal protein S26), CDK2 (cyclin-dependent kinase 2) 
and UBASH3A (ubiquitin associated and SH3 domain containing A). An independent study 
confirmed the association of UBASH3A with chronic autoimmune destruction and type 1 
diabetes [75]. To date, 59 susceptibility loci were identified with more than 40 associated 
genes implicated for type 1 diabetes [71] (Figure 1-8).  
 
Figure 1-8 Suscpetiability genes for type 1 diabetes, adapted from [71].  
 
 
The pathogenesis of type 2 diabetes is underscored by the interplay between impaired beta-
cell function and insulin sensitivity [76]. Despite of the extensive efforts for years, linkage 
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and candidate-gene studies only identified PPARG (peroxisome proliferator-activated 
receptor gamma), KCNJ11 (potassium inwardly-rectifying channel, subfamily J, member 
11) and TCF7L2 (transcription factor 7-like 2, T-cell specific, HMG-box) as susceptibility 
genes for the polygenic form of type 2 diabetes [77]. The advent of GWAS accelerated the 
detection of susceptibility loci for type 2 diabetes. It was suggested that published GWAS 
more frequently mapped susceptibility genes for beta-cell dysfunction compared to genes 
for insulin resistance [78]. For example, ADCY5 (adenylate cyclase 5), PROX1 (prospero 
homeobox 1), GCK (glucokinase, hexokinase 4), GCKR (glucokinase/hexokinase 4 
regulator), and DGKB/TMEM195 (diacylglycerol kinase, beta/ transmembrane protein 195) 
were implicated for fasting glucose/beta-cell dysfunction , whereas GCKR was the only 
gene significantly associated with insulin resistance in the MAGIC (Meta-Analyses of 
Glucose and Insulin-related traits Consortium) study [79]. In the DIAGRAM+ 
(DIAbetes Genetics Replication and Meta-analysis plus additional cohorts) study, 10 
genes including MTNR1B (melatonin receptor 1B), SLC30A8 (solute carrier family 
30/zinc transporter, member 8), THADA (thyroid adenoma associated), TCF7L2, KCNQ1 
(potassium voltage-gated channel, KQT-like subfamily, member 1), CAMK1D 
(calcium/calmodulin-dependent protein kinase ID), CDKAL1 (CDK5 regulatory subunit 
associated protein 1-like 1), IGF2BP2 (insulin-like growth factor 2 mRNA binding protein 
2), HNF1B (HNF1 homeobox B), and CENTD2 (ArfGAP with RhoGAP domain, 
ankyrin repeat and PH domain 1) were associated with beta-cell function, whereas only 
PRARG, FTO (fat mass and obesity associated), and KLF14 (Kruppel-like factor 14) 
showed association with insulin sensitivity [80].  
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1.2 Aim of this thesis 
As aforementioned, despite the extensive research efforts, the pathophysiology of diabetic 
retinopathy remains elusive, as a multitude of questions in respect of the retinopathy 
development were unexplored. One of the salient features of the chronic development of 
retinopathy is manifested in the clinical diagnosis as the classification of retinopathy into 
multiple severity stages. However, so far there have been few epidemiological studies 
aiming to uncover the progression and remission of retinopathy during the duration of 
diabetes, and the influence of population risk factors on this development. Additionally, in 
genetics studies, the heritable components underlying the severity of retinopathy with the 
consideration of the multi-state development were rarely addressed. Finally, studies to date 
that assessed genetic determinants for diabetic retinopathy were weakly powered in the 
study sample size and variants ([28,81–83]), with a large fraction of genetic susceptibility 
for diabetic retinopathy remaining unexplained.    
 
Thus, the corollary to these neglected questions was the birth of this thesis, which , focused 
on answering three clinically important questions: (1) given the longitudinal nature of the 
GoDARTS (Genetics of Diabetes Audit and Research in Tayside Scotland) study cohort 
and the categorical feature of retinopathy data, can we decipher determinants that affect 
changes in retinopathy severity over the duration of diabetes? (2) With the abundance of 
genomic data for the GoDARTS cohort, can we estimate heritability and genetic 
correlations explained by common SNPs for diabetic retinopathy and related risk factors? 
(3) With the additional independent retinopathy data available from IMI-SUMMIT 
(SUrrogate markers for Micro- and Macro-vascular hard endpoints for Innovative diabetes 
Tools; a pan-European research consortium funded by the Innovative Medicines Initiative; 
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www.imi-summit.eu), can our study with an increased sample size compared to any of the 
published GWAS [28,81–83], be more successful in detecting and replicating risk loci for 
diabetic retinopathy?  
 
Three studies were included in this thesis to answer these questions.  
(1) The influence of population risk factors on diabetic retinopathy severity over the 
duration of diabetes. The project plan was to capture the longitudinal data of retinopathy 
including intermediate retinopathy events during the follow-up in GoDARTS diabetic 
patients, and model the patient data in a multi-state Markov model for the inference of 
covariate effects.  
 
(2) Heritability and genetic correlations explained by common SNPs for diabetic 
retinopathy and related risk factors. The project plan was to utilise the Gibbs Sampling 
algorithm for the Bayesian inference of variance components in the analysis of narrow-
sense heritability and genetic correlation captured by common genome-wide SNPs for 
diabetic retinopathy and population risk factors.  
 
(3) The SUMMIT genome-wide meta-analysis of diabetic retinopathy. The project plan was 
to identify diabetic retinopathy risk loci in human genome by association mapping in the 
GoDARTS cohort and additionally with independent diabetic retinopathy samples from 
SUMMIT collaborators.  
 
Together, these three projects form a coherent and comprehensive investigation of clinical 
and genetic basis for the development of diabetic retinopathy, and should provide an 
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increased understanding of diabetic retinopathy pathogenesis and prognosis for scientists 
and clinicians.  
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Chapter 2  
Methods 
 
2.1 Description of clinical data 
The Health Informatics Centre (HIC) of the University of Dundee manages and supplies the 
anonymised patient data owned by the National Health Service (NHS) Tayside, in 
accordance with the Standard Operating Procedures approved by the Caldicott Guardians, 
for medical research purposes. Patients registered with a general practitioner (GP) in 
Scotland are allocated a unique 10-digit identification number, a Community Health Index, 
which is used for identifying patients’ information including the address, the GP 
registration status and the date of death for a deceased patient. Community Health Indices 
for Tayside patients are centralised in the Community Health Master Patient Index database 
held by the Tayside Health Board. The Community Health Index as a unique patient 
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identifier is in use of all heath care activities, and is useful in medical research for patients’ 
record linkage.  
 
2.1.1 DARTS database 
The diabetes audit and research in Tayside Scotland (DARTS) database is a comprehensive 
and up-to-date register of diabetes in Tayside, and it includes electronic records assimilated 
from multiple independent sources including the regional biochemistry and diabetes eye 
screening data [84]. The DARTS register has been shown as an enriched source \ in 
identifying diabetes in the Tayside population with high sensitivity and positive predictive 
value (0.96 and 0.95 respectively) [84].  
 
2.1.2 GoDARTS database 
Since October 1997, registered DARTS patients have been invited to give informed consent 
to DNA in the Genetics of DARTS (GoDARTS) study, supported by the Wellcome Trust 
United Kingdom Type2 Diabetes case control collaborative study and approved by the 
Tayside Committee for Medical Research Ethics. Between December 1998 and May 2009, 
17,602 patients (including 9,829 type 2 diabetic patients) of European ancestry were 
recruited in Tayside. Patients’ blood samples were collected for DNA (deoxyribonucleic 
acid) extraction and genotyping. Participants were allocated a unique anonymised system 
identifier. Clinical characteristics of participants were recorded at recruitment.  
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2.1.3 Diabetes eye screening data 
As of June 2011, the diabetes eye screening data originated from the SCI-DC (the Scottish 
Care Information – Diabetes Collaboration; that is, the Scottish national diabetes disease 
database) system includes the diagnosis since 1990 of diabetes-related eye conditions 
including cataract, glaucoma, laser photocoagulation treatment, diabetic retinopathy and 
maculopathy for 8,910 Tayside patients. The diabetes eye screening database is a 
constellation of ophthalmology data collated from multiple sources including national and 
regional retinopathy screening programs, diabetes clinics and regional hospitals, since the 
diagnosis of diabetes in patients. The diabetes eye screening data documented techniques 
and specialists for ophthalmic diagnosis. Diabetic retinopathy and maculopathy severity 
stages (Table 1-2 and Table 1-3) are determined from grading of single-field 45 degree 
retinal photographs for both eyes where staged mydriasis is given.  
 
2.1.4 Clinical phenotype data 
The Tayside laboratory system documents the outcome from clinical pathology tests 
performed in regional surgeries, clinics and hospitals. The clinical pathology data is dated 
from 1992 and available in biochemistry, haematology, microbiology, virology and 
serology sections. Measures of total cholesterol, serum creatinine, glycatedhaemoglobin 
(HbA1c), high-density lipoprotein cholesterol (HDL-c) and triglycerides that are relevant 
population risk factors in this study were ascertained from the Tayside laboratory 
biochemistry database. As of June 2011, biochemistry data for 17,575 GoDARTS patients 
has been available through the Tayside laboratory database. 
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Additional Tayside-based longitudinal patient data for blood pressure (BP including 
diastolic and systolic BP, or DBP and SBP), body mass index (BMI) and HbA1c variables 
has been available through the SCI-DC network. As of June 2011, the SCI-DC system 
included data from 9,498 GoDARTS individuals for BP, 9,509 individuals for BMI and 
9,510 individuals for HbA1c.  
 
In addition to the routinely collected clinical data, common clinical variables including 
BMI, total cholesterol, serum creatinine, BP, HbA1c, HDL-c, triglycerides and smoking 
status were measured in the participants at the GoDARTS recruitment time. As of June 
2011, 16,131 patients’ recruitment data is available. This number is lower than the total 
GoDARTS cohort as baseline phenotypic data was not collected between 1997 and 2004. 
  
2.1.5 Demographic data 
As of June 2011, 17,602 Tayside patients’ demographic data including the gender, the date 
of birth, the recruitment date of GoDARTS and the date of death if a patient is deceased, 
has been available through HIC.  
 
2.2 Description of genetic data 
In the GoDARTS study, Genomic DNA was extracted from blood specimens following the 
Promega Wizard or Qiagen procedures at Professor Colin Palmer’s laboratory at Ninewells 
Hospital and Medical School. DNA samples were normalised and tiled to 96 and 384 well 
plates for genotyping. 
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2.2.1 Affymetrix Genome-wide Human SNP Array 6.0 
The Affymetrix Genome-wide Human SNP Array 6.0 provides the genomic coverage for 
906,600 single-nucleotide polymorphisms (SNPs) of the human genome build 36, 
constituting of 482,000 historical SNPs an unbiased selection from Affymetrix Genome-
wide Human SNP Array 5.0 and 424,000 additional SNPs that are tag, mitochondrial, or 
sex chromosomal SNPs, or SNPs newly added to the dbSNP database or in recombination 
hotspots [85]. 4,000 GoDARTS diabetic patients that had received statin treatment since the 
recruitment were genotyped on the Affymetrix Genome-wide Human SNP Array 6.0 at the 
Affymetrix Service Laboratory, California. Prior to genotyping, DNA samples were quality 
assessed in order to eliminate experimental errors. Genotyping data intensities were 
normalised, and genotypes were called using the CHIAMO algorithm [72]. The Affymetrix 
Service Laboratory also provided preliminary quality control (QC) assessment on the 
genotype data. Further QC on this data was performed by the Wellcome Trust Case Control 
Consortium 2 (WTCCC2) study group as described in [86,87].  
 
2.2.2 Illumina HumanOmniExpress BeadChip 
The Illumina HumanOmniExpress BeadChip provides the coverage for over 700,000 tag 
SNPs of the human genome build 37, spanning up to 90% genomic regions for European 
and Asian ancestry populations of the International HapMap Project [79]. Supported by the 
SUMMIT consortium, additional 4,000 GoDARTS diabetic patients that mostly had not 
been genotyped on the Affymetrix Genome-wide Human SNP Array 6.0, and with serious 
retinal, renal and cardiovascular complications were genotyped on the Illumina 
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HumanOmniExpress BeadChip at the Diabetes Centre of the University of Lund, Sweden. 
Data normalization and genotype calling was implemented in the GenomeStudio Software 
(Illumina, Inc.) environment. 
 
2.2.3 1000 Genomes reference data 
The 1000 Genomes Project was initiated in 2008 with the aim to catalogue most of the 
genome variants with frequencies of 1% or higher in the populations studied. Given the 
high cost of deep sequencing for whole genomes and the limited number of haplotypes in 
any specific genomic region, the plan of the 1000 Genomes Project was to sequence 2,500 
samples from diverse ethnic populations at low-coverage (4X; that is, the amount of DNA 
sequence equivalent to 4 times across the genome), and the remaining unidentified variants 
for each individual can be frequently inferred from the sequence data for the overall sample 
[89,90]. 
 
To inform whether the strategy of light sequencing is adequate in meeting the goal of the 
project, three pilot studies were carried out: low-coverage (2-4X) sequencing of 179 
individuals from four demographic regions; high-coverage (20-60X) sequencing of a pair 
of mother–father–child trios; and sequencing of exomes (50X) in 697 individuals from 
seven populations [89]. The pilot studies published in October 2010 characterised 15 
million SNPs, 1 million short insertions and deletions, and 20,000 structural variants [89]. 
The pilot data and methods supported the design of the full-scale project [89]. 
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In October 2012, the 1000 Genomes Project Consortium published low-coverage genome-
wide and exome sequence data for 1,092 individuals from 14 populations [90]. The study 
identified 38 million SNPs, 1.4 million short insertions and deletions, and over 14,000 
larger deletions, with the promise for sequencing additional 1,500 individuals from 12 
different populations in the last phase of the project [90]. 
 
We utilised 1000 Genomes phase 1 integrated haplotype data version 3 (released in March 
2012) for genotype imputation and the assessment of population structure in the genotyped 
GoDARTS sample.  
 
2.3 The influence of population risk factors on diabetic 
retinopathy severity over the duration of diabetes 
2.3.1 Study sample 
We performed a prospective cohort study of diabetic retinopathy in the GoDARTS 
population sample. The ophthalmology data used in this study were from the complete 
calendar years 1990 to 2011. GoDARTS is a study of patients with a diagnosis of type 2 
diabetes, but we further reduced the chance of including misclassified type 1 diabetes 
patients by only considering subjects who were diagnosed with diabetes at 35 years of age 
or older. The cohort included patients who had at least two longitudinal retinal records. We 
observed that the numbers of diabetic retinopathy events and the distributions of follow-up 
time collected for both eyes were comparable, and to preclude the artefacts reflected as 
observed remission and recurrence of the proliferative phase of diabetic retinopathy, 
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produced from compounding longitudinal data from both eyes, we collated and analysed 
retinopathy data from the same eye. 
 
The primary start point for this study obtained from this data set was the first retinal record 
indicative of no retinopathy within one year from the date of diabetes diagnosis. Patients 
were followed until either the onset of severe non-proliferative/proliferative diabetic 
retinopathy, their date of death, or 16 years duration of diabetes. Intermediate retinopathy 
observations were included in this study.  
 
Additional independent data sets (e.g., demography and regional biochemistry database) 
were integrated through electronic record linkage. Population risk factors extracted were 
sex, smoking status (ever smoked against never smoked) and longitudinal records of age, 
BMI, total cholesterol, serum creatinine, DBP, HbA1c, HDL-c, SBP and triglycerides. 
Non-high density lipoprotein cholesterol (non-HDL-c) was estimated from total cholesterol 
and HDL-c measurements recorded on an identical date. As low-density lipoprotein 
cholesterol (LDL-c) measurements were often missing, throughout this study, non-HDL-c 
was considered as a valid surrogate for LDL-c estimation based on the Friedewald formula 
(LDL-c ≈ total cholesterol – HDL-c – k*triglycerides, where k is 0.20 if the measurements 
are in mg/dl and 0.45 if in mmol/l). The concordance was shown in this study as the 
Pearson’s correlation coefficient (0.987) we attained using weighted means of longitudinal 
non-HDL-c and LDL-c measures in the overall GoDARTS sample (16,928 patients). Time-
variant covariates were matched to a retinal event that occurred at the closest time point. 
Covariates measured on a quantitative scale were standardised by sample mean and 
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standard deviation (SD). In this study, we only included patients with the complete set of 
covariate data. 
 
2.3.2 Statistical analysis 
2.3.2.1 Multi-state Markov model 
A multi-state Markov model was fitted to the panel data of diabetic retinopathy in this 
study. The multi-state Markov model depicts the movement across a series of categorical 
states over the observational time. The detailed description of this statistical framework for 
the model was published elsewhere [91,92]. In brief, suppose at an arbitrary time t, an 
individual is observed in the discrete state i.  The movement into a state j (i ≠ j) at a later 
observational time t t    is dependent on the instantaneous propensity of moving from 
state i to j (the instantaneous incidence rate, or formally the transition intensity), time 
elapsed and additionally, time-dependent explanatory variables. Formally, the transition 
intensity is described by:  
 
0
{ ( ) | ( ) }
( ) limij
t
P S t t j S t i
q t
t 
  


   0.1 
where S(t) is the state observed at time t. Considering all possible state transitions, the 
corresponding transition intensities form the entries in a transition intensity matrix, where 
by convention rows sum to 0 and the transition intensities for no state change is 
conventionally defined as 
 ( ) ( )ii ij
j i
q t q t

    0.1 
In the model specification, a non-feasible or non-permitted instantaneous state transition is 
pre-set to 0.  
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In contrast to a transition intensity measure, which expresses an instantaneous propensity, 
given an elapsed time period, the probability of a state transition observed at two time 
points can be estimated from the matrix exponential operation of the scaled transition 
intensity. Formally, the transition probability of being in state j at time t + u given the state 
at time t is state i is represented as pij(t, t+u). The probability of a state transition does not 
suggest the number of transitions occurred for an observed state change during a time 
period, and the process may have passed through other states between time t and t + u.  
 
In a multi-state hidden Markov model, true underlying states are considered as unobserved 
and observed states are assumed to be reflective of hidden true states. For a patient at an 
observational time, the observed state is generally conditioned on the true state according to 
a categorical distribution.  
 
Covariates are introduced as proportional to the baseline transition rate expressed as 
 ( ) exp( )Tij ij ijq x q x    0.1 
where βij is the vector of regression coefficients associated with the vector of covariables x 
for the transition between the states i and j; T denotes the transposition of a matrix.  
 
In the process of parameter estimation, the estimates are iteratively updated until the 
likelihood for observing the data given a set of parameter is maximised. The “msm” 
package (version 1.1.1) in the R (version 2.14.2) programming environment includes 
maximum likelihood estimation (MLE) methods for a number of observational schemes 
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including intermittent observation time, observations from a hidden Markov process, censor 
states, or a mixture of these schemes.  
 
2.3.2.2 Likelihood ratio test and Akaike’s information criterion (AIC) 
To identify the better fitted model from the null and the alternative models in the study 
sample, the likelihood ratio test and the AIC statistic were considered. The likelihood ratio 
test statistic (D) is formally defined as 
 2log Null
Alternative
Likelihood
D
Likelihood
 
   
 
  0.1 
The probability distribution of the test statistic D is approximated by the chi-squared 
distribution with (df2 – df1) degrees of freedom, where df1 and df2 are numbers of 
parameters in the null and alternative models, respectively. Thus, the likelihood ratio test 
provides a p-value based statistical framework for hypothesis testing. However, the 
likelihood ratio test is applicable to nested models only, where the complex alternative 
model can be simplified into the null model by imposing constraints on the model 
parameters [93]. 
 
With more parameters in the fitting of a complex model, it is possible to inflate the 
likelihood of the parameter values given the observed data, with the consequence of 
overfitting (that is, when the model fitting is unduly complex, and the statistical inference is 
inaccurately based on the noise instead of the true relationship between variables). The AIC 
statistic penalises a model’s likelihood by the number of parameters involved, and is 
commonly used in model selection. The AIC is defined as 
 2 2log( )AIC k L    0.1 
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where k is the number of parameters, and L is the likelihood of a model. With multiple 
candidate models fitted to the same data, the most suitable model is selected from the 
lowestAIC value. The AIC measure is not restricted to the comparison of nested models 
[94].  
 
2.3.2.3 Model fitting and comparison 
The discrete, non-overlapping stages of diabetic retinopathy were translated into distinctive 
states in the multi-state model. The effect of explanatory variables on diabetic retinopathy 
development is modelled in an adapted form of proportional hazard model (Equation 0.1) 
[92]. Patients' diabetic duration at retinal examination was considered in the model. 
Between follow-up visits, patients' diabetic retinopathy development is usually 
unmonitored, and the exact time of transition from one state to the other is unknown. Thus, 
we specified a relevant sampling scheme to accommodate an intermittently-observed 
disease process.  
 
We postulated two baseline multi-state models, which together aimed to decipher the 
process underlying the development of diabetic retinopathy from the observed retinal event 
data by modelling distinct putative transition paths between states. In the first model, 
diabetic retinopathy development is modelled as one-way progression (Figure 2-1a; 
Equation 0.6), and misclassification was allowed to occur between adjacent states except 
for the absorbing state (Equation 0.7). The second model is specified by a two-way 
transition intensity matrix and an identical mis-classification probability matrix (Figure 
2-1b; Equation 0.7 and 0.8). The best-fitted model was selected from the likelihood ratio 
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tests and AIC statistic. The selected model was then used for assessing covariate effects.  
Covariate model selection procedures also utilised LR and AIC measures. 
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Figure 2-1 (a) A base multi-state Markov model describes one-way transition of four 
states of diabetic retinopathy. (b) A second base model describes two-way transition of 
four states of diabetic retinopathy. The process of entering the final absorbing state is 
irreversible. Rates of transition (or, transition intensities) are specified as qij, where 
transition occurs from the current state i to the future state j. 
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2.3.2.1 One-way transition with mis-classification 
The matrix of transition intensities is specified by 
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where each entry qij denotes the instantaneous risk of transition from state i to state j, and  
ii ij
j i
q q

   for i = 1,2,3,4. The matrix of classification probabilities is of the form 
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where each entry eij gives the probability of observing state j given that the true state is i, 
and 1ii ij
j i
e e

    for i = 1,2,3,4. 
 
2.3.2.2 Two-way transition with mis-classification 
The matrix of transition intensities is defined by 
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Entries of matrix Q2 are similarly defined as in matrix Q1. The classification probability 
matrix is specified identically as in E1. 
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2.4 Heritability and genetic correlations explained by 
common SNPs for diabetic retinopathy and related 
risk factors 
2.4.1 Study sample 
The study sample was ascertained from the GoDARTS cohort, which includes genetically 
unrelated individuals and some families with diabetes. Diabetic patients underwent a 
complete ophthalmologic examination in diabetes eye screening, as previously described. 
The worst eye grade of diabetic retinopathy for each patient up to the GoDARTS 
recruitment time was collated. Severity of diabetic retinopathy was classified as none, mild 
background retinopathy, observable background and severe non-proliferative/proliferative 
retinopathy based on the Scottish diabetic retinopathy grading scheme (Table 1-2). The 
diagnosis of severe non-proliferative/proliferative retinopathy was also identified from the 
evidence for laser photocoagulation treatment. Retinopathy samples were pooled from both 
type 1 and type 2 diabetic populations.  
 
We additionally extracted demographic data and biochemistry measurements taken 
immediately prior to or on the GoDARTS recruitment date. We log-transformed and 
subsequently standardised BMI, total cholesterol, serum creatinine, HbA1c, HDL-c, SBP 
and triglycerides. 
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2.4.2 Genotype data 
2.4.2.1 Typed SNP data quality control 
SNP data for 3,734 GoDARTS patients typed on the Affymetrix Genome-wide Human 
SNP Array 6.0 was included in this analysis. We included biallelic autosomal SNP markers 
based on the quality control (QC) criteria: missingness < 0.03, Hardy-Weinberg 
equilibrium (HWE; P > 10
−3
) and minor allele frequency (MAF) > 0.005. SNP alleles were 
aligned to the forward/+ strand, and the rs numbers and genome positions of SNPs were 
uplifted from the human genome build 36 to build 37. This retained 732,651 SNPs for the 
Affymetrix genotype data.  
 
Study subjects were checked for the match between clinical reported and genotype genders, 
and additionally were filtered based on the missingness threshold of 0.035, heterozygosity 
(the false discovery rate, or FDR, at level 0.01, following the Benjamini-Hochberge 
controlling procedure [95], or BH95). Population stratification was assessed in the 
multidimensional scaling analysis by integrating with SNP data of 1000 Genomes reference 
populations.  
 
2.4.2.2 Imputation 
We used the imputation technique to augment genome-wide SNPs in this study. Imputation 
is a statistical method for predicting unobserved genotypes in the study sample based on the 
correlation of observed study haplotypes guided by the reference haplotypes of a similar 
genetic population [96] (Figure 2-2). To reduce the computational burden, prior to 
imputation, insertions and deletions, structural variants, singletons (these are, SNPs that 
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have only one copy of the minor allele in the sample genotype data) and monomorphic 
SNPs (these are, SNPs with a single form of allele in the population studied) were removed 
from the 1000 Genomes Project European CEU data (phase 1 version 3; 379 individuals), 
resulting in over 12.3 million SNPs retained in the reference panel. To reliably impute our 
genotype data that includes genetic related individuals, we utilised the MaCH-Admix 
program (version beta 2.0.185), which has been developed with the capabilities of imputing 
individuals independently based on preceding calibration of model parameters [97]. More 
than 12.3 million SNPs were successfully imputed for the Affymetrix genotyped sample. 
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Figure 2-2 The method of genotype imputation applied to a genetically unrelated 
sample [98]. The study sample consists a set of genotypes that are present in a more 
densely genotyped reference panel (panel A). The haplotypes of the study samples are 
compared to that in the reference panel for a match (panel B). Missing genotypes are 
imputed to the study sample based on the genotypes in the matched haplotype (panel 
C).  
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2.4.2.3 Post-imputation genetic and sample data quality control 
We included imputed SNPs based on the MACH 2rˆ  measure (that is, the estimate for the 
squared correlation between imputed and true genotypes; [99]) ≥ 0.5 and MAF ≥ 0.01. We 
assessed minor allele counts for each imputed SNP, and none was below 10. We excluded 
SNPs that have triple alleles reported in the dbSNP database, and common SNPs (MAF   
0.05) with a HWE P value < 10
-3
 or less common SNPs (MAF < 0.05) with a HWE P value 
< 10
-6 
in diabetic retinopathy controls (these are defined as patients with four years’ 
duration of diabetes but without retinopathy, maculopathy, or evidence for laser 
photocoagulation treatment).  
 
We filtered out imputed SNPs with the MACH 2rˆ  measure   0.98, and used the most 
probable genotypes of these SNPs only for the estimation of identity-by-descent (IBD). We 
identified individuals marked by the same identifier but with the IBD estimate < 0.80, far 
less than the expected IBD estimate of 1.00. Additionally, we identified individuals with 
non-identical birth dates but strongly closely related (IBD > 0.80). We removed these mis-
identified individuals from the sample, resulting in a final sample of 3,701 individuals.  
 
2.4.3 Statistical analysis 
Owing to the intractability of the published software for estimating heritability of a 
polychotomous trait (for example, retinopathy) and genetic (or residual) correlation 
between polychotomous and quantitative traits (for example, retinopathy with one of the 
described risk factors) from genome-wide SNP data, we used Gibbs sampling for 
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estimating variance components. The strategy for Bayesian inference in multivariate 
models using Gibbs sampling was previously published [100,101], and thanks to the work 
of Dr. Minghui Wang, Birmingham University, the efficient implementation of these 
models was made feasible by reducing the computational time for Henderson's Mixed 
Model Equations in Gibbs sampling. We leveraged his software for the analysis of 
heritability and genetic correlations in common genome-wide SNPs for diabetic retinopathy 
and related risk factors. We briefly describe the basis for these models.  
 
2.4.3.1 Phenotype correlations 
Phenotype correlations between a pair of quantitative traits, a single ordinal trait with a 
continuous outcome, and two ordinal traits, namely, Pearson, polyserial and polychoric 
correlations respectively, were estimated using the “polycor” package (version 0.7.8) in the 
R programming environment (version 3.0.0). Confidence intervals were estimated from 
Fisher transformation as follows [102] 
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where r is the sample correlation coefficient. The z statistic is approximately normally 
distributed with mean and variance [102] 
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where ρ is the population correlation coefficient; N  is the sample size.  
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2.4.3.2 Genetic similarity matrix estimation 
The genetic similarity matrix is estimated from the sum of products of SNP correlation 
coefficients for pairs of individuals in Fortran 90 programming environment, which enables 
efficient computation with millions of SNPs. We used whole genome imputed SNP dosage 
data to construct the relatedness matrix ( Gˆ ) from standardised genotypes [103] as follows: 
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where individuals i and j can be the same or different individuals, and xil (xjl) is the 
genotype dosage based on the minor allele in individual i (j) at locus l with allele frequency 
lp  and 1l lq p  , where there are L loci in total under consideration. This pairwise 
relatedness measure can be either positive or negative in value, and thus, the term of 
“similarity” is prevailing in literature instead of “relationship” in describing this matrix.  
 
To ensure allele frequencies used in computing the genetic similarity matrix was unbiased 
by sample structure, we kept 6,830,657 imputed autosomal SNPs with minor allele 
frequencies more than 0.01 in the genetically unrelated sample (IBD less than 0.05) for the 
estimation of the genetic similarity matrix.  
 
Several related estimation approaches with slight modifications for the genetic similarity 
matrix have been published, including a relatedness matrix constructed from cantered 
genotypes 
1
1ˆ ( 2 )( 2 )
L
ij il l jl l
l
G x p x p
L 
    [103] and an adjustment in estimating the 
standardised genotype relatedness matrix for the same individuals using 
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   , in order to minimise sampling noise [104]. These 
matrices performed similarly in modelling of narrow-sense heritability [103]. However, 
occasionally one or more of these matrices may not be invertible, rendering the modelling 
process intractable, and thus any matrix that is positive definitive [105] is preferred.  
 
2.4.3.3 Analysis of a single trait 
With the estimated genetic similarity matrix, we used univariate mixed models to partition 
phenotypic variations of single quantitative or polychotomous traits into genetic and 
residual variations, and the theoretical strategies were previously presented [100,104,106]. 
For a quantitative trait, the linear mixed model relating phenotypes to genetic relatedness is 
described by 
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where y is a vector of single-trait quantitative measures for n individuals; β is a vector of 
regression coefficients of fixed effects for the overall mean and covariates; g is an n-vector 
of total additive genetic effects, and is treated as random effects normally distributed with 
variance 2g  and correlation structure represented by additive genetic relatedness matrix Gn; 
X is a design matrix relating fixed effects to individuals; ε is an n-vector of residual terms 
normally distributed with variance 2  and correlation structure represented by identity 
matrix In. MVNn represents multivariate normal distribution of order n. Therein, the 
variance structure of the response variable (V) is  
 2 2n g nV G I      0.1 
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The coefficient of heritability 2
gh   is estimated by  2 2 2/g g    . 
 
An ordered categorical trait in the studies of quantitative genetics is considered as discrete 
observed classes derived from an underlying risk gradient that is often unobserved, through 
fixed thresholds [107]. This latent quantitative variable is named liability (l) in genetics 
studies [107]. For example, considering hypertension versus non-hypertension, the 
observation would be in the hypertensive category, if the blood pressure measurement 
(SBP/DBP) at the rest state exceeds the threshold of 140/90 mmHg. The liability model is 
defined as [107] 
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where l is an n-vector of liabilities which are multivariate normally distributed with mean  
Xβ + g and variance-covariance matrix 2
nI  ; by convention, residual variance for liabilities 
is parameterised as 2 1   [107]; other terms are identically defined as in the linear mixed 
model, but are quantified on a liability scale. 
 
In the liability model, individuals with observed ordinal categories (y = {yi} where i 
indexes the ith individual) have liabilities bounded by a pair of threshold values in the set 
( min 1 2 1 maxct t t t t      where there are c + 1 hypothetical thresholds for c mutually 
exclusive but exhaustive categories; the extreme thresholds  min 0t t  and max ct t ) [107]. 
For example, if a liability value is between 0t  and 1t , the assignment is into the first 
category . Formally, the categorical assignment is described by 
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where j is the categorical response (j = 1, 2, …, c) for individual i, and 0 1( , ,..., )ct t t t  is a 
vector of thresholds; other terms were described before. It is the convention to fix 0t   , 
1 0t   and ct    so as to centre the liability distribution [107]. In the threshold model for 
categorical traits, an unselected sample that reflects the prevalence of categories in the 
population is required for unbiased inference of heritability.  
 
2.4.3.4 Analysis of correlated traits 
With the estimated genetic similarity matrix, we also applied multivariate mixed models to 
partition phenotypic variations for a pair of related traits to genetic and residual variations 
and covariance for genetic and residual effects. In this analysis, each individual has 
measurements for two different traits such that in the matrix form,  
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where the subscripts are used to differentiate the two traits; each of 
(1)  and (2)  represents 
the observed quantity if the trait is continuous, or the measure of liability if the phenotype 
is polychotomous; other terms have been previously described, and are expressed on the 
same scale as the variable η. In this form, the variance-covariance matrices are 
 
(1) (1) (2)
(1) (2) (2)
2
(1)
2
(2)
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g g g
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G Var g Var G
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 
 
  
           
  0.1 
 
(1) (1) ( 2)
(1) ( 2) ( 2)
2
(1)
2
(2)
( ) nR Var Var I
  
  
 

  
  
           
 0.1      
where    is the kronecker product operator; G is the variance-covariance matrix of 
additive genetic effects across two traits; R is the variance-covariance matrix of residual 
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terms of two traits; 
( )
2
ig
  (
( )
2
i
 ) is the genetic (residual) variance for the ith trait, and 
(1) ( 2 )g g
  
(
(1) ( 2 ) 
 ) is the genetic (residual) covariance between the two traits; other term were 
previously described. The genetic (residual) correlation coefficient rg (re) is defined as 
(1) ( 2)
(1) ( 2)
g g
g
g g
r

 
   (
(1) ( 2)
(1) ( 2)
r
 

 

 
 ).  
 
2.4.3.5 Bayesian Markov chain Monte Carlo (MCMC) inference 
Analysis of single and joint quantitative traits to estimate model parameters including 
variance and covariance for genetic and residual components can be readily implemented 
using the restricted maximum likelihood (REML) method [104,108]. However, the analysis 
of single polychotomous trait or the joint analysis of ordinal and quantitative traits becomes 
intractable with the REML estimation procedure, and thus at the current time, no REML-
based software is available for this analysis. The Bayesian MCMC approach provides an 
alternative strategy for estimating variance components in the analysis of variations of 
single or joint traits of quantitative and/or polychotomous nature. In this study, ten 
independent Markov chains were run for each trait or combination of traits based on 
random initials for genetic and residual variance, with starting values for fixed effects and 
random effects set to zero. To ensure stochastic sampling, random seeds were set for these 
independent chains. For the univariate mixed model, a single MCMC chain was run for 3 
million iterations, with first 0.5 million samples discarded (burn-in), and thereafter samples 
were saved every 100 iterations. For a bivariate mixed model where both phenotypes were 
quantitative, a pair of chains was run according to the same specification. Either stationary 
chain was used in this study. If an MCMC diagnostic indicates more MCMC samples 
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required for either chain and both chains passed the stationarity test, samples from both 
chains were combined. If only one chain reached stationarity but more MCMC samples 
required, ten short MCMC chains were run in parallel, using the last sample of the 
stationary chain as the initial parameter values. Each of these short chains was run with 
random seeds for 0.1 million iterations without burn-in, and samples were saved every 100 
iterations. Short chains were merged with the long chain. These strategies aimed to 
augment MCMC samples without re-implement MCMC sampling from the start, which 
was computationally intensive. As we anticipated intense compute time for a bivariate 
mixed model where at least one phenotype was ordinal, four chains were run for 1 million 
iterations, with first 0.5 million samples burnt in, and thereafter sampling at the interval of 
100 iterations. These MCMC samples were assessed for stationarity, and were combined.  
 
In contrast to the REML method, which evaluates the probability of observed data given a 
set of parameter values (that is, the likelihood), the Bayesian approach estimates the 
probability of a set of parameter values given observed data (that is, the posterior 
probability). In Bayes’ theorem, the posterior probability is proportional to the product of 
the likelihood and the prior probabilities for the set of parameters. In combination with the 
Bayesian approach, MCMC methods construct a Markov chain for each model parameter 
and sample from the target distribution [107]. Gibbs sampling algorithm is a special case of 
MCMC methods, in which the joint posterior probability distribution is unknown, and each 
model parameter is sampled from the conditional posterior probability distribution [107]. 
 
In the analysis of single quantitative trait, the joint posterior probability based on model 0.1 
is written as 
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2 2 2 2
2 2 2 2 2 2
( , , , | , , , , , , )
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   
  
     
  0.1 
where 2( | , , , )p y X g    is the likelihood function; ( )p  , 
2( | , )n gp g G  , 
2 2( | , )g g gp v S  and 
2 2( | , )p v S    are prior distributions for model parameters β (regression coefficients for the 
fixed effect), g (total additive genetic effects), 2
g  (additive genetic variance) and 
2
  
(residual variance), respectively; other terms are defined identically as in Model 0.1. The 
prior distribution for  regression coefficients β is a uniform distribution [100], and total 
additive genetic effects g are sampled from multivariate normal distribution as specified in 
Model 0.1. The prior distribution for genetic and residual variance is inverse-gamma 
distribution with probability density function [100]  
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where 
gv  and 
2
gS   ( v  and 
2S ) are hyper-parameters for genetic (residual) variance. We 
specified slightly informative prior parameters with 3gv v   and 
2 2 1gS S  . The Gibbs 
sampler updates conditional posterior probabilities for each of the model parameters (β, g, 
2
g  and 
2
 ) sequentially through  
 2 2 2( , | , , ) ( | , , , ) ( | , )n gp g y X p y X g p g G        0.1 
 2 2 2 2 2( | , , ) ( | , ) ( | , )g g g g n g g gp g v S p g G p v S     0.1 
 2 2 2 2 2 2( | , , , , , , ) ( | , , , ) ( | , )p g y X v S p y X g p v S              0.1 
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In the analysis of a single polychotomous trait, joint posterior probability distribution for 
Model 0.1 is similar to that for based on a single quantitative trait (Model 0.1) 
 
2 2 2 2
2 2 2 2 2 2
( , , , , , | , , , , , , )
( | , ) ( | , , , ) ( ) ( ) ( | , ) ( | , ) ( | , )
g n g g
n g g g g
p g l t y X G v S v S
p y l t p l X g p t p p g G p v S p v S
  
   
  
     
 0.1 
where l is a vector of liabilities; t is a set of thresholds previously defined for Model 0.1; 
( | , )p y l t  is the likelihood function; 2( | , , , )p l X g   , p(t) are prior distributions for 
parameters l and t, respectively; other terms have been described previously. 
2( | , , , )p l X g    is a multivariate normal density function, and p(t) has a uniform 
distribution [100]. Parameter values were iteratively updated through a conditional 
posterior probability density function derived from (Model 0.1) by the Gibbs sampler, and 
these formulae were omitted here.  
 
In the analysis of a pair of quantitative traits, based on Model 0.1, if we let  (1) (2)( , )
T T T    
and (1) (2) (1) (2)( , , , )
T T T T Tg g    , where T denotes transposition and η represents quantitative 
outcome y for the two traits, the joint posterior distribution is described by 
 ( , , | ) ( | , ) ( | ) ( ) ( )p G R y p y R p G p G p R     0.1 
where p(y|θ,R) is the likelihood function, and p(θ|G), p(G) and p(R) are prior probabilities 
for model parameters θ, G and R, respectively; for simplicity, genetic similarity matrix (Gn), 
the design matrix for fixed effects (X) are omitted; other terms have been previously 
described in Model 0.1. In the analysis of a pair of quantitative and ordinal traits jointly, η 
simultaneously represents quantitative outcome for the quantitative trait and liability for the 
ordinal trait, and joint posterior distribution is written as 
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where yc and ηc are observed categorical outcome and liability respectively for the ordinal 
traits in the bivariate model; other terms were previously described. Prior uncertainty about 
genetic and residual covariance matrix G and R is an inverse Wishart distribution of order 3 
(that is, genetic variance for the two traits respectively and covariance between these two) 
specified by [101] 
 
1
( 3 1)
2 2 12
1
( 3 1)
2 2 12
3 1
| , | | exp
2
3 1
| , | | exp
2
gv g
g g g
v
v
G v S G tr S G
v
R v S R tr S R
 
  
  

  

     
   
   
    
   
  
  0.1 
where | G |  (| R |) is the determinant of the genetic (residual) covariance matrix; tr denotes 
the operation of trace for a square matrix; 
gv  and 
2
gS  ( v  and 
2S ) are parameters for the 
genetic (residual) variance matrix, and were set as slightly informative prior parameters 
with 5gv v   and 
2 2
2gS S I  ; tr denotes the trace operation.  
 
2.4.3.6 MCMC stationarity diagnostics 
The “coda” package (version 0.16.1) in the R programming environment (version 3.0.0) 
provides utilities for diagnosing convergence of MCMC chains. In this study, quality 
control (QC) for MCMC chains was based on the Geweke and Heidelberg-Welch 
diagnostics, and additionally, the Gelman-Rubin multi-sequence diagnostic was applied to 
assess the stationarity of multiple MCMC chains.  We only used MCMC data that passed 
through the stationarity diagnostics.  
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The Geweke test estimates the difference of means for a model parameter sampled from 
two non-overlapping parts (by default, the initial 0.1 and final 0.5 portions) in the same 
Markov chain [109]. When the Markov chain is convergent, no difference in the means is 
observed (the null hypothesis) [109]. If MCMC chain reaches stationarity, the Geweke’s 
standard Z-score should be between -1.96 and 1.96 in keeping with alpha level (the false 
positive rate) of 0.05.  
 
Additionally, we used the Heidelberg-Welch diagnostic for assessing whether a sequence of 
parameter values or a proportion of this sequence converged to a stationary distribution 
(that is, the target probability distribution, described fully in [110]). The Heidelberg-Welch 
diagnostic also provides the assessment whether an MCMC chain should be run for longer 
to have narrow halfwidth (half the width of the credible interval around the mean). The 
halfwidth test statistic is the halfwidth normalised by the posterior mean, and to pass the 
halfwidth test, the test statistic should be smaller than a target value (0.1 by default). If the 
posterior mean of MCMC samples is close to 0, the halfwidth test statistic is substantially 
large, resulting in the failure of the halfwidth test. In this case or the case where multiple 
parallel MCMC chains were run, the halfwidth test was not necessary and therefore not 
applied. 
 
The Gelman-Rubin multi-sequence diagnostic estimates the within-chain and between-
chain variances [111]. If the chains have reached stationarity, these are unbiased estimates 
of the variance of the stationary distribution. Otherwise, the within-chain variance is an 
underestimate for the variance of the stationary distribution, and the between-chain 
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variance is an overestimate for the same parameter. The potential scale reduction factor is 
the reflection of the overdispersion of the stationary distribution variance compared to the 
within-chain variance. If this test statistic is larger than 1.2, we consider these parallel 
MCMC chains have not reached stationarity.  
 
2.5 The SUMMIT genome-wide meta-analysis of diabetic 
retinopathy 
2.5.1 Study sample 
In the GoDARTS cohort, the data has been based on diabetic retinopathy, maculopathy data 
and the evidence for laser photocoagulation treatment ascertained from the June 2011 
release of the SCI-DC diabetes eye screening data set. Observable background, severe non-
proliferative and proliferative retinal events (Table 1-2) are registered in the national and 
regional retinal screening service or the validation database, and these programs have 
vigorous adherence to the national clinical guidelines. Evidence for laser photocoagulation 
treatment, diabetic maculopathy and data of no-retinopathy were included from all retinal 
examinations documented in the diabetes eye screening data. Diabetic retinopathy was 
defined as the diagnosis of observable background, severe non-proliferative and 
proliferative retinopathy, or the evidence for laser photocoagulation treatment based on the 
worst affected eye. Individuals with diabetes duration of at least 4 years (Figure 2-3), free 
of any retinopathy or maculopathy (Table 1-2 and Table 1-3) and if alive, with available 
retinal records within between January 2006 and June 2011 were included as controls. This 
definition aimed to ensure the case-control selection was robust. 
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Figure 2-3 Duration of diabetes for genotyped retinopathy cases (n = 2447) and 
controls
*
 (n = 2968) in the GoDARTS cohort prior to the SUMMIT whole-genome 
meta-analysis. Negative duration of diabetes is likely to be noise associated with 
primary retinopathy data. *No restriction on patients’ diabetes duration or the last 
date of retinopathy data.  
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In addition, we had the support from the SUMMIT cohorts for genome-wide meta-analysis. 
The SUMMIT study of retinopathy meta-analysis in type 1 and type 2 diabetic cohorts 
included the EURODIAB (Epidemiology and Prevention of Diabetes) IDDM (Insulin-
Dependent Diabetes Mellitus) complications study [112], the FinnDiane (Finnish Diabetic 
Nephropathy) study [70] and the SDR (Scania Diabetes Registry) cohort [113].  
 
The EURODIAB cohort is a cross-sectional study of microangiopathy and acute 
complications in 3,250 type 1 diabetic patients recruited from 16 nations in Europe [112]. 
Patients aged 15-60 stratified by age, diabetes duration and gender were invited for 
enrolment [112,114]. Two-field retinal photographs were taken for both eyes, and graded 
with reference to standard photographs [114].  
 
The FinnDiane cohort is a cross-sectional study of genetic and environmental influences for 
nephropathy in 4,800 adults with type 1 diabetes recruited across Finland [70,115]. Cohort 
subjects were diagnosed before age 35 and offered insulin treatment from the first year of 
diagnosis [70,115].  
 
The SDR cohort is a longitudinal study of diabetes and chronic complications in southern 
Sweden since 2000 [113,116]. At the time of the study, the SDR cohort recruited 1,264 
type 1 and 5,123 type 2 diabetic patients [113].  
 
In the SUMMIT meta-analysis, diagnosis of diabetic retinopathy was based on information 
on fundus photography, ophthalmoscopy or laser treatment for diabetic retinopathy. To be 
informative for the definition of proliferative retinopathy, the specification for the fundus 
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photograph was at least 45-degree coverage of the retina or 30-degree coverage of the 
macula. Diabetic retinopathy was defined as type 1 or type 2 diabetic patients with at least 
moderate background retinopathy (ETDRS>40, NSC, SDRGS=R2), mild background 
retinopathy (ESDRS=30-39, NSC) with duration of diabetes at retinopathy assessment < 10 
years, or treated with panretinal laser therapy. Controls were defined as individuals with no 
recorded background retinopathy, maculopathy or panretinal laser therapy. These 
individuals should have at least 4 years duration of diabetes. If retinal photographs were 
unavailable but positive evidence of no laser treatment was available, individuals with 
duration of diabetes > 20 years were also included in the study as controls. Individuals with 
maculopathy were excluded from the control sample. 
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Table 2-1 Equivalence of diabetic retinopathy coding in differeent clinical 
classification systems, tabluated by Professor Colin Palmer and Dr Alex Doney, 
University of Dundee. ETDRS: the Early Treatment Diabetic Retinopathy Study; 
NSC: the National Screening Committee; SDRGS: the Scottish Diabetic Retinopathy 
Grading Scheme; BDR: background diabetic retinopathy; NPDR: non-proliferative 
diabetic retinopathy; PDR: proliferative diabetic retinopathy. 
 
ETDRS NSC SDRGS 
10 None R0 None R0 None 
20 Microaneurysms only R1 Background R1 Mild BDR 
35 Mild NPDR 
43 Moderate NPDR R2 Pre-proliferative 
 
 
R2 Moderate BDR 
47 Moderately Severe NPDR 
53 A-D Severe NPDR R3 Severe BDR 
53 E Very severe NPDR 
61 Mild PDR 
65 Moderate PDR 
R3 Proliferative 
 
R4 PDR 
 
71, 74 High risk PDR 
81, 85 Advanced PDR 
 
2.5.2 Genotype data 
This study constitutes of Work Package 1 that focussed on genetic markers for type 1 and 2 
diabetes complications in SUMMIT, and Natalie Van Zuydam, Oxford University, kindly 
offered to perform pre-imputation quality control and imputation in GoDARTS samples 
typed on Affymetrix Genome-wide Human SNP Array 6.0 and Illumina 
HumanOmniExpress BeadChip for SUMMIT project use within GoDARTS research 
groups. Harshal Deshmukh (Dundee University), Niina Sandholm (Helsinki University) 
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and Emma Ahlqvist (Lund University) performed genome-wide association scans of 
diabetic retinopathy for the EURODIAB, FinnDiane and SDR cohorts, respectively. 
 
Genome-wide genotyping information is provided in Table 2-2. Standard quality control 
filters were applied (Table 2-3). In this study, bilallelic autosomal SNPs were included, and 
the coding of SNPs was aligned to the forward/+ strand of the human genome build 37. 
 
Study subjects were reviewed for the match between clinical reported and genotype genders, 
and additionally were filtered for heterozygosity. Population stratification was assessed in 
the multidimensional scaling analysis (plotted with 1000 Genomes reference populations).  
 
Genome-wide SNP markers were imputed to 1000 Genomes reference data (phase 1 
version 3; 379 individuals). SHAPEIT (version v1.ESHG, [117]) was used for inferring 
haplotypes in the study samples, and IMPUTE (version 2, [96]) was employed for genotype 
imputation in haplotype data. The resulting imputed data is in genotype probabilities. In the 
FinnDiane and SDR studies, MACH (version 1.0, [118]) was also used for genotype 
imputation, and the resulting genotypes are expressed in dosages, which was suited for 
association analysis, where genotype dosages was required. Genotype probabilities can also 
be transformed to dosages in custom scripts following the formula as in [119]: 
2
0
(G x)* x
x
P

 where x is the additively coded genotype value; G is the variable for 
genotype; (G x)P  is the genotype probabilities. Imputed variant data that failed the quality 
control procedures (Table 2-3) are not reported. 
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Table 2-2 Genotyping information for the meta-analysis study cohorts. 
 
Cohort Genotyping chip(s) 
EURODIAB Illumina HumanOmniExpress BeadChip 
FinnDiane Illumina 610Quad chip 
GoDARTS Affymetrix Human SNP Array 6.0 and Illumina HumanOmniExpress 
BeadChip 
SDR Illumina HumanOmniExpress BeadChip 
 
 
Table 2-3 Quality control (QC) filters applied to genome-wide meta-analysis study 
cohorts.HWE-P: Hardy–Weinberg equilibrium P value; INFO: the IMPUTE software 
quality control measure [99]; SCR: sample call rate; MAC: minor allele count; 
MACH r2: the MACH software quality control measure [99]; MAF: minor allele 
frequency; VCR: variant call rate. 
 
Cohort Pre-imputation QC Post-imputation QC 
EURODIAB HWE-P>10
-6
; 
MAF>0.01; VCR>0.95 
HWE-P>10
-6
; INFO>0.40; MAF>0.01 
FinnDiane HWE-P>10
−7; 
MAF> 
0.01; SCR>0.95, 
VCR>0.90 
HWE-P>10
-4
 for MAF<0.05; HWE-P>5.7×10
-7
 
for MAF>0.05; INFO>0.40 or MACH r
2
>0.30; 
MAF/MAC>0.01/10 
GoDARTS HWE-P>10
-6
; 
MAF>0.01; VCR>0.99 
HWE-P>10
-6
; MACH r
2
>0.50; MAF>0.01 
SDR HWE-P>10
−7
; 
SCR>0.98; VCR>0.95 
HWE-P>10
-4
 for MAF<0.05; HWE-P>5.7×10
-7
 
for MAF>0.05; INFO>0.40 or MACH r
2
>0.30; 
MAF>0.01 
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Table 2-4 Imputation software employed for the whole-genome meta-analysis study 
cohorts. IMPUTE2 (version 2.3.0); MACH (version 1.0); SHAPEIT (version 2). 
 
Cohort Imputation software 
EURODIAB SHAPEIT with IMPUTE2 
FinnDiane SHAPEIT with IMPUTE2; MACH 
GoDARTS SHAPEIT with IMPUTE2 
SDR SHAPEIT with IMPUTE2; MACH 
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2.5.3 Statistical analyses 
The genetically unrelated sample was defined by an IBD estimate <0.05 between any pair 
of individuals, and the genetically mixed sample was inclusive of related and unrelated 
samples. Genome-wide association analyses were performed in each study cohort, and the 
whole genome meta-analysis of diabetic retinopathy was analysed by Dr. Niina Sandholm, 
Helsinki University. Subsequently, I annotated and summarised the data of genome-wide 
meta-analysis was annotated and summarised for this study. Genome-wide association 
analysis methodologies in each study are provided in Table 2-5. We used SNPTEST 
(version 2.4.1) for the genome-wide association analysis of the unrelated sample, and the 
genotype uncertainty was accounted for in the likelihood score test. In the analysis of the 
genetically mixed sample, EMMAX (version beta, [120]) or GEMMA (version 0.93, [121]) 
was used for efficient implementation of linear mixed models for genome-wide variants, 
accounting for population structure in the genetically mixed sample.  
 
As EMMAX or GEMMA provides P values as the test statistic as opposed to the log odds 
ratio as the effect estimate in SNPTEST, genome-wide meta-analysis for the genetically 
mixed sample was implemented in METAL (released on 2011-03-25, [122]) based on the Z 
score approach. In this approach, P values were transformed into Z scores according to the 
standard normal cumulative distribution function, and the sign of the Z score is reflective an 
increased or decreased risk associated with the reference allele [122]. Z scores were 
combined across studies in a weighted sum, and the weights are proportional to the square 
root of study sample sizes [122]. In the genetically unrelated sample, fixed effect meta-
analysis of genome-wide variants was implemented in GWAMA (version 2.1, [123]). This 
86 
 
 
 
methodology is based on the inverse variance weighting, in which the effect estimates 
weighted by the inverse of squared standard error were combined across studies [123].  
 
Heterogeneity of effect sizes across studies were assessed by Cochran’s Q test and I2 index 
[124]. Cochran’s Q statistic is the weighted sum of squared difference of study effects and 
the pooled effect in the meta-analysis. The weights are identically defined as in the Z score 
method or the fixed effect inverse variance model [124]. Cochran’s Q statistic follows the 
chi-square distribution with the degree of freedom being the number of studies subtracted 
by one. I
2
 index depicts the variation across studies attributable to heterogeneity rather than 
by chance, and the estimation equation is described in [124].  
 
With the use of the CaTS (version 0.01) [125], we estimated power for each additive 
association test of single markers in the genome-wide meta-analysis of diabetic retinopathy, 
assuming the prevalence rate of 9.59% as in GoDARTS with a variability of relative risks 
and SNP minor allele frequency. Relative risk and odds ratio is interconvertible by [126] 
 
   1 ref ref
OR
RR
P P OR

  
  0.1 
where OR  is the odds ratio;
refP  is the baseline prevalence in the non-exposed group; RR is 
the relative risk. 
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Table 2-5 Genome-wide association analysis information of each cohort. EMMAX 
(version beta); GEMMA (version 0.93); SNPTEST (version 2.4.1). PC1: the first 
principal component; PC2: the second principal component.  
 
Cohort Analysis software Covariates 
EURODIAB SNPTEST and EMMAX Age, diabetes duration, PC1, PC2, sex 
FinnDiane SNPTEST and EMMAX Age, diabetes duration, HbA1c, PC1, PC2, sex 
GoDARTS SNPTEST and GEMMA Age, HbA1c , sex  
SDR SNPTEST and EMMAX Age, diabetes duration, HbA1c, sex 
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Chapter 3  
The influence of population risk factors on 
diabetic retinopathy severity over the 
duration of diabetes 
 
3.1 Introduction 
The multi-stage clinical classification of diabetic retinopathy development has prompted 
the wide use of categorical data analysis strategy in clinical studies. Commonly, cross-
sectional studies use diabetic retinopathy case and control samples in logistic regression 
analysis and/or contingency tables for modelling population risk factor effects [127–130]. 
Other studies have utilised the longitudinal nature of diabetic retinopathy progression in 
proportional hazard models [131,132]. To date, however, only one study [92] has included 
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intermediate states from longitudinal, multi-state diabetic retinopathy data in the analysis, 
an approach which provides an increased ability to decipher the stage-wise development of 
retinopathy compared with a simple survival analysis.  In the Genetics of Diabetes Audit 
and Research in Tayside Scotland (GoDARTS) database, we have ongoing, longitudinal 
collection of diabetic retinopathy clinical outcome from 1990 for Tayside patients with 
diabetes, and additionally we have access to all biochemistry measurements for these 
patients. These rich data resources enable us to investigate changes in patients’ retinal 
status over the duration of their diabetes. A multi-state Markov model was developed to 
analyse panel data of a complex, multi-staged disease process in continuous time [133]. 
This longitudinal analysis approach has recently been applied in a wide range of medical 
fields, including hepatic cancer [134], diabetic complications [92,135], breast cancer 
screening [136] and liver cirrhosis [137]. The early study [92] on diabetic retinopathy using 
the multi-state Markov approach was not able to assess the clinical effects of relevant risk 
factors on diabetic retinopathy state transitions, possibly owing to insufficient 
computational power back in the mid-1990s. In this study we have used the GoDARTS 
database to incorporate longitudinal measures of multiple risk factors and assess their role 
in the specific developmental stages of diabetic retinopathy. 
 
3.2 Results 
3.2.1 Characteristics of the study sample 
Overall 49,959 retinal measurements were studied in 4,758 diabetes patients who were 
retinopathy free at diagnosis of diabetes. At the end of this study, 100 patients developed 
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severe non-proliferative/proliferative diabetic retinopathy. The raw data on clinical 
characteristics, observed state transitions, numbers of retinal events over duration of 
diabetes, and the prevalence of diabetic retinopathy with and without stratification by first-
year DBP, SBP and HbA1c is shown in Table 3-1, Table 3-2, Table 3-3, Figure 3-1 and 
Figure 3-2.  
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Table 3-1 Death, diabetes treatment, cardiovascular (a constellation of coronary 
artery disease, ischaemic stroke and lower extremity arterial disease) and chronic 
kidney disease (estimated glomerular filtration rate < 60) profiles for diabetic 
retinopathy patients included in the longitudinal study.  
 
Diabetic retinopathy 
patients n (%) 
4758 (100%) 
Death n (%) 711 (14.9%) 
Diabetes treatment (n, %) Diet only (1285, 27.0 %), Insulin (428, 9.0 %), Oral agents 
(2444, 51.4 %), Oral agents and Insulin (148, 3.1 %) 
Cardiovascular disease n 
(%) 
1427 (30.0 %) 
Chronic Kidney Disease 
n (%) 
1171 (24.6 %) 
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Table 3-2 Frequency counts of the transition across states in successive clinical visits 
and the longitudinal diabetic retinopathy events (in parentheses). State 1: no-
retinopathy; State 2: mild background retinopathy; State 3: observable background 
retinopathy; State 4: severe non-proliferative/proliferative retinopathy. Interval 
censored retinal states 21, 31 and 32 were defined to represent multiple observed 
states on the same record date, which were either state 1 or 2, either of state 1 and 3, 
and one of the set of state 2 and 3, respectively. A right censor was considered to be 
state-unknown (either state 1, 2, 3 or 4). 
 
 To 
From State 1 State 2 State 3 State 
4 
State 2 
or 1 
State 
3 or 
1 
State 
3 or 
2 
Right 
censor 
 (39282) (4478) (1011) (100) (561) (64) (143) (4320) 
State 1 32198 2273 549 34 338 13 63 3619 
State 2 1640 1777 190 30 91 3 21 611 
State 3 442 187 243 30 3 19 32 49 
State 2 or 
1 198 170 2 4 126 2 1 38 
State 3 or 
1 18 6 3 0 3 26 8 0 
State 3 or 
2 28 65 24 2 0 1 18 3 
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Table 3-3 The numbers of individuals occupying each observed state (non-censored 
state) at one year interval in the GODARTS panel data of retinopathy. A prior 
retinopathy event recorded the latest in relation to the time point specified was used in 
the estimation, even if more than one retinal event was recorded per year. The last 
observed retinal event for each patient were summed at the closest, later time point, 
and with a non-absorbing retinal event, the last observed retinal event was not 
accumulated into the estimation at a later time interval. The diagnosis of severe non-
proliferative/proliferative retinopathy, an absorbing retinal event, was accumulated 
into the later estimations till 16 years. 
 
Year 
No-
retinopathy 
Mild 
background 
retinopathy 
Observable 
background 
retinopathy 
Severe non-
proliferative/proliferative 
retinopathy Total 
1 4662 44 50 2 4758 
2 4485 175 81 10 4751 
3 4256 260 89 15 4620 
4 3984 318 89 21 4412 
5 3630 348 88 24 4090 
6 3202 356 91 30 3679 
7 2796 329 84 39 3248 
8 2344 344 67 50 2805 
9 1906 349 58 58 2371 
10 1526 335 58 64 1983 
11 1215 303 39 81 1638 
12 894 261 28 89 1272 
13 675 232 20 94 1021 
14 480 198 14 96 788 
15 323 148 13 99 583 
16 196 117 6 100 419 
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Figure 3-1 Prevalence of diabetic retinopathy in the GODARTS panel data by 
duration of diabetes. This shows the retinopathy state as a percentage of the sample, 
recorded at each year of duration of diabetes from 1 to 16 years of diabetes duration. 
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Figure 3-2 Prevalence of diabetic retinopathy states in the GoDARTS panel data, 
stratified by first-year DBP, SBP and HbA1c respectively. Sample sizes for DBP: 
tertile 1 (n = 1573), tertile 2 (n = 1690), and tertile 3 (n = 1495). Sample sizes for SBP: 
tertile 1 (n = 1609), tertile 2 (n = 1853), and tertile 3 (n = 1296). Sample sizes for 
HbA1c: tertile 1 (n = 1668), tertile 2 (n = 1514), and tertile 3 (n = 1576). DBP tertile 
cutoffs: 77.0 mmHg and 86.0 mmHg; SBP tertile cutoffs: 132.0 mmHg and 150.0 
mmHg; HbA1c tertile cuffoffs: 45.0 mmol/mol (6.3%) and 57.0 mmol/mol (7.4 %). 
State 1: no-retinopathy; State 2: mild background retinopathy; State 3: observable 
background retinopathy; State 4: severe non-proliferative/proliferative retinopathy. 
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3.2.2 Baseline model without risk factor adjustment 
Initial unadjusted modeling demonstrated the better fit of the two way transition model 
(one-way transition model AIC = 32042.2; two-way transition model AIC = 31574.2, p < 
0.0001). A comparison between the observed and model-predicted prevalence indicated a 
close fit of the model to the DR data and so supported the internal validity of the model 
(Figure 3-3). This model indicated that the rates of remission from mild background 
diabetic retinopathy to diabetic retinopathy free state and from observable background 
diabetic retinopathy to mild background diabetic retinopathy were significantly faster than 
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the rates of progression (2.0 times faster and 4.2 times faster respectively), with the 
remission from observable to mild being almost double the rate of that observed for mild to 
no retinopathy (Table 3-4). The expected total length of time for diabetic retinopathy free, 
mild background retinopathy, observable background and severe non-
proliferative/proliferative retinopathy states were 12.6 (95% confidence interval or CI: 
12.41, 12.83) years, 2.91 (95% CI: 2.70, 3.11) years, 0.37 (95% CI: 0.27, 0.48) years and 
0.11 (95% CI: 0.06, 0.19) years, respectively. For the maximum follow-up time (16 years), 
the estimated transition matrix showed 26%, 4.3% and 2% probabilities that a patient free 
of diabetic retinopathy will progress to mild background, observable and severe non-
proliferative/proliferative retinopathy, respectively (Table 3-5). In the two-way transition 
model, the probabilities for correctly classifying retinopathy-free, mild background, 
observable, pre-proliferative/proliferative states were 0.971 (95% CI: 0.941, 0.986), 0.656 
(95% CI: 0.503, 0.781), 0.613 (95% CI: 6.16 × 10
-2
, 0.974) and 0.438 (1.53 × 10
-4
, 1.000), 
respectively (Table 3-6). To investigate whether the maximum likelihood estimates of the 
two-way transition model converged to reliable values, we ran the base model using 
multiple sets of initial values randomly generated from the standard uniform distribution. 
For eight out of nine models used random initial values, the point estimates of transition 
intensities and classification probabilities were close to the estimates derived from the 
default crude initial values generated by the “msm” package (Table 3-7 and Table 3-8).  
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Table 3-4 Estimated ratios of transition intensities, with standard errors (SE) and 
lower (L) and upper (U) bound of 95% CI estimated from the delta method, in the 
two-way transition base model. State 1: no-retinopathy; State 2: mild background 
retinopathy; State 3: observable background retinopathy; State 4: severe non-
proliferative/proliferative retinopathy. 
 
Transitions intensities Estimates SE L U 
State 2 → State 1 vs. State 1 → State 2   2.04 0.17 1.74 2.40 
State 3 → State 2 vs. State 2 → State 3   4.20 0.70 3.04 5.82 
State 1 → State 2 vs. State 2 → State 3 1.05 0.15 0.80 1.38 
State 2 → State 3 vs. State 3 → State 4 0.84 0.35 0.37 1.92 
State 1 → State 2 vs. State 3 → State 4 0.88 0.34 0.42 1.86 
State 2 → State 1 vs. State 3 → State 2 0.51 0.09 0.36 0.73 
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Table 3-5 The estimated transition probability matrix for 16 years’ time interval and 
95% CI (in parentheses) for the two-way transition base model. State 1: no-
retinopathy; State 2: mild background retinopathy; State 3: observable background 
retinopathy; State 4: severe non-proliferative/proliferative retinopathy.  
 
 To    
From State 1 State 2 State 3 State 4 
State 1 0.677  
(0.654,0.700) 
0.260  
(0.237,0.281) 
0.043  
(0.031,0.057) 
0.020 
(0.011,0.035) 
State 2 0.531  
(0.481,0.581) 
0.329  
(0.286,0.370) 
0.071  
(0.047,0.099) 
0.069  
(0.037,0.116) 
State 3 0.368  
(0.288,0.442) 
0.296  
(0.224,0.356) 
0.079  
(0.041,0.127) 
0.257  
(0.139,0.424) 
State 4 0  
(0,0) 
0  
(0,0) 
0  
(0,0) 
1  
(1,1) 
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Table 3-6 The maximum likelihood estimates of the probability classification matrix 
and 95% CI (in parentheses) for the two-way transition base model. State 1: no-
retinopathy; State 2: mild background retinopathy; State 3: observable background 
retinopathy; State 4: severe non-proliferative/proliferative retinopathy. 
 
 Observed State    
True State State 1 State 2 State 3 State 4 
State 1 0.971  
(0.941,0.986) 
0.019  
(0.017,0.022) 
9.62×10
-3
  
(8.56×10
-3
,0.011) 
4.4×10
-4
  
(2.14×10
-4
,9.07×10
-4
) 
State 2 0.311  
(0.267,0.360) 
0.656  
(0.503,0.781) 
0.026  
(0.018,0.037) 
7.51×10
-3
  
(4.66×10
-3
,0.023) 
State 3 0.145  
(0.100,0.205) 
0.232 
(0.136,0.369) 
0.613  
(0.063,0.974) 
0.010 
(4.28×10
-4
,0.196) 
State 4 3.12×10
-3
  
(3.39×10
-6
,0.743) 
9.26×10
-3
  
(6.44×10
-6
,0.576) 
0.550  
(0.032,0.978) 
0.438  
(1.53×10
-4
,1.000) 
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Table 3-7 Point estimates of transition intensity modelled in the diabetic retinopathy 
two-way transition base model using initial parameter estimates calculated from the 
“crudeinits.msm” function and random deviates generated from standard uniform 
distribution. State 1: no-retinopathy; State 2: mild background retinopathy; State 3: 
observable background retinopathy; State 4: severe non-proliferative/proliferative 
retinopathy. 
 
 
Transition intensities estimates 
Log-
likelihood 
 
S1=>S2 S2=>S1 S2=>S3 S3=>S2 S3=>S4  
Crude initial  0.048 0.099 0.046 0.194 0.055 -15770.1 
Random initial 1 0.048 0.100 0.047 0.173 0.032 -15773.5 
Random initial 2 0.048 0.099 0.046 0.193 0.055 -15770.1 
Random initial 3 0.048 0.099 0.046 0.176 0.035 -15773.9 
Random initial 4 0.048 0.099 0.046 0.175 0.027 -15774.2 
Random initial 5 0.048 0.099 0.046 0.194 0.053 -15770.3 
Random initial 6 0.053 0.113 0.056 0.137 0.102 -15731.5 
Random initial 7 0.048 0.099 0.046 0.192 0.053 -15770.2 
Random initial 8 0.048 0.099 0.046 0.193 0.054 -15770.2 
Random initial 9 0.048 0.099 0.046 0.193 0.053 -15770.2 
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Table 3-8 Point estimates of classification probability modelled in the diabetic retinopathy two-way transition base model using 
initial parameter estimates calculated from the “crudeinits.msm” function and random deviates generated from standard uniform 
distribution. State 1: no-retinopathy; State 2: mild background retinopathy; State 3: observable background retinopathy; State 4: 
severe non-proliferative/proliferative retinopathy. 
 
 
Classification probability estimates 
 
S1=>S1 S1=>S2 S1=>S3 S1=>S4 S2=>S1 S2=>S2 S2=>S3 S2=>S4 
Crude initial  0.971 0.019 0.010 0.000 0.311 0.656 0.025 0.008 
Random initial 1 0.971 0.019 0.010 0.001 0.313 0.657 0.026 0.005 
Random initial 2 0.971 0.019 0.010 0.000 0.312 0.656 0.025 0.007 
Random initial 3 0.971 0.019 0.010 0.000 0.311 0.657 0.026 0.006 
Random initial 4 0.971 0.019 0.010 0.000 0.310 0.658 0.027 0.006 
Random initial 5 0.971 0.019 0.010 0.000 0.312 0.656 0.025 0.007 
Random initial 6 0.974 0.016 0.010 0.000 0.365 0.613 0.018 0.004 
Random initial 7 0.971 0.019 0.010 0.000 0.311 0.655 0.026 0.008 
Random initial 8 0.971 0.019 0.010 0.000 0.311 0.656 0.025 0.007 
Random initial 9 0.971 0.019 0.010 0.000 0.311 0.656 0.025 0.008 
 
S3=>S1 S3=>S2 S3=>S3 S3=>S4 S4=>S1 S4=>S2 S4=>S3 S4=>S4 
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Classification probability estimates 
Crude initial  0.145 0.232 0.613 0.010 0.003 0.009 0.550 0.438 
Random initial 1 0.132 0.207 0.621 0.039 0.008 0.360 0.001 0.630 
Random initial 2 0.145 0.233 0.612 0.010 0.003 0.010 0.552 0.435 
Random initial 3 0.133 0.208 0.626 0.033 0.011 0.109 0.109 0.772 
Random initial 4 0.133 0.204 0.626 0.037 0.012 0.016 0.028 0.944 
Random initial 5 0.144 0.233 0.611 0.012 0.007 0.014 0.555 0.424 
Random initial 6 0.163 0.188 0.597 0.052 0.000 0.861 0.111 0.028 
Random initial 7 0.145 0.231 0.613 0.012 0.007 0.007 0.553 0.433 
Random initial 8 0.145 0.232 0.612 0.011 0.003 0.011 0.557 0.428 
Random initial 9 0.145 0.233 0.611 0.012 0.008 0.004 0.565 0.423 
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Figure 3-3 Expected prevalence modelled by the two-way transition base model, compared to the observed prevalence. State 1: no-
retinopathy; State 2: mild background retinopathy; State 3: observable background retinopathy; State 4: severe non-
proliferative/proliferative retinopathy. 
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3.2.3 Assessment of tradition risk factors 
We standardised values of BMI, cholesterol, creatinine, DBP, HbA1c, HDL-c, SBP, 
triglycerides and non-HDL-c (Table 3-9). As we have the full longitudinal medical record 
of each patient we adjusted each specific retinal event using risk factor data that was 
measured as close to that event as available. We found that BMI, DBP, HbA1c, SBP 
provided generally very close measures for each retinal assessment, probably due to their 
measure by diabetes specialists (Table 3-9). However, measures of vascular risk such as 
cholesterol, creatinine, HDL-c, triglycerides and non-HDL-c were measured more distally 
to the retinal screening events (Table 3-9). 
 
In a univariate analyses there was a significant effect on progression rates for age of 
diagnosis, age, cholesterol, DBP, HbA1c, SBP, triglycerides, and non-HDL-c, even after 
Bonferroni correction (threshold 0.0038) (Table 3-10 and Table 3-11). In contrast, there 
was no significant effect of BMI, serum creatinine, HDL-c, sex and smoking status (Table 
3-10 and Table 3-12). We then examined the effects of the risk factors on the individual 
transitions between disease states.  An increase in HbA1c level by one standard deviation 
(SD) (15.83 mmol/mol, 1.4%) had a 42% increased risk of progression from the no 
retinopathy state to mild background retinopathy, a 32% increased risk of progression from 
mild background retinopathy to observable background retinopathy, and a 123% increased 
risk in progression from observable background retinopathy to severe non-
proliferative/proliferative retinopathy (Table 3-11). Conversely, a reduction in the HbA1c 
level by one SD was associated with a 24% increased possibility of recovering from mild 
background retinopathy to the retinopathy free state (Table 3-11), but the HbA1c level was 
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unrelated to the regression from observable background retinopathy to mild background 
retinopathy in this cohort. A raised level of DBP by one SD (10.41 mmHg) elevated the 
risk for developing observable background retinopathy from the mild background 
retinopathy by 87% (Table 3-11). SBP was also significant risk factor for progression to 
mild background retinopathy from the initial retinopathy-free state (Table 3-11), and the 
reduction in SBP by one SD (17.28 mmHg) was associated a 20% increased chance of 
regression back to the retinopathy-free state (Table 3-11). The risk effect of cholesterol and 
non-HDL-c on the progression from the mild background retinopathy to observable 
background retinopathy reached statistical significance in the univariate models (Table 
3-11), but was insignificant after adjustment in the multivariate model (Table 3-11). In the 
multivariate analysis, at the 5% significance level, triglyceride values influenced the 
transition from the retinopathy-free state to mild background retinopathy (Table 3-11), 
which however was statistically insignificant in the univariate assessment (Table 3-11). 
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Table 3-9 Mean and standard deviation (SD) of longitudinally measured covariates, 
and time difference between a covariate measurement date and the closest date of 
retinal events.  
* The lower quartile, median and upper quartile of the time difference (in days). A negative 
value in time difference indicates a covariate measured prior to a retinal event. 
 
 
 
 
 
 
 
 
  
Longitudinal covariate Mean SD Record time
* 
BMI (kg/m
2
) 30.77 5.43 0,0,0 
Cholesterol (mmol/l) 4.57 1.05 -50,0,31 
Serum creatinine (µmol/l) 89.81 24.31 -57,0,39 
DBP (mmHg) 77.01 10.41 0,0,0 
HbA1c % (mmol/mol) 7.2% (54.94) 1.4% (15.83) 0,0,0 
HDL-c (mmol/l) 1.27 0.35 -60,0,29 
SBP (mmHg) 139.60 17.28 0,0,0 
Triglycerides (mmol/l) 2.14 1.08 -182,0,90 
Non-HDL-c (mmol/l) 3.26 1.04 -78,0,29 
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Table 3-10 Likelihood ratio tests of single-covariable model against the two-way 
transition model (base model AIC: 31574.2).  
 
Covariate  LR Statistic D DF P AIC 
Diabetes diagnosis age 61.786 5 5.19 × 10-12 31522.4 
Age  60.317 5 1.05 × 10-11 31523.9 
Sex 3.451 5 6.31 × 10-1 31580.8 
Smoking 7.333 5 1.97 × 10-1 31576.9 
BMI 3.119 5 6.82 ×10-1 31581.1 
Cholesterol 71.054 5 6.18 × 10-14 31513.1 
Serum creatinine 6.981 5 2.22 × 10-1 31577.2 
DBP 84.247 5 1.11 × 10-16 31500.0 
HbA1c 196.379 5 0.00 31387.8 
HDL-c 14.135 5 1.48×10-2 31570.1 
SBP 51.344 5 7.35×10-10 31532.9 
Triglycerides 25.141 5 1.31×10-4 31559.1 
Non-HDL-c 80.744 5 5.55×10-16 31503.5 
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Table 3-11 The estimates and 95% CI (in parentheses) of hazard ratios (HR) for diabetic retinopathy progression (state 1-2, 2-3, 3-4) 
and regression (state 2-1, 3-2). State 1: no-retinopathy; State 2: mild background retinopathy; State 3: observable background 
retinopathy; State 4: severe non-proliferative/proliferative retinopathy. Covariates were z-transformed in relation to the mean and 
standard deviation presented in Table 3-9, and all hazard ratios refer to per standard deviation of covariate. Risk factors 
statistically significant in the single-covariate test after the Bonferroni adjustment (the statistical significance level: 0.0038) are 
shown. 
 
 Cholesterol DBP HbA1c SBP Triglycerides Non-HDL-c 
 Single-covariate analysis (HR,95%CI) 
State 1 - State 2 0.99  
(0.92,1.06) 
1.09  
(1.01,1.17) 
1.41  
(1.32,1.51) 
1.17  
(1.09,1.26) 
0.93  
(0.87,1.00) 
0.98  
(0.92,1.05) 
State 2 - State 1 0.95  
(0.78,1.15) 
0.85  
(0.70,1.03) 
0.75  
(0.64,0.88) 
0.76  
(0.63,0.92) 
0.85  
(0.70,1.03) 
0.93  
(0.77,1.12) 
State 2 - State 3 1.99  
(1.63,2.44) 
2.20  
(1.77,2.74) 
1.60  
(1.32,1.94) 
1.35  
(1.07,1.70) 
1.30  
(1.11,1.52) 
2.02  
(1.67,2.45) 
State 3 - State 2 0.95  
(0.69,1.31) 
0.91  
(0.63,1.31) 
0.86  
(0.64,1.14) 
1.00  
(0.71,1.40) 
0.84  
(0.59,1.20) 
0.98  
(0.71,1.35) 
State 3 - State 4 1.33  
(0.87,2.03) 
1.12  
(0.64,1.96) 
2.46  
(1.57,3.84) 
0.76  
(0.43,1.33) 
1.48  
(1.06,2.07) 
1.28  
(0.94,1.74) 
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 Cholesterol DBP HbA1c SBP Triglycerides Non-HDL-c 
 Multi-covariate analysis (HR,95%CI) 
State 1 - State 2 0.99  
(0.82,1.19) 
0.98  
(0.90,1.07) 
1.42  
(1.32,1.52) 
1.20  
(1.11,1.30) 
0.92  
(0.85,0.99) 
0.98  
(0.81,1.19) 
State 2 - State 1 1.11  
(0.70,1.78) 
1.01  
(0.82,1.25) 
0.76  
(0.64,0.89) 
0.79  
(0.64,0.97) 
0.95  
(0.76,1.18) 
0.91  
(0.55,1.50) 
State 2 - State 3 0.86  
(0.40,1.86) 
1.87  
(1.46,2.40) 
1.32  
(1.08,1.60) 
0.96  
(0.76,1.22) 
0.99  
(0.78,1.24) 
1.94  
(0.84,4.45) 
State 3 - State 2 0.84  
(0.44,1.58) 
0.86  
(0.58,1.29) 
0.88  
(0.66,1.16) 
1.14  
(0.78,1.67) 
0.91  
(0.62,1.33) 
1.19  
(0.58,2.45) 
State 3 - State 4 1.69  
(0.62,4.55) 
0.92  
(0.53,1.58) 
2.23  
(1.16,4.29) 
0.87  
(0.52,1.46) 
1.27  
(0.89,1.81) 
0.72  
(0.26,1.99) 
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Table 3-12 The estimates and 95% CI (in parentheses) of hazard ratios (HR) for 
statistically insignificant (Bonferroni threshold: 0.0038) covariates modelled in the 
two-way transition process in a single-covariate analysis. Quantitative covariates were 
z-transformed in relation to the mean and standard deviation presented in Table 3-9, 
and all hazard ratios refer to per standard deviation of covariate. State 1: no-
retinopathy; State 2: mild background retinopathy; State 3: observable background 
retinopathy; State 4: severe non-proliferative/proliferative retinopathy.  
 
 
Sex (Male) Smoking BMI Creatinine HDL-c 
State 1 - State 
2 
1.05 
(0.91,1.20) 
0.91 
(0.78,1.07) 
0.97 
(0.91,1.04) 
1.05 
(0.97,1.13) 
1.03 
(0.96,1.10) 
State 2 - State 
1 
0.95 
(0.68,1.32) 
1.22 
(0.81,1.84) 
0.89 
(0.74,1.07) 
1.10 
(0.92,1.30) 
1.07 
(0.91,1.25) 
State 2 - State 
3 
0.76 
(0.50,1.14) 
1.53 
(0.93,2.52) 
0.91 
(0.75,1.11) 
1.16 
(1.01,1.33) 
0.69 
(0.54,0.89) 
State 3 - State 
2 
0.93 
(0.51,1.67) 
1.14 
(0.58,2.25) 
0.88 
(0.65,1.18) 
1.08 
(0.83,1.40) 
1.05 
(0.76,1.43) 
State 3 - State 
4 
1.51 
(0.60,3.80) 
1.34 
(0.40,4.43) 
1.14 
(0.72,1.79) 
0.72 
(0.39,1.34) 
1.15 
(0.68,1.93) 
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3.3 Conclusions 
Our analysis has demonstrated that in the development of diabetic retinopathy, the initial, 
asymptomatic phase was stable, followed by transient mid-stages, and that substantial rates 
of disease regression could be observed. The risk of diabetic retinopathy progression from 
the retinopathy-free state to mild background retinopathy, from mild background 
retinopathy to observable background retinopathy and from observable background 
retinopathy to severe non-proliferative/proliferative retinopathy was strongly positively 
associated with glycaemic exposure. We also found a significant risk effect of DBP on the 
progression of mild background retinopathy to observable background retinopathy and of 
SBP on the state transition from the retinopathy-free state to mild background retinopathy. 
There was no evidence in this study that the risk effects for diabetic retinopathy state 
transitions were influenced by sex, smoking status, BMI, serum creatinine or HDL-c. We 
did not find the evidence for independent risk effects of cholesterol, triglycerides and non-
HDL-c on diabetic retinopathy state transitions with the adjustment for blood pressure and 
glycaemic control. This study has provided the first evidence to show that better HbA1c 
and SBP are strongly correlated with the regression from mild background retinopathy back 
to the retinopathy-free state. 
 
One of the strengths of this study is the 15-fold greater overall sample size compared to an 
earlier study on diabetic retinopathy using an identical approach and a substantially 
extended follow-up time. A potential limitation in this longitudinal study of historical 
events remains the paucity of follow-up data on the study subjects that were recruited more 
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recently. Also, half way through the follow up screening was switched from Polaroid films 
to digital images, although a similar grading category was followed. 
 
In this study, our data yielded an important novel estimation about the time spent in each 
state in this cohort. To date, most longitudinal studies on diabetic retinopathy development 
have been directed at estimating incidence and/or progression rate in a study sample, and 
few have examined the average length of time spent in each stage of diabetic retinopathy. 
In the late 1980s, the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) 
reported 0.4% of patients with diabetes diagnosed at 30 years of age or above and without 
retinopathy at the first retinal examination progressed to proliferative diabetic retinopathy 
within four years [138]. The United Kingdom Prospective Diabetes Study (UKPDS) 
identified 0.2% of 2,316 type 2 diabetic patients with no retinopathy at baseline required 
photocoagulation treatments at 3 years, 1.1% at 6 years and 2.6% at 9 years [139,140]. A 
recent study on 16,444 patients with type 2 diabetes without retinopathy at the first retinal 
examination found the cumulative incidence of non-proliferative retinopathy, severe non-
proliferative retinopathy and proliferative retinopathy was 36%, 4% and 0.68%, 
respectively after 5 years follow up, and after 10 years follow up, these estimates rose to 
66%, 16% and 1.5% respectively [141]. These findings broadly support the estimated total 
length of time in the retinopathy-free state reported in this study. .   
 
Extensive evidence from published randomised clinical trials [21,142,143], prospective 
[144–150] and retrospective [151] studies support our findings on HbA1c as an important 
risk factor on diabetic retinopathy progression (Table 3-11). The Diabetes Control and 
Complications Trial (DCCT) [21] reported a hazard rate of 1.63 (P<0.001) for the risk 
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effect of one SD of  HbA1C in type 1 diabetic patients. UKPDS [143] has found per one 
SD increase in the HbA1c variable a hazard rate of 1.48 (95% CI: 1.40, 1.61) and 1.96 (95% 
CI: 1.79, 2.16) respectively for microvascular complications in patients with type 2 diabetes. 
These results broadly support the hazard ratios we found in this study for HbA1c on 
diabetic retinopathy. Additionally, we demonstrate that lower HbA1c is associated with 
regression of retinopathy from mild background retinopathy to no retinopathy. However, 
once a more severe retinopathy state e.g. observable BDR is reached, the protective effect 
associated with lowering HbA1c is not observed, suggesting that good glycaemic control 
only facilitates retinopathy remission at an early stage.  
 
Previous studies have shown mixed results on the association between blood pressure and 
diabetic retinopathy. The UKPDS [140] demonstrated that the incidence of retinopathy was 
associated with SBP values in top vs. bottom tertiles and lowering blood pressure resulted 
in a marked reduction in development or progression of diabetic retinopathy. In one of the 
WESDR reports [145], in which a prospective cohort of type 1 diabetic patients was 
followed up for 14 years, the baseline DBP variable was a significant predictor of 
progression to PDR. A study in the late-1980s [152] showed no association of SBP and 
DBP variables in the highest and lowest quartiles with the incidence or the progression of 
retinopathy in type 2 diabetic patients. In contrast, it was shown in the same study that in 
type 1 diabetic patients, SBP and DBP were correlated with the progression of retinopathy.  
Our study firmly supports a role for blood pressure in diabetic retinopathy progression in 
individuals with type 2 diabetes. 
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In this study, we have applied an innovative approach for the analysis of population-based 
longitudinal retinopathy cohort data. Our findings delineated state-by-state transitions 
underlying diabetic retinopathy development, and our assessment of population risk factors 
influencing progressive and regressive state transitions yielded the evidence for the role of 
blood pressure and glycaemic control in diabetic retinopathy development. Furthermore, 
the analytical approach utilised in this study holds the potential to be extended for 
investigating the additional independent effect from anti-diabetic oral agents on the course 
of diabetic retinopathy, or the interaction between anti-diabetic medications with HbA1c on 
the development diabetic retinopathy. These lines of interest on the front of 
pharmacoepidemiology may deserve a separate, thorough investigation, with additional 
input from population prescribing data sets. However, we have the confidence that the 
strategy we applied here will become the cornerstone for increasingly more clinical studies.  
  
Chapter 4  
Heritability and genetic correlations 
explained by common SNPs for diabetic 
retinopathy and related risk factors 
 
4.1 Introduction 
Diabetic retinopathy and the related metabolic traits are highly heritable [69,70,143,153–
156]. Uncovering the genetic influences underlying these traits and the genetic correlation 
between these related traits is the area of clinical interest. Recently, high-throughput array 
scans including genome-wide association studies (GWAS) identified putative genetic 
signals for diabetic retinopathy . However, significant genetic variants discovered in 
GWAS for a number of clinical traits explain only a limited fraction of the phenotypic 
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variance, substantially lower than the expected narrow-sense heritability, a genetic measure 
for the ratio of additive genetic variance over phenotypic variance. Yang et al [104] 
discovered that the missing proportion of heritability for GWAS may be linked to 
incomplete linkage disequilibrium (LD) between causal variants and genetic markers, and 
small effects associated with genetic variants against a stringent genome-wide significance 
P value threshold. Simultaneously, common GWAS SNPs explains a considerable portion 
of “missing” heritability [104,157].  
 
The restricted maximum likelihood (REML) analytical approach for decomposing 
phenotypic variation has been developed to study narrow-sense heritability for quantitative 
or dichotomous traits only based on common genome-wide SNP data, and additionally 
genetic and residual correlations between two quantitative traits or two binary traits 
[104,108,157]. However, clinically relevant phenotypes are frequently measured as an 
ordinal trait, as with the diabetic retinopathy phenotype. In studying narrow-sense 
heritability and genetic/residual correlations, a feasible analytical strategy is also needed for 
ordinal traits. Here, we explored the Bayesian Markov chain Monte Carlo approach, and 
uncovered the heritable proportion of the phenotypic variance for diabetic retinopathy and 
related risk factors in the GoDARTS cohort, and for the first-time, estimated the pairwise 
genetic and residual correlations for diabetic retinopathy and related risk factors.  
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4.2 Results 
4.2.1 Characteristics of the study data 
In this study, our base population consists of the GoDARTS sample genotyped on the 
Affymetrix 6 chip, which had random selections of retinopathy patients from the diabetic 
population. This study consisted of separate samples for genetically related individuals with 
identical by descent (IBD) estimates more than 0.05, and genetically unrelated individuals 
with IBD estimates less than 0.05. The clinical characteristics of the study population are 
provided in Table 4-1, and these characteristics were similar between genetically related 
and unrelated samples. Phenotypic correlations of body mass index (BMI), cholesterol 
(CHL), serum creatinine (CRE), glycosylated haemoglobin/HbA1c (HBA), high-density 
lipoprotein cholesterol/HDL-c (HDL), systolic blood pressure (SBP), triglycerides (TG) 
and retinopathy (RET) estimated in both samples are provided in Table 4-2 and Table 4-3. 
Here, we report consistent correlations observed in genetically related and unrelated 
samples of diabetes. We found positive phenotypic correlations of BMI-HBA, CHL-HBA, 
HBA-TG, BMI-TG, CHL-TG, CHL-RET, CRE-RET, HBA-RET and negative phenotypic 
correlations of BMI-HDL, HBA-HDL and HDL-TG (Table 4-2 and Table 4-3). The point 
estimates of phenotypic correlation coefficients of CRE-HDL were almost the same (Table 
4-2), but with the adjustment for multiple testing, this correlation in the genetically related 
sample was insignificant with P>0.05, owing to the smaller sample size.  
  
Table 4-1 Characteristics of the related sample (the IBD estimate between at least one 
pair of individuals > 0.05) and the unrelated sample (the IBD estimate between any 
pair of individuals   0.05). Retinopathy category 0: no-retinopathy; category 1: mild 
background retinopathy; category 2: observable background retinopathy; category 3: 
severe non-proliferative/proliferative retinopathy. 
 
(a) Quantitative traits.  
 Related sample Unrelated sample 
Trait Mean SD n Mean SD n 
Age (years) 64.2 10.8 1255 65.5 10.7 3039 
Diabetes duration 
(years) 7.0 6.6 1255 7.8 7.1 3039 
BMI (kg/m
2
) 31.0 5.6 1193 30.8 5.6 2970 
Cholesterol (mmol/l) 4.7 1.1 1193 4.6 1.1 2970 
Serum creatinine 
(µmol/l) 95.0 25.7 1193 96.5 25.4 2970 
HbA1c % (mmol/mol) 
7.5 
(58.9) 
 1.4% 
(15.4) 1193 
7.5% 
(58.3)  
1.4% 
(15.2) 2970 
HDL-c (mmol/l) 1.3 0.4 1193 1.4 0.4 2970 
SBP (mmHg) 141.6 18.5 1193 141.6 18.3 2970 
Triglycerides (mmol/l) 2.4 1.4 1193 2.2 1.3 2970 
 
(b) Dichotomous traits.   
 
 Related sample Unrelated sample 
Trait Counts (n, %) Counts (n, %) 
Sex F (601, 48%) M (654, 52%) F (1401, 46%) M (1638, 54%) 
 
(c) Polychotomous traits. Retinopathy categories: 0 (without retinopathy), 1 (mild background retinopathy), 2 (observable background 
retinopathy), 3 (severe non-proliferative/proliferative retinopathy). 
 
 Related sample Unrelated sample 
Trait Counts (n, %) Counts (n, %) 
Retinopathy 0 (372, 30%) 1 (442, 36%) 2 (267, 22%) 3 (158, 13%) 0 (806, 27%) 1 (1091, 37%) 2 (657, 22%) 3 (432, 15%) 
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Table 4-2 Pearson correlation coefficients and 95% confidence intervals (separate lines below) for quantitative risk factors of 
diabetic retinopathy in the GoDARTS related (n = 1193) and unrelated (n = 2970) sample. BMI: body mass index; CHL: cholesterol; 
CRE: serum creatinine; HBA (HbA1c): glycosylated haemoglobin; HDL (HDL-c): high-density lipoprotein cholesterol; SBP: systolic 
blood pressure; TG: triglycerides. 
*
Significance at the 0.05 level adjusted for 21 hypotheses using Fisher-transformed correlation 
coefficients. 
 
 Related sample Unrelated sample 
  BMI CHL CRE HBA HDL SBP BMI CHL CRE HBA HDL SBP 
CHL 0.019      0.007      
 -0.037      -0.029      
 0.076      0.043      
CRE -0.007 -0.046     -0.071
*
 -0.108
*
     
 -0.064 -0.103     -0.106 -0.143     
 0.050 0.010     -0.035 -0.072     
HBA 0.113
*
 0.099
*
 -0.027    0.110
*
 0.131
*
 -0.046    
 0.057 0.042 -0.084    0.074 0.096 -0.082    
 0.169 0.155 0.029    0.145 0.166 -0.010    
HDL -0.116
*
 0.093
*
 -0.070 -0.112
*
   -0.181
*
 0.153
*
 -0.071
*
 -0.067
*
   
 -0.172 0.037 -0.127 -0.167   -0.216 0.117 -0.107 -0.102   
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 Related sample Unrelated sample 
  BMI CHL CRE HBA HDL SBP BMI CHL CRE HBA HDL SBP 
 -0.060 0.149 -0.014 -0.055   -0.146 0.188 -0.036 -0.031   
SBP 0.054 0.001 -0.011 -0.017 0.097
*
  0.025 0.100
*
 -0.010 0.021 0.096
*
  
 -0.003 -0.056 -0.067 -0.074 0.040  -0.011 0.065 -0.046 -0.015 0.060  
 0.110 0.058 0.046 0.040 0.153  0.060 0.136 0.026 0.057 0.132  
TG 0.113
*
 0.391
*
 0.004 0.214
*
 -0.295
*
 0.012 0.196
*
 0.292
*
 -0.009 0.185
*
 -0.372
*
 0.052 
 0.057 0.342 -0.052 0.159 -0.346 -0.045 0.161 0.259 -0.045 0.150 -0.403 0.016 
 0.169 0.438 0.061 0.267 -0.242 0.069 0.230 0.325 0.027 0.219 -0.341 0.088 
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Table 4-3 Phenotypic correlation coefficients and 95% confidence intervals (separate 
lines below) between diabetic retinopathy and related quantitative risk factors in the 
GoDARTS related and unrelated sample. CHL: cholesterol; CRE: serum creatinine; 
HBA: HbA1c; RET: retinopathy; TG: triglycerides. 
*
Significance at the 0.05 level 
adjusted for 7 hypotheses using Fisher-transformed correlation coefficients.  
 
RET BMI CHL CRE HBA HDL SBP TG 
Related sample 
n = 1178 
-0.080
*
 0.058
*
 0.239
*
 0.189
*
 -0.052 0.022 -0.013 
-0.137 0.001 0.184 0.133 -0.109 -0.035 -0.070 
-0.023 0.115 0.292 0.243 0.005 0.079 0.045 
Unrelated sample -0.036 0.110
*
 0.123
*
 0.201
*
 0.031 0.060
*
 -0.060
*
 
n = 2903 -0.072 0.074 0.087 0.166 -0.005 0.024 -0.096 
 0.001 0.146 0.159 0.236 0.068 0.097 -0.023 
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4.2.2 Heritability explained by common genome-wide SNPs for 
diabetic retinopathy and related risk factors 
We estimated heritability explained by common genome-wide SNPs with the adjustment 
for age, sex and duration of diabetes in the genetically related and unrelated samples using 
the Markov chain Monte Carlo (MCMC) sampling strategy. The heritability estimate is the 
total additive genetic variance normalised by total phenotypic variance. MCMC data is 
valid (mixed) or formally described as having reached stationarity if it approximates the 
unknown target distribution of the parameter of interest. In this study, MCMC data for each 
trait passed through the Geweke and Heidelberg-Welch stationarity tests. The trace plots 
provide a visual tool for inspecting parameter values sampled. Any systematic upward or 
downward trends indicate poor mixing of MCMC data. The traces of MCMC data in this 
study showed small fluctuations, suggesting of good mixing of MCMC chains (Appendix 
Figure A-1). In the density plots, genetic variance parameter estimates were positively 
skewed (Appendix Figure A-1), because values for variance are always non-negative. As a 
convention, the residual variance was pre-defined to be 1 for any categorical trait in the 
liability threshold model. Autocorrelations of MCMC data is an assessment for the 
efficiency of mixing. The autocorrelation plot suggests higher autocorrelations of MCMC 
samples in the genetically unrelated sample compared to the related sample (Appendix 
Figure A-1), owing to a larger sample size and more total additive genetic effect parameters 
sampled in the MCMC algorithm. We obtained 25,000 MCMC samples for the heritability 
estimation for each trait in the related and unrelated samples.  
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Long-range linkage disequilibrium blocks that span known SNP markers and unknown 
genomic variations were anticipated in the genetically related sample, and thus it was 
probable that estimates of heritability and genetic correlation may be higher in the 
genetically related sample, even with a smaller sample size compared to that in the 
unrelated sample. The heritability estimates were close in both samples for CHL, CRE, 
HBA and SBP (Table 4-4). BMI and TG showed higher heritability in the genetically 
related and unrelated samples, respectively (Table 4-4). 22% and 34% of phenotypic 
variations of diabetic retinopathy were heritable in the genetically related and unrelated 
samples, respectively (Table 4-4). 
 
As aforementioned, densities of variance parameter estimates were positively skewed, and 
thus, the posterior median was used as the posterior estimator. The other alternative 
posterior estimator, the posterior mode, required the mathematical integration of joint 
posterior probabilities, which became an intractable mathematical problem with this model. 
Since the posterior distribution were non-symmetric, we used 95% highest posterior density 
(HPD) interval, which is the credible interval in parameter space that has 95% posterior 
probabilities, with the minimal density in the interval greater than or equal to the density of 
any point outside of the interval. In simple terms, the HPD interval can be interpreted as the 
range of parameter values that occur 95% of time with repeated sampling of probable 
parameter values for a given data, where the true parameter values are considered as 
dispersed following a distribution. In contrast, the frequentist confidence interval estimation 
involves no sampling, and it is interpreted as the range of parameter values that cover the 
true, fixed parameter value for 95% of time, if the study data is hypothetically repeatedly 
sampled from the population. P values are associated with the frequenstist hypothesis 
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testing, whereas in Bayesian inference, the Bayes factor is used in comparing competing 
models for the same data for the better-fitted model. The Bayes factor is analogous to the 
frequentist likelihood ratio, and it provides a means for assessing the strength of evidence. 
However, the Bayes factor is difficult to compute for mixed models we described here, and 
thus, it was not feasible to estimate P values adjusted for multiple testing in this study. A 
comprehensive review on MCMC Bayesian inference is provided in [107]. 
127 
 
 
 
Table 4-4 Genetic (Vg) and residual (Ve) variance that have been used for estimating 
heritability (hg
2
) explained by common genome-wide SNPs in the GoDARTS sample. 
1,193 (2,970) genetically related (unrelated) subjects’ data were used in the 
heritability estimation of BMI, CHL, CRE, HBA, HDL, SBP and TG; 1,236 (2,985) 
genetically related (unrelated) subjects’ data were used in the heritability estimation 
of RET. BMI: body mass index; CHL: cholesterol; CRE: serum creatinine; HBA 
(HbA1c): glycosylated haemoglobin; HDL (HDL-c): high-density lipoprotein 
cholesterol; RET: retinopathy; SBP: systolic blood pressure; TG: triglycerides. 
**
Residual variance is a pre-specified parameter for categorical traits.  
 
 Related sample Unrelated sample 
Trait Vg Ve hg
2
 Vg Ve hg
2
 
BMI 
0.47 (0.22, 
0.72) 
0.50 (0.27, 
0.72) 
0.49 (0.24, 
0.72) 
0.30 (0.12, 
0.49) 
0.65 (0.47, 
0.82) 
0.31 (0.13, 
0.51) 
CHL 
0.17 (0.07, 
0.32) 
0.77 (0.62, 
0.89) 
0.18 (0.07, 
0.33) 
0.19 (0.08, 
0.33) 
0.75 (0.62, 
0.87) 
0.20 (0.08, 
0.34) 
CRE 
0.18 (0.08, 
0.33) 
0.62 (0.49, 
0.74) 
0.23 (0.09, 
0.40) 
0.15 (0.07, 
0.26) 
0.65 (0.54, 
0.74) 
0.19 (0.08, 
0.32) 
HBA 
0.18 (0.07, 
0.33) 
0.76 (0.61, 
0.89) 
0.19 (0.07, 
0.34) 
0.20 (0.08, 
0.36) 
0.74 (0.59, 
0.86) 
0.21 (0.08, 
0.37) 
HDL 
0.38 (0.17, 
0.61) 
0.57 (0.37, 
0.77) 
0.40 (0.19, 
0.62) 
0.21 (0.08, 
0.37) 
0.73 (0.59, 
0.86) 
0.23 (0.09, 
0.39) 
SBP 
0.17 (0.06, 
0.32) 
0.81 (0.66, 
0.94) 
0.18 (0.07, 
0.32) 
0.13 (0.06, 
0.24) 
0.85 (0.74, 
0.94) 
0.14 (0.06, 
0.24) 
TG 
0.23 (0.08, 
0.43) 
0.76 (0.58, 
0.92) 
0.24 (0.09, 
0.42) 
0.30 (0.13, 
0.49) 
0.68 (0.50, 
0.84) 
0.31 (0.14, 
0.50) 
RET 
0.29 (0.06, 
0.78) 
1.00 (1.00, 
1.00)
**
 
0.22 (0.07, 
0.45) 
0.51 (0.08, 
1.35) 
1.00 (1.00, 
1.00)
 **
 
0.34 (0.10, 
0.59) 
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4.2.3 Genetic correlation explained by common genome-wide 
SNPs for diabetic retinopathy and related risk factors 
We estimated pairwise genetic correlations for diabetic retinopathy and related risk factors 
in the bivariate mixed model with the adjustment for age, sex and duration of diabetes, 
using MCMC sampling (Appendix Figure B-1 and Appendix Figure B-2). The genetic 
(residual) correlation coefficient is the additive genetic (residual) covariance of a pair of 
traits normalized by genetic (residual) standard deviation of each trait. The number of 
MCMC samples collected for each pair of traits is provided in Appendix Table B-1.  
 
In the related sample, we identified negative genetic correlation of HDL-TG (Table 4-5), 
and significant residual correlations of HDL-TG, BMI-TG, CHL-TG and HBA-TG (Table 
4-5). Genetic and residual correlations of diabetic retinopathy with related risk factors were 
insignificant at the 0.05 significance level in the related sample (Table 4-7). In the unrelated 
sample, we identified significant residual correlations at the 0.05 significance level of BMI-
HBA, BMI-HDL, BMI-SBP, CHL-HDL, CHL-SBP, CHL-TG, CRE-HDL, HBA-TG and 
HDL-TG (Table 4-6). Diabetic retinopathy showed positive residual correlation with 
cholesterol in the unrelated sample (Table 4-7). Out of all pairs of traits studied, significant 
residual correlations of CHL-TG, HBA-TG and HDL-TG were consistently observed in the 
related and unrelated samples. However, we could not preclude the existence of genetic and 
residual correlations for pairs of traits that were insignificant in this study due to the wide 
credible intervals.  
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Table 4-5 Posterior median and 95% highest posterior density intervals of the genetic (upper triangle) and residual (lower triangle) 
correlation coefficient in the genetically related sample for retinopathy-related population risk factors. Sample size: 1,193 patients. 
BMI: body mass index; CHL: cholesterol; CRE: serum creatinine; HBA (HbA1c): glycosylated haemoglobin; HDL (HDL-c): high-
density lipoprotein cholesterol; RET: retinopathy; SBP: systolic blood pressure; TG: triglycerides. 
*
Significant at the 0.05 level. 
 
 
Related sample 
 
BMI CHL CRE HBA HDL SBP TG 
BMI 
 
-0.36 
(-0.74, 0.12) 
0.39 
(-0.06, 0.74) 
0.20 
(-0.31, 0.64) 
-0.29 
(-0.68, 0.13) 
0.16 
(-0.35, 0.64) 
-0.19 
(-0.64, 0.29) 
CHL 0.07 
(-0.15, 0.32)  
0.15 
(-0.36, 0.60) 
0.05 
(-0.46, 0.54) 
0.34 
(-0.16, 0.74) 
0.18 
(-0.33, 0.65) 
0.07 
(-0.46, 0.56) 
CRE -0.02 
(-0.28, 0.22) 
0.03 
(-0.12, 0.16) 
 
0.20 
(-0.30, 0.64) 
0.27 
(-0.18, 0.68) 
0.10 
(-0.40, 0.57) 
0.07 
(-0.44, 0.55) 
HBA 0.04 
(-0.20, 0.26) 
0.04 
(-0.10, 0.17) 
-0.06 
(-0.22, 0.08) 
 
-0.34 
(-0.73, 0.14) 
-0.05 
(-0.54, 0.46) 
0.03 
(-0.49, 0.52) 
HDL 0.00 
(-0.30, 0.31) 
0.05 
(-0.19, 0.23) 
-0.21 
(-0.46, 0.00) 
-0.04 
(-0.23, 0.17) 
 
0.10 
(-0.42, 0.57) 
-0.48
*
 
(-0.80, -0.02) 
SBP 0.09 
(-0.16, 0.30) 
0.01 
(-0.13, 0.14) 
-0.10 
(-0.24, 0.04) 
0.03 
(-0.09, 0.17) 
0.07 
(-0.12, 0.26) 
 
0.14 
(-0.38, 0.63) 
TG 0.28
*
 
(0.04, 0.53) 
0.42
*
 
(0.28, 0.56) 
0.08 
(-0.08, 0.24) 
0.27
*
 
(0.12, 0.41) 
-0.39
*
 
(-0.56, -0.20) 
0.02 
(-0.13, 0.17) 
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Table 4-6 Posterior median and 95% highest posterior density intervals of the genetic (upper triangle) and residual (lower triangle) 
correlation coefficient in the genetically unrelated sample for retinopathy-related population risk factors. BMI: body mass index; 
CHL: cholesterol; CRE: serum creatinine; HBA (HbA1c): glycosylated haemoglobin; HDL (HDL-c): high-density lipoprotein 
cholesterol; RET: retinopathy; SBP: systolic blood pressure; TG: triglycerides. 
*
Significant at the 0.05 level. 
 
 
Unrelated sample 
 
BMI CHL CRE HBA HDL SBP TG 
BMI 
 
0.18 
(-0.31, 0.62) 
0.17 
(-0.31, 0.61) 
-0.29 
(-0.69, 0.18) 
-0.26 
(-0.68, 0.23) 
-0.35 
(-0.72, 0.11) 
0.36 
(-0.09, 0.73) 
CHL -0.13 
(-0.31, 0.03)  
0.18 
(-0.29, 0.62) 
-0.06 
(-0.54, 0.43) 
0.22 
(-0.29, 0.65) 
0.13 
(-0.36, 0.59) 
0.38 
(-0.08, 0.75) 
CRE 0.02 
(-0.15, 0.16) 
-0.05 
(-0.18, 0.07) 
 
0.08 
(-0.42, 0.52) 
0.23 
(-0.24, 0.64) 
0.13 
(-0.35, 0.56) 
0.15 
(-0.33, 0.59) 
HBA 0.23
*
 
(0.06, 0.43) 
0.08 
(-0.04, 0.22) 
-0.06 
(-0.18, 0.07) 
 
-0.12 
(-0.61, 0.37) 
-0.05 
(-0.53, 0.43) 
0.16 
(-0.34, 0.62) 
HDL -0.18
*
 
(-0.35, -0.01) 
0.17
*
 
(0.03, 0.30) 
-0.16
*
 
(-0.31, -0.03) 
-0.09 
(-0.23, 0.06) 
 
0.04 
(-0.45, 0.51) 
-0.43 
(-0.76, 0.04) 
SBP 0.20
*
 
(0.04, 0.37) 
0.13
*
 
(0.02, 0.23) 
-0.09 
(-0.20, 0.01) 
0.06 
(-0.05, 0.18) 
0.08 
(-0.04, 0.19) 
 
0.19 
(-0.29, 0.64) 
TG 0.17 
(-0.04, 0.35) 
0.28
*
 
(0.12, 0.41) 
0.00 
(-0.16, 0.15) 
0.21
*
 
(0.04, 0.36) 
-0.44
*
 
(-0.57, -0.30) 
0.05 
(-0.10, 0.17) 
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Table 4-7 Posterior median and 95% highest posterior density intervals of genetic (residual) correlation coefficient, rg (re), between 
retinopathy and related population risk factors. BMI: body mass index; CHL: cholesterol; CRE: serum creatinine; HBA (HbA1c): 
glycosylated haemoglobin; HDL (HDL-c): high-density lipoprotein cholesterol; RET: retinopathy; SBP: systolic blood pressure; TG: 
triglycerides. 
*
Significant at the 0.05 level. 
 
 Related sample Unrelated sample 
Trait rg re rg re 
RET-BMI 0.33 (-0.30, 0.81) -0.25 (-0.68, 0.12) 0.19 (-0.46, 0.71) 0.00 (-0.29, 0.27) 
RET-CHL 0.10 (-0.51, 0.65) 0.17 (-0.05, 0.39) -0.46 (-0.81, 0.04) 0.37 (0.12, 0.64)
 *
 
RET-CRE 0.32 (-0.27, 0.77) 0.16 (-0.10, 0.36) 0.16 (-0.40, 0.67) 0.09 (-0.12, 0.28) 
RET-HBA 0.13 (-0.47, 0.65) 0.14 (-0.07, 0.34) 0.34 (-0.25, 0.78) 0.05 (-0.22, 0.27) 
RET-HDL 0.09 (-0.55, 0.68) -0.20 (-0.55, 0.10) -0.15 (-0.67, 0.47) -0.03 (-0.27, 0.21) 
RET-SBP -0.11 (-0.66, 0.50) 0.08 (-0.12, 0.31) 0.27 (-0.31, 0.72) 0.04 (-0.16, 0.20) 
RET-TG -0.06 (-0.66, 0.55) 0.13 (-0.11, 0.40) -0.10 (-0.67, 0.49) 0.10 (-0.18, 0.38) 
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4.3 Conclusions 
In this study, we analysed the narrow-sense heritability and genetic correlations captured by 
common whole-genome SNPs for the severity of retinopathy and related population risk 
factors in the GoDARTS diabetic population. Whilst the same methodology for analysing 
heritability and the genetic/residual correlation was also applicable to a genetically mixed 
samples, the partition of the study cohort into genetically related and unrelated samples 
permitted separate considerations for similar environment effects and stronger genetic 
similarities amongst related individuals compared to those unrelated. This study was based 
on MCMC Bayesian inference, which made the analysis of multi-categorical clinical data 
of diabetic retinopathy in univariate and bivariate mixed models feasible. We found 
statistically significant heritability estimates for BMI (49%), CHL (20%), CRE (23%),  
HBA (21%), HDL (40%), SBP (18%) and TG (31%) in the GoDARTS study data, and the 
estimates for BMI, HDL, SBP and TG were similar to the reported values using a 
comparable approach in a non-diabetic population [108]. We found that 34% of retinopathy 
phenotypic variations wereinherited additive genetic effects. In both related and unrelated 
samples, we identified positive residual (environmental) correlations for TG with CHL and 
HBA, respectively, and additionally confirmed negative genetic and residual correlation for 
TG with HDL, which was previously reported [108]. Residual correlation of diabetic 
retinopathy with CHL was observed in the unrelated sample. These residual correlations 
suggest shared environmental aetiology for the observed physiological relation between 
lipids and lipids with glycaemic exposure. We found no significant genetic correlation 
between any of the metabolic traits with retinopathy; however, the sample sizes we had in 
this study may be the limiting factor for the accurate determination of plausible genetic 
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correlations between retinopathy and related risk factors, using the MCMC estimation 
approach.  
 
We estimated the genetic similarity matrix based on 6,830,657 imputed autosomal SNPs, 
which was substantially a larger set of genetic variants compared to genotyped SNPs used 
in previous studies [104,108,157]. In one study [108], it was reported that extra SNPs had 
little additional effects on the heritability estimates, once analysed SNPs reached a certain 
size. The Gibbs sampling approach we applied was computationally intensive and required 
days and sometimes months of computation for bivariate mixed models, which may be an 
opportunity for further algorithm development to accelerating mixing of MCMC samples 
and reducing compute time.  
 
This study estimated narrow-sense heritability (34%) captured by genome-wide SNPs for 
the severity of diabetic retinopathy, which was analysed as an ordinal variable including all 
stages of retinopathy defined by the Scottish diabetic retinopathy grading scheme 2007 
v.1.1. This estimate was supported by previous evidence that the narrow-sense heritability 
of proliferative diabetic retinopathy was 0.52 ± 0.31 [70], and the broad-sense heritability 
estimate was 27% for the severity of diabetic retinopathy [69]. Few studies reported the 
heritability estimate for total cholesterol (CHL). Previous studies identified that the 
heritability estimates in the non-diabetic population for BMI, CRE, HBA, HDL, SBP and 
TG can be as high as 58% [158], 64.1% [159], 59% [160], 46% [161],  57% [159] and 36% 
[162], respectively. These results provided strong evidence for the heritability estimates in 
this study. 
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In this study, we estimated genetic and residual correlation for diabetic retinopathy and 
related risk factors. Negative genetic correlation (posterior median: -0.48; 95% highest 
posterior density/HPD interval: -0.80, -0.02) was observed for HDL-TG in the related 
sample. Although this result was not replicated in the unrelated sample of this study 
(posterior median: -0.43; 95% HPD interval: -0.76, 0.04) owing to a large credible interval, 
genetic correlations of HDL-TG were consistently observed in the non-diabetic related 
(unrelated) sample of Atherosclerosis Risk in Communities (ARIC) [108], with the 
maximum likelihood estimate/MLE: -0.59, 95% confidence interval/CI: -0.84, -0.34 (MLE: 
-0.57, 95% CI: -0.94, -0.20). The ARIC study included 530 related (the relatedness 
coefficient between 0.35 and 0.65) individuals and 5,647 unrelated (the relatedness 
coefficient less than 0.025) individuals. This large genetic correlation between HDL-TG is 
directly reflective of a known physiological relationship [163]. In the ARIC study [108],  
no significant genetic correlation was detected for BMI-HDL, BMI-SBP, BMI-TG, HDL-
SBP, SBP-TG, which is consistent with findings from our study. Compared to the ARIC 
study [108], we had approximately half of the size in the unrelated sample, and additionally, 
we had similarly ranged credible intervals. In this study, it is probable that the current 
sample size is not adequate in power to estimate genetic and residual correlations with 
modest effect sizes. 
 
We found large residual correlations for CHL-TG, HBA-TG, HDL-TG in the related and 
unrelated samples, and RET-CHL in the unrelated sample. Observed residual correlations 
for lipids are likely attributed to a known environmental aetiology [163].  The residual 
correlation of HBA-CHL shown in this study suggests shared environmental aetiology to 
hyperglycaemia and hyperlipidaemia, supported by studies of heart diseases and diabetes 
135 
 
 
 
[164], although the full explanation for this link remains elusive. We detected a strong 
residual correlation for RET-CHL, which suggests the increased susceptibility of 
retinopathy may be associated with hyperlipidaemia due to a common environmental 
exposure including diet and lifestyle. The physiological relation between HBA, CHL and 
RET may be further characterised in studies for common genetic and environmental 
aetiology underlying hyperglycaemia, hyperlipidaemia and retinopathy, in a single analysis 
using multi-variate mixed models.  
 
A drawback of this study lies within the use of clinical data unadjusted for the treatment 
effects of hyperglycaemia, hyperlipidaemia and hypertension. However, given the 
successful detection of known genetic and residual correlations between lipids, we consider 
the analytical approach applied here is robust for studying treatment-unadjusted clinical 
response data. 
 
In summary, this study found a large portion of phenotypic variation in retinopathy and 
related risk factors in the diabetic population is heritable, as captured by common genome-
wide SNPs. These findings are complementary to discoveries made in the population-based 
association studies for diabetic retinopathy and related risk factors using common genome-
wide SNPs [28,71–73]. This study provided the evidence for genetic and environmental 
correlations between metabolic traits in the diabetic populations, which has been previously 
observed in non-diabetic population [108]. This is consistent with the premise of the 
analysis of genetic correlated phenotypes in genome-wide association scans [165]. We 
detected positive environmental correlation of retinopathy with total cholesterol, and 
cholesterol with HbA1c, which prompts joint correlation analysis of retinopathy with lipids 
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and glycaemic exposure for improving clinical management of diabetic retinopathy. In 
agreement with a previous study using a similar approach [108], we found the precision for 
heritability and correlation estimates from genome-wide SNPs could be improved with an 
increased sample size in future studies.  
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Chapter 5  
The SUMMIT genome-wide meta-analysis 
of diabetic retinopathy 
 
5.1 Introduction 
As demonstrated in the previous chapter, mounting evidence suggests there is a strong 
heritable genetic contribution to the development of retinopathy in the GoDARTS 
population sample. To date, genome-wide association studies (GWAS) have been shown to 
be a fruitful strategy in identifying natural genetic variations and causal genes associated 
with type 1 and type 2 diabetes [72,80,166,167], pharmacoresponses in the type 2 diabetic 
population [86] and additional diabetes-related complex traits [168]. However, the  handful 
of diabetic retinopathy GWAS that are published have not identified any loci with genome 
wide significance [28,81–83]. These analyses are based upon limited sample sizes of 
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diabetic retinopathy cases and controls, and for example, the whole-genome meta-analysis 
of severe diabetic retinopathy, the largest retinopathy data analysis of all published 
retinopathy GWAS, included 937 cases and 1,856 controls. These sample sizes are 
underpowered to identify retinopathy risk loci with moderate effects. 
 
Compared to these previous analyses, in this study, the GoDARTS cohort contributed 1,942 
diabetic retinopathy cases and 2,014 controls in the discovery phase of a whole-genome 
association scan, and overall with collaborators in SUMMIT, the meta-analysis included 
5,422 cases and 4,302 controls in the GWAS analysis, which becomes the largest GWAS of 
diabetic retinopathy to date. In addition, this study analysed 1000 Genomes imputed genetic 
variants, which is the largest set of variants being studied for the association with diabetic 
retinopathy. Through these initiatives, we aimed at achieving adequate power to detect 
diabetic retinopathy susceptibility loci from genome-wide genetic variants, and robustly 
identify causal genes. 
 
5.2 Results 
5.2.1 Characteristics of the GoDARTS study sample 
Clinical characteristics of the GoDARTS study sample are provided in Table 5-1. Controls 
have minimally higher mean of age and lower mean of serum creatinine and HbA1c, but 
other clinical profiles are comparable. 
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Table 5-1 Clinical characteristics of retinopathy cases (n = 1942) and controls (n = 
2014) of the GoDARTS cohort.  
 
 Cases Controls 
Trait Mean SD Mean SD 
Age (years) 60.1 11.5 68.9 10.8 
BMI (kg/m
2
) 30.3 5.5 31.4 6.1 
Cholesterol (mmol/l) 4.7 1.1 4.5 1.0 
Serum creatinine (µmol/l) 100.3 28.9 89.7 27.2 
DBP (mmHg) 76.0 10.3 76.9 10.6 
HbA1c % (mmol/mol) 7.8% (61.4) 1.5% (16.4) 7.1% (54.5) 1.2% (13.4) 
HDL-c (mmol/l) 1.3 0.4 1.3 0.4 
SBP (mmHg) 142.8 18.8 139.2 18.0 
Triglycerides (mmol/l) 2.1 1.2 2.3 1.3 
Non-HDL-c (mmol/l) 3.4 1.1 3.2 1.0 
Sex (%) F (44.4%) M (55.6%) F (45.3%) M (54.7%) 
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5.2.2 Meta-analysis study data 
The meta-analysis study included 9,724 individuals from EURODIAB, FinnDiane, 
GoDARTS and SDR cohorts in 1000 Genomes imputed variants (Table 5-2 and Table 5-3). 
GoDARTS and SDR population samples comprised of genetically unrelated individuals 
and related relatives. Genome-wide meta-analyses were performed independently in 
genetically unrelated samples and mixed samples (section 2.8.3). 
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Table 5-2 Sample sizes for meta-analysis study cohorts. Sizes for genetically unrelated 
samples are shown in the brackets. 
 
Cohort Cases Controls Total 
EURODIAB (T1D) 201 249 450 
SDR (T1D) 490 (472) 142 (140) 632 (612) 
SDR (T2D) 1151 (1066) 865 (815) 2016 (1881) 
GoDARTS (T1,2D) 1142 (1022) 882 (778) 2024 (1800) 
GoDARTS-SUMMIT (T1,2D) 800 (725) 1132 (1020) 1932 (1745) 
FinnDiane (T1D) 1638 1032 2670 
Total 5422 (5124) 4302 (4034) 9724 (9158) 
 
 
Table 5-3 1000 Genomes imputed genetic variants included in the meta-analyses of 
genetically mixed  and genetically unrelated (numbers enclosed in the brackets) study 
samples. QC: quality control.  
 
Cohort Pre-QC genetic variants Post-QC genetic variants 
EURODIAB (T1D) 37,524,910 (37,524,910) 9,091,275 (9,091,275) 
SDR (T1D) 15,077,368 (15,091,253) 7,044,378 (7,051,662) 
SDR (T2D) 15,078,384 (15,092,269) 9,258,178 (9,267,780) 
GoDARTS (T1,2D) 13,658,156 (13,658,156) 8,364,025 (8,364,025) 
GoDARTS-SUMMIT (T1,2D) 15,005,754 (15,005,754) 9,037,594 (9,037,594) 
FinnDiane (T1D) 14,324,304 (14,337,518) 9,330,927 (9,344,876) 
Meta-analysis --- 9,508,089 (10,444,012) 
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5.2.3 Loci associated with diabetic retinopathy 
The resulting Manhattan plots of meta-analysis association results are shown in Figure 5-1, 
which showed top association signals clustered on chromosome 1 (1p34-p32 and 1q43), 
chromosome 2 (2p12-p11.1, 2q11.2 and 2q32.1), chromosome 3 (3p24.3 and 3q24), 
chromosome 4 (4q28-q32), chromosome 5 (5p14 and 5q31.3), chromosome 6 (6p21 and 
6q16.1), chromosome 9 (q13-q21.2), chromosome 11 (11q21), chromosome 12 (12p11.22), 
chromosome 13 (13q32), chromosome 17 (17q25.1), chromosome 19 (19q13.11) (Table 
5-4 and Table 5-5).  
 
The resulting quantile-quantile plots are shown in Figure 5-2, and the genomic inflation 
factor estimates are 1.00 and 1.01, respectively. The quantile-quantile plot of meta-analysis 
in the mixed genetic relatedness samples showed more associations with significant P 
values observed than expected (Figure 5-2b), although P values of both analyses were 
strongly correlated (Figure 5-3). P values of the top independent signal SNPs were close to 
the genome-wide significance (that is, 5.00×10
-8
) (Table 5-4). Top signal variants in 
independent regions of associations with P value < 10
-5
 are provided in Appendix Table C-
1, and the functional annotation of the closest gene is shown in Appendix Table C-2. Four 
independent signal SNPs had P values below 10
-6
, with the highest significant locus being 
rs10746970 (P value of 2.22×10
-7
). Heterogeneity of genetic effects was minimally small 
for top ranked SNPs in the meta-analysis (Table 5-4). In the regional association plots 
(Figure 5-4), the four top ranked SNPs each showed strong linkage disequilibrium with 
adjacent SNPs, suggestingthe association signal originated from a single region. We found 
that top signal SNPs are close to genes that are implicated in carbohydrate/lipid metabolic 
processes, function, activity of neuronal and glial cells, and transcription regulation (Table 
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5-5). As of 18 October 2014, none of these top independent association SNPs was 
previously reported in the database of published GWAS 
(http://www.genome.gov/gwastudies/) [169]. 
 
With the estimated prevalence (9.59%) of diabetic retinopathy in GoDARTS at the 
recruitment time, statistical power for achieving genome-wide significance in each single-
marker test of the genome-wide meta-analysis rose with increased relative risk and minor 
allele frequencies (MAFs) (Table 5-6 and Figure 5-5). With the current sample size, 
maximum achievable power at the relative risk of 1.1 or less was 0.025, and when the 
relative risk was 1.5 or more and MAF was 0.05 or greater, power was 0.973 or greater 
(Table 5-6).   
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Figure 5-1 Manhattan plots of meta-analysis association results in the genetically 
unrelated samples (a) and mixed samples (b). The genome-wide significance threshold 
(P value of 
85 10 ) is shown as the horizontal line.  
 
(a) 
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(b) 
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Figure 5-2 Quantile-quantile plots of meta-analysis association results in the 
genetically unrelated samples (a) and mixed samples (b). 95% confidence intervals are 
shown as the shaded area.  
 
(a) 
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(b) 
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Figure 5-3 Correlations of meta-analysis P values, provided by Dr William Rayner, 
Oxford University, based on the genetically unrelated sample analysed by the 
SNPTEST software (version 2.4.1) and the genetically mixed samples analysed by 
EMMAX beta or GEMMA (version 0.93). 
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Figure 5-4 Regional association plots for top independent signal SNPs of (a) 
rs10746970, (b) rs1653654, (c) rs75125621 and (d) rs2657795 in the SUMMIT meta-
analysis of diabetic retinopathy. In the association region, neighbouring SNPs were 
coloured according to the linkage disequilibrium (r
2
) with the index SNP (purple). 
Blue spikes indicate loci of high recombination rates within the 400 K base pair (bp) 
either side of the index SNP.  
 
 (a) 
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(b) 
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Table 5-4 Top independent (defined by >100 Kbp) signal SNPs in the whole-genome meta-analysis of diabetic retinopathy. Chr: 
chromosome. 
 
Chr. Position
a
 SNP 
Effective 
allele 
frequency
 b
 
Effective/ 
alternative 
allele
c
 OR (95% CI)
d
 
Meta 
P value
e
 
I
2
 (%), 
P value
f
 
 
Effect 
directions
g
 
9 77817536 rs10746970 0.68 A/T 1.19 (1.11, 1.27) 2.22 × 10
-7
 0, 6.46 × 10
-1
 ++++++ 
2 81987573 rs1653654 0.03 A/G 0.63 (0.51, 0.78) 4.27 × 10
-7
 0, 8.32 × 10
-1
 ---?-- 
17 71368680 rs75125621 0.03 G/A 0.61 (0.49, 0.77) 6.13 × 10
-7
 60, 4.03 × 10
-2
 -+-?-- 
4 145350264 rs2657795 0.21 A/C 0.82 (0.76, 0.89) 8.25 × 10
-7
 2, 3.98 × 10
-1
 ------ 
2 184738091 rs1682430 0.89 C/T 1.24 (1.10, 1.39) 1.07 × 10
-6
 21, 2.71 × 10
-1
 +++??+ 
5 141158686 rs10072382 0.02 A/G 1.99 (1.52, 2.62) 1.30 × 10
-6
 28, 2.41 × 10
-1
 +?+?++ 
13 93033916 rs9516067 0.56 A/G 1.16 (1.09, 1.24) 1.81 × 10
-6
 51, 6.69 × 10
-2
 ++++++ 
1 35627132 rs6425936 0.50 A/G 0.76 (0.68, 0.85) 1.83 × 10
-6
 16, 3.08 × 10
-1
 -??--- 
6 37583911 rs810855 0.21 C/T 0.83 (0.77, 0.90) 1.98 × 10
-6
 0, 7.97 × 10
-1
 ------ 
1 80022362 rs55939932 0.02 T/C 0.48 (0.36, 0.65) 2.01 × 10
-6
 0, 8.98 × 10
-1
 ---?-- 
3 146324544 rs163757 0.36 A/T 0.86 (0.80, 0.93) 2.79 × 10
-6
 0, 9.99 × 10
-1
 ------ 
1 240674842 rs35428289 0.21 A/G 1.22 (1.12, 1.32) 3.11 × 10
-6
 0, 4.73 × 10
-1
 ++++++ 
12 27969088 rs10771375 0.44 G/A 0.87 (0.81, 0.93) 3.13 × 10
-6
 0, 8.48 × 10
-1
 ------ 
11 93564393 rs601711 0.64 T/C 1.17 (1.09, 1.25) 3.35 × 10
-6
 0, 4.55 × 10
-1
 ++++++ 
1 41835871 rs4660191 0.97 G/A 1.75 (1.38, 2.21) 3.71 × 10
-6
 6, 3.76 × 10
-1
 -+++++ 
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Chr. Position
a
 SNP 
Effective 
allele 
frequency
 b
 
Effective/ 
alternative 
allele
c
 OR (95% CI)
d
 
Meta 
P value
e
 
I
2
 (%), 
P value
f
 
 
Effect 
directions
g
 
6 93361564 rs7750013 0.94 C/A 1.45 (1.22, 1.73) 4.05 × 10
-6
 0, 7.35 × 10
-1
 ++++++ 
19 32473222 rs8113622 0.33 T/G 0.86 (0.80, 0.92) 4.06 × 10
-6
 0, 6.13 × 10
-1
 ------ 
3 22624716 rs73033654 0.08 T/C 1.30 (1.15, 1.47) 4.20 × 10
-6
 34, 1.78 × 10
-1
 +++-++ 
2 101346696 rs7579862 0.19 G/A 1.19 (1.08, 1.30) 4.22 × 10
-6
 0, 5.36 × 10
-1
 +++??+ 
5 26698737 rs72758936 0.03 A/G 0.63 (0.52, 0.77) 4.33 × 10
-6
 39, 1.61 × 10
-1
 +--?-- 
 
a 
Human genome build 37, assembly hg19. 
 
b, c & d 
Effective allele frequency, effective/alternative allele, odd ratio and 95% CI were extracted from the meta-analysis of the genetically 
unrelated samples, whereas in the genetically mixed samples, estimates of effective allele frequency and odds ratio may be biased. 
 
e & f 
Meta and heterogeneity P values were extracted from the meta-analysis of the genetically mixed samples, which included more 
individuals, but this modelling strategy does not provide the estimation of odds ratios. 
 
g 
Directions of effect (that is the sign of log odd ratio) were extracted from the meta-analysis of the genetically unrelated samples in the order 
of EURODIAB, GoDARTS Affymetrix and Illumina genotyped samples, SDR type 1 and 2 diabetes samples and FinnDiane. 
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Table 5-5 The closest gene and the gene functional annotation for top independent (defined by >100 Kbp) signal SNPs in the whole-
genome meta-analysis of diabetic retinopathy. The regulatory region of a gene is defined by <250 Kbp upstream from the 
transcription start site (TSS), and >250 Kbp upstream from TSS is characterised as intergenic.  
 
Locus SNP Region Closest Gene Gene Function 
9q13-q21.2 rs10746970 Regulatory OSTF1 Ossification 
2p12-p11.1 rs1653654 Intergenic CTNNA2 Structural constituent of cytoskeleton 
17q25.1 rs75125621 Intronic SDK2 Cell adhesion 
4q28-q32 rs2657795 Regulatory HHIP Carbohydrate metabolic process 
2q32.1 rs1682430 Intergenic ZNF804A Transcriptional control 
5q31.3 rs10072382 Regulatory PCDH1 Nervous system development 
13q32 rs9516067 Intronic GPC5 Carbohydrate metabolic process 
1p34.3 rs6425936 Regulatory SFPQ DNA recombination and repair, RNA splicing 
6p21 rs810855 Regulatory MDGA1 Neuron migration 
1p33-p32 rs55939932 Regulatory ELTD1 Neuropeptide signaling pathway 
3q24 rs163757 Exonic PLSCR5 Unknown 
1q43 rs35428289 Intronic GREM2 Regulation of cytokine activity 
12p11.22 rs10771375 Regulatory KLHL42 Regulation of microtubule-based process 
11q21 rs601711 Intronic VSTM5 Transmembrane protein 
1p34.2 rs4660191 Intronic FOXO6 Sequence-specific DNA binding transcription factor activity 
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Locus SNP Region Closest Gene Gene Function 
6q16.1 rs7750013 Intergenic EPHA7 Retinal ganglion cell axon guidance 
19q13.11 rs8113622 Intergenic ZNF507 Regulation of transcription 
3p24.3 rs73033654 Regulatory ZNF385D Regulation of transcription 
2q11.2 rs7579862 Regulatory NPAS2 Cellular lipid metabolic process, central nervous system development 
5p14 rs72758936 Regulatory CDH9 Cell-cell adhesion 
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Figure 5-5 Power estimates for a additive single-marker test in a genome-wide meta-analysis/association studty of diabetic 
retinopathy, with retinopathy prevalence of 9.59% estimated in the GoDARTS diabetic populaiton at the recruitment time. The data 
were stratified by minor allele frequencies (MAF) and the effect sizes (relative risk) displayed in panels from left to right. Power and 
the case/control size (assuming equally sized cases and controls) were shown on the y- and x-axes respectively.  
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Table 5-6 Power estimates for each addititive single-marker test of genome-wide 
meta-analysis of diabetic retinopathy (5,422 cases and 4,302 controls). MAF: minor 
allele frequency. The assumed prevalence rate was 9.59% as in GoDARTS at the 
recruitment time. 
 
Relative risk MAF Power 
1.1 0.05 0.000 
1.1 0.10 0.001 
1.1 0.20 0.006 
1.1 0.30 0.015 
1.1 0.40 0.023 
1.1 0.50 0.025 
1.2 0.05 0.011 
1.2 0.10 0.124 
1.2 0.20 0.545 
1.2 0.30 0.771 
1.2 0.40 0.838 
1.2 0.50 0.827 
1.3 0.05 0.209 
1.3 0.10 0.787 
1.3 0.20 0.994 
1.3 0.30 1.000 
1.3 0.40 1.000 
1.3 0.50 1.000 
1.5 0.05 0.973 
1.5 0.10 1.000 
1.5 0.20 1.000 
1.5 0.30 1.000 
1.5 0.40 1.000 
1.5 0.50 1.000 
2.0 0.05 1.000 
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2.0 0.10 1.000 
2.0 0.20 1.000 
2.0 0.30 1.000 
2.0 0.40 1.000 
2.0 0.50 1.000 
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5.3 Conclusions 
In this study, we performed the largest genome-wide meta-analysis to date of retinopathy 
from patients with type 1 and type 2 diabetes. This study considered genetic unrelated and 
mixed relatedness samples separately, as the unbiased estimation of odds ratio requires the 
study sample reflective the underlying population that consists of largely genetically 
unrelated individuals. Besides, so as to increase study power, linear mixed model was 
applied to the analysis of the genetically mixed sample, which in contrary to the logistic 
regression approach employed separately for the unrelated sample, does not provide an 
estimate for odds ratio. Thus, we included the statistics from these analyses. In the current 
study, we identified the most significant signal SNP rs10746970 (P value of 2.22×10
-7
). In 
this study, we found diabetic retinopathy risk loci 1q43, 2q32.1, 6q16.1 13q32 identified in 
this study are in close proximity to regions of 1q13-42, 2q31-47, 6q22-27 and 13q14-32 
that were previously reported in smaller sized genome-wide association studies of diabetic 
retinopathy [28,81–83]. Additionally, we discovered previously unreported retinopathy risk 
loci of 1p34-p32, 2p12-p11.1, 2q11.2, 3p24.3, 3q24, 4q28-q32, 5p14, 5q31.3, 6p21, q13-
q21.2, 11q21, 12p11.22, 17q25.1 and 19q13.11 (Table 5-9). The identification of extensive 
susceptibility loci is suggestive of polygeneic effects contributing to the development of 
diabetic retinopathy. The closest genes to these loci have been implicated in multiple 
physiological processes including carbohydrate/lipid metabolism, functional activity in the 
neuronal and glial cells, and transcription regulation.  
 
The strongest signal SNP rs10746970 is located in the intergenic region of OSTF1 
(osteoclast stimulating factor 1) at 9q13-21.2. Encoded OSTF1 is an intracellular protein, 
and its known function include the indirect stimulation of the formation of osteoclasts and 
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bone resorption, a continual bone renewal process involving bone breaking down by 
osteoclasts, releasing of minerals in the medium of bone fluid into the circulation [170]. 
The OSTF1 protein is expressed in brain, platelets and white blood cells including 
monocytes, neutrophils, and lymphocytes (based on the protein expression databases of 
MOPED [171], PaxDb [172] and MaxQB [173]). OSTF1 was studied in a SNP array of 
candidate genes for osteoporosis, an imbalance between the resorption and the formation of 
bone [174]. However, as of 18 October 2014, neither this SNP nor the closest gene OSTF1 
was reported in the GWAS Catalog. . Patients with the genetic disorder of 9q21 deletions 
showed mental retardation with speech delay, epilepsy and facial dysmorphy [175]. The 
physiological role of OSTF1 in the aetiology of diabetic retinopathy is currently unknown. 
 
The second strongest association signal rs1653654 is in an intergenic region of CTNNA2, 
catenin (cadherin-associated protein) alpha 2 at 2p12-p11.1. Catenin alpha-2 is a scaffold 
protein in the cytoskeleton, and its function is implicated in cell-cell adhesion, cell 
morphogenesis and differentiation of the nervous system. Catenin alpha-2 is highly 
expressed in the brain (based on the protein expression databases of MOPED, PaxDb and 
MaxQB). No reported association was found for rs1653654 in any published GWAS. 
However, the CTNNA2 gene was reported in the genome-wide association analyses of eye 
colours [176], bipolar disorder [177], Alzheimer’s disease [178], orthostatic hypotension 
[179] and excitement-seeking [180]. The connection of CTNNA2 with diabetic retinopathy 
awaits further investigations.  
 
These support suggestive functional associations of top ranked SNPs in the meta-analysis 
with diabetic retinopathy. However, statistically significant SNPs identified in this study 
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were novel (Appendix Table A-1). These variants and the nearest genes have not been 
reported in candidate polymorphism, genome-wide linkage or previous genome-wide 
association studies (Table 5-7, Table 5-8 and Table 5-9). None of the previous GWAS 
signals shown in Table 5-9 achieved the genome-wide significance in our meta-analysis 
after correction for multiple testing (data not shown). 
 
A major strength of this study is the deeply phenotyped data of retinopathy in the large, 
homogenous European diabetic cohorts. This should help control population stratification 
and reduce differential environmental influences. This study attained cohort samples 
overall close to 10,000 subjects, which increased the opportunity of discovering retinopathy 
susceptibility loci. Another advantage of this study is the utility of 1000 Genomes 
imputation which increased the size of genetic variants to several fold greater compared to 
Hapmap Phase II imputation. This should help increasing the probability of identifying 
association variants across the allele frequency spectrum, including relatively rare variants. 
In addition, this study analysed diabetic retinopathy associations in both genetically 
unrelated and mixed samples. Association data from the genetically unrelated sample 
provided an unbiased estimation of effect size for the genetic effect. The analysis of the 
genetically mixed sample enlarged the study sample sizes, resulting in a modest increase in 
the association results.  
 
In this study, we made every effort to standardise different clinical classification and 
grading systems for diabetic retinopathy between cohorts in SUMMIT. However, the 
complete compatibility of diabetic retinopathy phenotype definitions across studies may be 
difficult to attain. Additionally, the use of imputation to augment the number of genetic 
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variants in the study may introduce inaccurately predicted genotypes, as this is reflected by 
the mean correlation between imputed and true genotypes of 0.82 to 0.91 [181]. When this 
error rate is applied to the scale of several million variants, the size of inaccurately imputed 
genotypes may be substantial. Thirdly, we did not adjust retinopathy for the duration of 
diabetes, as negative durations were observed (Figure 2-3), despite of cross-validation of 
diabetes diagnosis dates with laboratory biochemistry records. Thus, the fidelity of dates of 
retinopathy screening in the database may be open to questioning, which however, was 
recognised as a drawback of an observational study in contrast to a prospective cohort, as 
the retinal screening was initiated in the early 1990s when the recording, entry, and 
annotation of the vast amount of retinopathy data was completely manual. In our data, we 
observed retinopathy cases declining over the durations of diabetes since the time of 
diabetes diagnosis, whilst the number of retinopathy controls peaked at approximately 5 
years of duration of diabetes. This was likely reflective of possible imprecision of diabetes 
diagnosis dates in the GoDARTS database, and a more probable justification is that patients 
with diabetes may be undiagnosed for years till the manifestation of secondary 
complications, such as retinopathy. Finally, population outliers were identified from 
multidimensional scaling of identity by descent (IBD) and subsequently removed. Thus, 
within the genetically unrelated sample, there was no further population stratification such 
as genetic relatedness to be accounted for, whereas in the genetically mixed sample, linear 
mixed model used in the analysis captured genetic relatedness simultaneously [121]. Thus, 
further adjustment by principal components was not imperative as exemplified by previous 
GWAS publications [182].  
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We estimated statistical power of each additive test of markers in the genome-wide meta-
analysis of diabetic retinopathy. This data was suggestive of a rapid rise in power for 
detecting genome-wide significant SNPs with an increase of the relative risk from 1.1 to 1.3. 
This trend was supported by a previous study (Figure 5-6) [87]. Additionally, the study 
power was 0.973 or greater for SNPs with MAF of 0.05 or greater, which was supportive of 
the proposition that diabetic retinopathy is a polygenic phenotype with each genetic variant 
conferring a small risk. These rare variants may remain undetected in this meta-analysis. 
Nevertheless,  power estimation assumed the same rate of diabetic retinopathy prevalence 
across study cohorts, and the actual power of this meta-analysis may be influenced by the 
prevalence rate within each cohort. 
 
In summary, this study utilised the whole-genome meta-analysis approach to investigate 
genetic susceptibility of diabetic retinopathy. We observed strong genetic associations with 
diabetic retinopathy across the genome, but none have achieved the stringent genome wide 
significance. A number of these association regions were confirmed by smaller-sized 
association studies of diabetic retinopathy. While the pathophysiology of diabetic 
retinopathy remains elusive, genes in the pathways of carbohydrate/lipid metabolism, the 
functional activity in the neuronal and glial cells, and transcription regulation are 
implicated in the development of diabetic retinopathy. We expect the addition of further 
cohorts to the genome-wide meta-analysis from the CHARGE (Cohorts for Heart and 
Aging Research in Genomic Epidemiology) and East Asia Eye consortiums where we hope 
to achieve over 10,000 cases versus 10,000 controls. This is likely to improve the statistical 
power for detecting variants with moderate effect sizes, and thus P values of diabetic 
retinopathy association results are more likely to attain the genome-wide significance.   
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Table 5-7 Genetic variants of candidate genes for diabetic retinopathy (DR) in the 
European heritage population reported in a systematic meta-analysis [183].  INDEL: 
insertion-deletion polymorphisms; PDR: proliferative DR. 
 
Gene  Variant Risk 
allele 
DR 
definition 
Type of 
diabetes 
P Reference 
ACE INDEL at 
intron 16 
287 bp 
deletio
n 
No DR vs. 
any DR 
Type 1 0.54 [184–189] 
    Type 2 0.92 [186,190–192] 
    Total  0.72  
   No DR vs. 
PDR 
Type 1 0.44 [184,185,187,188] 
    Type 2 0.56 [192] 
    Total  0.30  
   NPDR vs. 
PDR 
Type 1 3.0×10-4 [187] 
    Type 2 0.19 [192,193] 
    Total 0.05  
NOS3 rs3138808 393 bp 
inserti
on 
No DR vs. 
any DR 
Type 1 3.6×10-3 [194] 
    Type 2 0.62 [195] 
    Total  0.45  
VEGF rs2010963 G No DR vs. 
any DR 
Type 2 0.16 [196,197] 
AKR1
B1 
rs759853 T No DR vs. 
any DR 
Type 1 1.0×10
-4 [198,199] 
    Type 2 0.68 [200] 
    Total 0.21  
AKR1
B1 
microsatel
lite 
z No DR vs. 
any DR 
Type 1 0.38 [198,201,202] 
    Type 2 0.05 [203] 
    Total 0.81  
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  z No DR vs. 
PDR 
Type 1 0.20 [202] 
    Type 2 0.05 [203] 
    Total 0.79  
  z-2 No DR vs. 
any DR 
Type 1 0.12 [198,201,202] 
    Type 2 9.1×10-3 [203] 
    Total 0.03  
  z-2 No DR vs. 
PDR 
Type 1 0.80 [202] 
    Type 2 9.1×10-3 [203] 
    Total 0.42  
  z+2 No DR vs. 
any DR 
Type 1 0.07 [202] 
    Type 2 0.30 [203] 
    Total 0.04  
  z+2 No DR vs. 
PDR 
Type 1 0.88 [198,201,202] 
    Type 2 0.30 [203] 
    Total 0.46  
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Table 5-8 Human chromosome regions showing evidence of linkage to diabetic 
retinopathy (DR) (logarithm of odds, LOD > 1) [204]. NPDR/PDR: non-
proliferative/proliferative DR.  
 
Locus Closest 
microsatellite 
marker 
Diabetic retinopathy 
definition 
Population LOD 
score 
Reference 
1p36 D1S3669 Retinopathy score in 
worst eye  
Pima Indians 3.10 [153] 
1p36 GGAT2A07  Any DR Mexican 
Americans 
1.24 [205] 
2q37 AFM112yd4  Severe NPDR/PDR Mexican 
Americans 
1.11 [205] 
3p26 GATA22G12 Severe NPDR/PDR Mexican 
Americans 
1.29 [205] 
3q12 GATA68D03 Severe NPDR/PDR Mexican 
Americans 
1.40 [205] 
3q12 GATA68D03 Any DR Mexican 
Americans 
2.41 [205] 
3q26 D3S3053, 
D3S2427 
Presence of at least one 
microaneurysm, 
haemorrhage or PDR 
Pima Indians 1.36 [206] 
7p15 GATA41G07 Any DR Mexican 
Americans 
1.02 [205] 
9q21 D9S1120, 
D9S910 
Presence of at least one 
microaneurysm, 
haemorrhage or PDR 
Pima Indians 1.46 [206] 
12p13 GATA49D12 Any DR Mexican 
Americans 
2.47 [205] 
12q23 GATA85A04 Severe NPDR/PDR Mexican 
Americans 
1.03 [205] 
15q25 ATA28G05 Any DR Mexican 
Americans 
1.07 [205] 
15q26 GATA22F01 Any DR Mexican 
Americans 
1.16 [205] 
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Table 5-9 Diabetic retinopathy (DR) associated SNPs reported in GWAS to date. DR characterisation in references [81], [82], [83] 
and [28] is moderate-to-severe non-proliferative and proliferative DR (PDR) in type 2 diabetic patients, non-proliferative and PDR 
in type 2 diabetic patients, diabetic macular edema and PDR in type 1 diabetic patients, and PDR in type 2 diabetic patients, 
respectively.  
 
Locus SNP Population Reference 
allele 
OR (95% 
CI) 
P Closest 
Gene 
Function Reference 
6p12.1 rs6909083 Mexican 
Americans 
-- -- 1.80×10-5 TINAG Nephrogenesis [81] 
6q22.31 rs17083119 Mexican 
Americans 
-- -- 2.76×10-5 C6orf179 Unknown [81] 
1q23 rs1033465 Mexican 
Americans 
-- -- 4.50×10-5 TNFSF18 T lymphocyte survival in 
peripheral tissues 
[81] 
1q13 rs11583330 Mexican 
Americans 
-- -- 5.35×10-5 GNAI3 Transmembrane signaling 
pathways 
[81] 
1q42.11 rs3014267 Mexican 
Americans 
-- -- 6.58×10-5 CDC42BPA Peripheral actin formation and 
cytoskeletal reorganization 
[81] 
15q13.3 rs11635920 Mexican 
Americans 
-- -- 7.18×10-5 FMN1 Unknown [81] 
2q34 rs6726798 Mexican 
Americans 
-- -- 8.66×10-5 FN1 Cell adhesion and migration 
processes 
[81] 
10q21.1 rs11812882 Mexican -- -- 8.85×10-5 CISD1 Regulation of oxidation [81] 
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Locus SNP Population Reference 
allele 
OR (95% 
CI) 
P Closest 
Gene 
Function Reference 
Americans 
2q35 rs1106412 Mexican 
Americans 
-- -- 8.9×10-5 USP37 Ubiquitin specific hydrolysis [81] 
3p24.2 rs11927173 Mexican 
Americans 
-- -- 9.4×10-5 UBE2E2 Ubiquitin conjugation [81] 
8q22.3 rs3098241 Mexican 
Americans 
-- -- 9.7×10-5 DCAF13 Signal transduction, pre-mRNA 
processing and cytoskeleton 
assembly 
[81] 
1p32.1 rs2811893 Taiwanese T 1.50 
(1.03:2.20) 
3.1×10-7 MYSM1 Transcription regulation [82] 
4q32.1 rs4470583 Taiwanese A 1.16 
(0.70:1..92) 
4.3×10-7 RPS14P7 Ribosomal protein [82] 
5q15 rs13163610 Taiwanese A 3.59 
(1.36:9.47) 
3.2×10-16 KIAA0825 Unknown [82] 
10p12.31 rs12219125 Taiwanese T 1.62 
(1.02:2.58) 
9.3×10-9 PLXDC2 Unknown [82] 
10q11.22 rs4838605 Taiwanese C 1.58 
(1.00:2.52) 
1.9×10-9 ARHGAP22 Regulation of cell motility [82] 
10q21.1 rs4462262 Taiwanese C 1.54 
(0.79:2.99) 
9.2×10-9 IPMK Nuclear mRNA export [82] 
13q32.1 rs2038823 Taiwanese C 2.33 
(1.13:4.77) 
4.7×10-11 HS6ST3 Proliferation, differentiation, 
adhesion, migration, 
inflammation and blood 
coagulation 
[82] 
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Locus SNP Population Reference 
allele 
OR (95% 
CI) 
P Closest 
Gene 
Function Reference 
6q27 rs227455 Caucasian C 0.53 1.6×10-7 C6orf118 Unknown [83] 
16p11.2 rs151320 Caucasian A 0.58 3.1×10-6 CCDC101 Regulation of transcription [83] 
17p11.2 rs11871508 Caucasian A 0.27 4.8×10-6 TVP23B Unknown [83] 
13q14.11 rs238252 Caucasian C 1.41 6.3×10-6 AKAP11 Cell cycle control [83] 
16p12.1 rs11074904 Caucasian C 0.58 7.8×10-6 SULT1A1 Sulfate conjugation of 
hormones, neurotransmitters, 
drugs, and xenobiotic 
compounds 
[83] 
10p12.31 rs17670074 Caucasian A 1.58 8.1×10-6 PLXDC2 Unknown [83] 
13q22.2 rs9565164 Taiwanese C 1.7 4.4×10-7 TBC1D4 Unknown [28] 
2q31.1 rs1399634 Taiwanese A 1.5 4.2×10-6 LRP2 Cell signaling  [28]  
2q37.1 rs2380261 Taiwanese T 1.5 4.7×10-6 ARL4C Cholesterol transport [28] 
 
The study by Fu et al. [81]: Reference allele and odds ratio were not represented for these imputed SNPs. 
The study by Huang et al. [82]: Genotypes were dominantly coded, in contrast to the additive coding of genotypes in other referenced 
studies. 
The studies by Grassi et al. [83] and Sheu et al. [28]: 95% confidence intervals of odds ratio were not reported.  
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Figure 5-6 Power (solid lines) and genome coverage (dotted lines) assuming increasing 
relative risks (above each plot) with a range of sample sizes and frequencies of relative 
risk allele (RAF) in the CEU and YRI Hapmap population samples, adapted from [87]. 
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Chapter 6  
Concluding remarks 
 
Deciphering the pathophysiology of diabetic retinopathy has been a long endeavour for 
research scientists. During the past two decades, the establishment and the growth of 
densely phenotyped diabetic retinopathy cohorts exemplified by GoDARTS raised the 
opportunity for studying common clinical risk factors for retinopathy at a population-wide 
scale [10,11,15,17,20]. Much of the aetiology of diabetic retinopathy remains elusive. Thus, 
the main objective of our research was to study clinical and genetic determinants of diabetic 
retinopathy in the GoDARTS cohort. Retinopathy risk factors adjusted in the current 
studies for this thesis did not form the exhaustive list, but rather the most common life style 
factors towards the development of retinopathy in the diabetic population. It is possible that 
other confounding factors with moderate risk effect may exist, and yet to be further studied. 
For example, pregnancy was one of the contributing factors towards the exacerbation of 
diabetic retinopathy in 10% of cases [218].  
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First, we utilised the multi-state Markov model for studying the influence of common 
population risk factors on the progression and remission of diabetic retinopathy by 
capturing longitudinal retinal events in 4,758 GoDARTS patients since the diagnosis of 
diabetes for up to 16 years’ follow up. As this statistical model was computational intensive 
for each single analysis, the application of this methodology to a genome-wide scale 
became futile. In the later study, we used one-time measures of diabetic retinopathy to 
investigate heritability and genetic correlation for diabetic retinopathy and related risk 
factors explained by common genome-wide SNPs. The estimated narrow-sense heritability 
for diabetic retinopathy captured by whole-genome SNP data was supportive of common 
genetic polymorphisms underpinning diabetic retinopathy. This provided a strong basis for 
the genome-wide meta-analysis of diabetic retinopathy with the SUMMIT collaborators 
(EURODIAB, FinnDiane and SDR cohorts).  
 
In the genetic study of retinopathy, we pooled samples from type 1 and type 2 diabetic 
populations, as we aimed to attain greater study power to detect moderate genetic effects. 
Despite that the clinical profiles of type 1 and type 2 diabetes may differ considerably, 
retinal vascular dysfunctions, such as haemorrhages, occlusion and retinal 
neovascularisation was previously shown to be common in both types of diabetes [207,208]. 
Akin to the previous studies [207,208], the sample pooling approach we adopted here for 
studying retinopathy was considered unbiased and sensitive in detecting retinal 
abnormalities. In the following sections, we will discuss the main conclusions for these 
studies. 
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6.1 The influence of population risk factors on diabetic 
retinopathy severity over the duration of diabetes 
As described in Chapter 3, in the GoDARTS, the severity of diabetic retinopathy of each 
patient was captured by a series of follow-up observations for the duration of diabetes. This 
enabled us to delineate the rates of transitions across retinopathy states dependent upon the 
influence of common population risk factors. The key finding was that glycaemic exposure 
and blood pressure were strongly associated with the progression and remission of diabetic 
retinopathy. This discovery was consistent with previously reported diabetic retinopathy 
studies in which case-control or time-to-event phenotypes were analysed [21,142–151,155]. 
In this study, we found that with the adjustment of glycaemic exposure and blood pressure, 
the evidence for independent associations with transition rates across retinopathy states was 
insignificant for cholesterol, triglycerides and non-HDL-c. Our data suggested that the 
evidence for BMI, serum creatinine, HDL-c, sex and smoking influencing diabetic 
retinopathy progression and regression may be weak in the single covariate analyses after 
the adjustment of multiple testing. 
 
There are a number of conflicting reports of the risk effect of cholesterol, triglycerides, 
non-HDL-c, BMI, serum creatinine, HDL-c, sex and smoking status [209–211]. We 
suggest that these disagreements may have arisen from sources including covariates 
adjusted in these analyses, the units of these covariates (direct measures or transformed 
scales), the sample sizes of these studies, the ethnicity of the study sample, and the study 
definition of retinopathy (case-control, ordinal categorical phenotypes, time-to-retinopathy, 
or time serial data of retinopathy as in this study). The analytical approach we presented 
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here is permissible in the future research to study the stage-by-stage development of 
diabetic retinopathy influenced by therapeutic medicine and genetic variants. Further work 
is required to optimise the computational performance of the methodology in order for its 
application to genome-wide association analysis of millions of genetic variants. 
Nevertheless, our results are valuable for clinical prognosis and treatment of diabetic 
retinopathy. Indeed the Scottish Diabetes Research Group is now investigating this 
methodology to optimise retinal screening intervals at the population level. Importantly, the 
long duration of diabetes for patients in the states of no-retinopathy and mild background 
retinopathy due to the tight regulation of blood pressure and glycaemic exposure provides 
the evidence for a stratified approach to personalise screening intervals. This may have a 
great impact on increasing the efficacy and decreasing the cost of the national screening 
programme. 
 
6.2 Heritability and genetic correlations explained by 
common SNPs for diabetic retinopathy and related 
risk factors 
The study presented in Chapter 4 was motivated by the observation that a large proportion 
of narrow-sense heritability and genetic correlations of metabolic traits in a non-diabetic 
population sample were captured by common genome-wide SNPs [108]. However, the 
methodology (the restricted maximum likelihood estimation) was only applicable to traits 
quantitative in nature, and it is computationally intractable for the analysis of ordinal traits 
such as diabetic retinopathy. Therefore, a Markov chain Monte Carlo (MCMC) sampling 
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algorithm was the only feasible method for a study of this kind. Dr Minghui Wang, 
Birmingham University, developed the software for running an efficient Gibbs sampler (an 
MCMC algorithm), and we applied it for the estimation of narrow-sense heritability and 
genetic correlation for diabetic retinopathy and related risk factors with the adjustment for 
age, sex and duration of diabetes in the GoDARTS Affymetrix 6 genotyped samples.  
 
In this study data, we found that up to 34% phenotypic variations of diabetic retinopathy 
were accounted for by total additive genetic variations. In the analysis of genetic and 
residual correlations, the wide credible intervals of our estimates limited our ability to make 
more meaningful inference. However, at the 5% significance level, retinopathy with 
cholesterol showed positive residual correlation in the genetically unrelated sample. Our 
data confirmed the negative genetic and residual correlation between triglycerides and 
HDL-c [108]. Triglycerides also showed residual correlation with total cholesterol and 
glycaemic exposure. 
 
We expect to discover more genetically correlated traits with diabetic retinopathy based on 
genome-wide SNP data with a larger sample. The main constraint with this plan lies within 
the slow convergence with the MCMC method, which took days and weeks to complete the 
analytical process at the current sample size. However, the utility of this methodology was 
vital, as the alternative, time-saving method remains applicable to pairs of numerical or 
binary traits [108]. In addition, for this methodology, it required an unbiased population 
sample, which is reflective of retinopathy prevalence in the population. Thus, due to this 
limitation, we did not include the GoDARTS Illumina genotyped samples that were 
selected for retinopathy. Future studies may be motivated to investigate an approach for 
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correcting ascertainment bias for ordinal traits in a non-random sample. The methodology 
we utilised here is also applicable to family data, where genome-wide variant data is 
unavailable, but trait phenotypes and familial relationship are known. In this case, the 
results of heritability and genetic correlations are accounted for by all genetic effects 
including additive, dominant, epistatic, maternal and paternal effects [63]. Future studies 
may also be interested in investigating pleiotropic effects of genome-wide variants [165]. 
Overall, this study may be the cornerstone of future studies of correlated clinical 
phenotypes.  
 
6.3 The SUMMIT genome-wide meta-analysis of diabetic 
retinopathy 
In Chapter 5, we presented the largest whole-genome meta-analysis of diabetic retinopathy 
to date, which included 9,724 retinopathy patients with either type 1 or type 2 diabetes. In 
this study, we identified top ranked association SNPs after the adjustment for age, sex and 
glycaemic exposure for diabetic retinopathy, and rs10746970 at 9q13-q21.2 was the 
strongest association signal (P value of 2.2 × 10
-7
). The association regions of 1q43, 2q32.1, 
6q22-27, and 13q14-32 were confirmed by previously published smaller-scaled association 
studies of diabetic retinopathy [28,81–83]. The closest genes are implicated in 
carbohydrate/lipid metabolism, functional activity in the neuronal and glial cells, and 
transcription regulation. These findings support the argument that a large number of genetic 
variants with moderate effects contribute to the development of diabetic retinopathy [212].  
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It is possible that SNPs with minor allele frequencies < 1%, un-genotyped loci with weak 
linkage disequilibrium with the genotyped/imputed SNPs, and copy number variants that 
have not been investigated in this study are also accountable for the predisposition of 
diabetic retinopathy [213]. It is increasingly likely that these challenges are solvable 
through the whole-genome sequencing technologies [214,215]. The plan for the next phase 
of this project is to seek the locus-based and whole-genome meta-analysis replication of 
diabetic retinopathy with the CHARGE (Cohorts for Heart and Aging Research in Genetic 
Epidemiology) [216] and East Asia Eye consortiums. With an increased sample size, it is 
hopeful that the top ranked association SNPs may be replicated to attain higher statistical 
significance. As the GoDARTS study is a source of high quality phenotype and genotype 
data of diabetic retinopathy, there may also an opportunity to integrate metabolomics and 
gene expression, when available, to investigate the complex system behaviour of diabetic 
retinopathy pathophysiology [217]. In conclusion, this study is the latest and the largest 
effort in mapping diabetic retinopathy susceptibility loci in the human genome. The follow-
up work may shed additional light on the pathological mechanism of diabetic retinopathy. 
 
6.4 Future studies 
This series of studies provided the stepping stone for future studies. For instance, research 
interest may arise from the study of the extreme phenotypes that may be retinopathy cases 
with good glycaemic control or progressed to retinopathy shortly after diabetes diagnosis. 
Wherever the dates of diabetes diagnosis were accurate, we would encourage the use of 
diabetes duration in the analysis. Despite of the unparalleled research efforts in the 
susceptibility of diabetic retinopathy, much of the genetic architecture linking 
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polymorphisms with cellular functions remains an under-explored area. Newer research 
motivation lies within the paradigm that genetic polymorphisms mediate functional impacts 
through differential gene transcription and mRNA translation. For example, the study by 
Pasquali et al. [219] formed the strong evidence that genetic polymorphisms of type 2 
diabetes are frequently mapped to non-coding regions of genes, and the observed risk 
alterations were attributable to the susceptibility loci differentially interacting with 
transcription factors regulating gene transcription (Figure 6-1). Similarly, the regulatory 
link between genetic polymorphisms and gene expression has been shown in other clinical 
phenotypes [220].  
 
In 2011, the study by Bixler et al. [221] showed that expression alterations of 5% genes in 
the retina under the diabetic state were not reversible by the insulin treatment in rats, 
implicating dysregulated gene expressions underlying the pathophysiology of diabetic 
retinopathy. In the following year, Kandpal et al. [222] identified transcriptomic signatures 
for diabetic retinopathy in mice and these differentially expressed genes were associated 
with a diverse range of cellular functions including inflammation, microvasculature and 
glucose metabolism. These observed expression changes were inhibited by attenuating the 
activity of RAGE or p38 MAP kinase [222]. In the same year, the study by Brondani et al. 
[223] became the first study to date investigating genetic polymorphisms (within the gene 
of uncoupling protein 1) associated with diabetic retinopathy through the correlation with 
differentially expressed genes (uncoupling protein 1 and superoxide dismutase-2) in human 
retina. However, few genetic polymorphisms and retina-expressed genes were examined in 
this study [223]. This offers the unprecedented potential for leveraging genome-wide 
polymorphism data in studying regulated gene expressions underlying the pathophysiology 
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of diabetic retinopathy. A study of this kind may demonstrate regulatome influenced by 
genetic polymorphisms associated with diabetic retinopathy, and also highlight possible 
interaction of genetic variants in the regulatory network. This may provide a detailed 
functional annotation of genetic polymorphisms underlying the susceptibility of diabetic 
retinopathy.  
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Figure 6-1 Alleles haboured at an enhancer cluster differentially regulate gene 
expression in the pancreatic islet [219]. In the pancreatic islet, the wild-type allele 
enhances the binding of transcription factor to the enhancer, and subsequently 
induces high-level transcription (the top panel). The type 2 diabetes risk allele inhibits 
the binding of transcription factor to the enhancer, leading to reduced gene expression 
in the pancreatic islet (to bottom panel). This was associated with pancreatic 
dysfunction.  
 
 
 
6.5 Publications 
The longitudinal analysis of diabetic retinopathy described in Chapter 3 was published 
[224]. We also participated in the replication of diabetic retinopathy risk loci for the 
Candidate gene Association Resource (CARe) study [225].  
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Appendix A MCMC data inspection tools: trace, density and 
autocorrelation plots 
A trace plot provides a visual tool for assessing the convergence of MCMC (here, Gibbs sampling) data. In a trace plot, sampled parameter 
values are plotted against the iteration number. Frequently, sampling data is collected after a period of software running, to ensure only non-
convergent data is filtered out. The MCMC sampling data is also named as a (Markove) chain, as this is sampled from population 
distributions guided by the Markov chain. The trace is informative of whether the data has converged to its stationary distribution (the 
unobserved distribution of true parameter values). An MCMC algorithm is efficient (mixed well), if it samples the space of parameter values 
rapidly. The trace plot is also informational of whether sampling is efficient. 
 
The sampled data may be convergent, if the distribution of sampled values does not show a systematic trend of upward or downward 
variations, as the iteration number increases. In a trace plot, this is recognised by a constant mean and variance.  
  
203 
 
 
 
Appendix Figure A-1 Traces [226] for (a) convergent MCMC data, (b) mixed convergence data with non-convergent initial values and (c) 
poor convergence data with unacceptable mixing. 
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(a) Sampled data appeared centred at 3, with very small fluctuations, suggesting that the MCMC chain may have converged. The example 
MCMC data traversed regions with low density. Therefore, it can be concluded that data is well mixed and converged. 
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(b) A chain with initial non-convergent values settled to convergence as sampling proceeded. The initial sampled data should be discarded. 
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(c) The trace explored very narrow range of parameter values within a period of iterations, indicating of poor mixing. The upward trend 
indicates the MCMC data is non-convergent. 
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MCMC data is a series of parameter values 1Y , 2Y , ..., NY  at equally spaced sampling time 1X , 2X , ..., NX . The lag k  autocorrelation is 
defined by 
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 [227]. It is anticipated that in a well-mixed MCMC data, autocorrelation would decrease with an 
increasing lag k . For example, the autocorrelation between the 1st sampled value of parameters and the 100
th
 value should be smaller than 
the autocorrelation between the 1
st
 value and 10
th
 value. Consistently high autocorrelations would indicate poor mixing, which is manifested 
in an autocorrelation plot as similarly heights of bars (values of autocorrelation).  
 
The density plot visually presents the distribution of sampled MCMC data, and can be used in inferring the statistical characteristics of this 
distribution (for example, the mode and the dispersion of the MCMC data). 
  
208 
 
 
 
Appendix B MCMC data plots for univariate mixed models 
 
Appendix Figure B-1 Trace, density and autocorrelation plots of genetic (Vg) and/or residual (Ve) variance, heritability (hg
2
) 
captured by common genome-wide SNPs for BMI and RET (an examplified sample) are shown. BMI: body mass index; RET: 
retinopathy.  
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Appendix C MCMC data plots for bivariate mixed models 
 
Appendix Figure C-1 Trace, density and autocorrelation plots of genetic (rg) and residual (re) correlation coefficients captured by 
common genome-wide SNPs for BMI-TG and HDL-TG (an examplified sample)are shown. BMI: body mass index; HDL (HDL-c): 
high-density lipoprotein cholesterol; TG: triglycerides.  
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Appendix Figure C-2 Density plots of genetic (rg) and residual (re) correlation coefficients captured by common genome-wide SNPs 
for RET-CHL and RET-CRE (an exemplified sample) are shown. CHL: cholesterol; CRE: serum creatinine; RET: retinopathy.  
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Appendix D The SUMMIT genome-wide meta-anlaysis of diabetic 
retinopathy 
 
Appendix Table D-1 Top signal SNPs in the indpendent regions (>100 Kbp) with the assocation significance (P value < 10
-5
) based on 
the SUMMIT genome-wide meta-analysis of diabetic retinopathy.  
 
Chr. Position
a
 SNP 
Effective 
allele 
frequency
 b
 
Effective/ 
alternative 
allele
c
 OR (95% CI)
d
 
Meta 
P value
e
 
I
2
 (%), 
P value
f
 
9 77817536 rs10746970 0.68 A/T 1.19 (1.11, 1.27) 2.22 × 10
-7
 0, 6.46 × 10
-1
 
2 81987573 rs1653654 0.03 A/G 0.63 (0.51, 0.78) 4.27 × 10
-7
 0, 8.32 × 10
-1
 
17 71368680 rs75125621 0.03 G/A 0.61 (0.49, 0.77) 6.13 × 10
-7
 60, 4.03 × 10
-2
 
4 145350264 rs2657795 0.21 A/C 0.82 (0.76, 0.89) 8.25 × 10
-7
 2, 3.98 × 10
-1
 
2 184738091 rs1682430 0.89 C/T 1.24 (1.10, 1.39) 1.07 × 10
-6
 21, 2.71 × 10
-1
 
5 141158686 rs10072382 0.02 A/G 1.99 (1.52, 2.62) 1.30 × 10
-6
 28, 2.41 × 10
-1
 
13 93033916 rs9516067 0.56 A/G 1.16 (1.09, 1.24) 1.81 × 10
-6
 51, 6.69 × 10
-2
 
1 35627132 rs6425936 0.50 A/G 0.76 (0.68, 0.85) 1.83 × 10
-6
 16, 3.08 × 10
-1
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Chr. Position
a
 SNP 
Effective 
allele 
frequency
 b
 
Effective/ 
alternative 
allele
c
 OR (95% CI)
d
 
Meta 
P value
e
 
I
2
 (%), 
P value
f
 
6 37583911 rs810855 0.21 C/T 0.83 (0.77, 0.90) 1.98 × 10
-6
 0, 7.97 × 10
-1
 
1 80022362 rs55939932 0.02 T/C 0.48 (0.36, 0.65) 2.01 × 10
-6
 0, 8.98 × 10
-1
 
3 146324544 rs163757 0.36 A/T 0.86 (0.80, 0.93) 2.79 × 10
-6
 0, 9.99 × 10
-1
 
1 240674842 rs35428289 0.21 A/G 1.22 (1.12, 1.32) 3.11 × 10
-6
 0, 4.73 × 10
-1
 
12 27969088 rs10771375 0.44 G/A 0.87 (0.81, 0.93) 3.13 × 10
-6
 0, 8.48 × 10
-1
 
11 93564393 rs601711 0.64 T/C 1.17 (1.09, 1.25) 3.35 × 10
-6
 0, 4.55 × 10
-1
 
1 41835871 rs4660191 0.97 G/A 1.75 (1.38, 2.21) 3.71 × 10
-6
 6, 3.76 × 10
-1
 
6 93361564 rs7750013 0.94 C/A 1.45 (1.22, 1.73) 4.05 × 10
-6
 0, 7.35 × 10
-1
 
19 32473222 rs8113622 0.33 T/G 0.86 (0.80, 0.92) 4.06 × 10
-6
 0, 6.13 × 10
-1
 
3 22624716 rs73033654 0.08 T/C 1.30 (1.15, 1.47) 4.20 × 10
-6
 34, 1.78 × 10
-1
 
2 101346696 rs7579862 0.19 G/A 1.19 (1.08, 1.30) 4.22 × 10
-6
 0, 5.36 × 10
-1
 
5 26698737 rs72758936 0.03 A/G 0.63 (0.52, 0.77) 4.33 × 10
-6
 39, 1.61 × 10
-1
 
6 79036864 rs1338321 0.63 G/A 1.16 (1.09, 1.25) 5.50 × 10
-6
 27, 2.32 × 10
-1
 
8 17983016 rs2739683 0.02 C/T 1.68 (1.36, 2.08) 6.10 × 10
-6
 0, 8.98 × 10
-1
 
1 35384605 rs6699355 0.87 T/C 0.78 (0.70, 0.87) 6.13 × 10
-6
 45, 1.02 × 10
-1
 
5 55643386 rs184989476 0.04 C/T 0.62 (0.50, 0.76) 6.33 × 10
-6
 21, 2.71 × 10
-1
 
8 127535431 rs10101440 0.87 T/G 0.80 (0.73, 0.88) 6.83 × 10
-6
 0, 4.23 × 10
-1
 
2 88720222 rs72929232 0.05 G/A 0.71 (0.62, 0.82) 6.87 × 10
-6
 29, 2.17 × 10
-1
 
22 21357602 rs396130 0.20 C/T 1.23 (1.13, 1.34) 7.45 × 10
-6
 0, 6.22 × 10
-1
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Chr. Position
a
 SNP 
Effective 
allele 
frequency
 b
 
Effective/ 
alternative 
allele
c
 OR (95% CI)
d
 
Meta 
P value
e
 
I
2
 (%), 
P value
f
 
14 86711866 rs186178322 0.02 A/T 1.74 (1.36, 2.22) 7.68 × 10
-6
 0, 8.28 × 10
-1
 
4 71430467 rs62323371 0.06 A/T 0.73 (0.64, 0.84) 8.03 × 10
-6
 0, 8.68 × 10
-1
 
3 95993574 rs1118907 0.14 G/T 0.79 (0.71, 0.87) 8.12 × 10
-6
 0, 6.65 × 10
-1
 
14 105239192 rs2494732 0.43 C/T 0.84 (0.78, 0.91) 8.22 × 10
-6
 0, 9.59 × 10
-1
 
14 65247373 rs8018785 0.18 C/T 0.82 (0.75, 0.90) 8.51 × 10
-6
 0, 7.53 × 10
-1
 
8 122124302 rs2196051 0.33 G/A 0.87 (0.80, 0.94) 8.75 × 10
-6
 0, 6.23 × 10
-1
 
5 1109646 rs139161838 0.02 A/G 0.50 (0.37, 0.67) 8.77 × 10
-6
 25, 2.54 × 10
-1
 
15 51827471 rs77245046 0.03 C/T 0.66 (0.54, 0.80) 9.12 × 10
-6
 38, 1.47 × 10
-1
 
2 121877105 rs11899778 0.23 C/T 1.21 (1.12, 1.30) 9.46 × 10
-6
 35, 1.69 × 10
-1
 
2 84852570 rs145123753 0.02 T/G 2.08 (1.49, 2.91) 9.65 × 10
-6
 0, 6.92 × 10
-1
 
13 86650174 rs17705805 0.20 T/G 1.18 (1.08, 1.29) 9.86 × 10
-6
 10, 3.48 × 10
-1
 
 
a 
Human genome build 37, assembly hg19. 
b, c & d 
Effective allele frequency, effective/alternative allele, odd ratio and 95% CI were extracted from the meta-analysis of the genetically 
unrelated samples, whereas in the genetically mixed samples, estimates of effective allele frequency and odds ratio may be biased. 
e & f 
Meta and heterogeneity P values were extracted from the meta-analysis of the genetically mixed samples, which included more 
individuals, but this modelling strategy does not provide the estimation of odds ratios. 
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Appendix Table D-2 The closest gene and gene functional annotation for top independent signal SNPs (>100 Kbp) with the 
assocation significance (P value < 10
-5
) based on the SUMMIT genome-wide meta-analysis of diabetic retinopathy. 
 
Locus SNP Closest Gene Gene Function 
9q13-q21.2 rs10746970 OSTF1 Ossification 
2p12-p11.1 rs1653654 CTNNA2 Structural constituent of cytoskeleton 
17q25.1 rs75125621 SDK2 Cell adhesion, retinal laminar neuron integrity 
4q28-q32 rs2657795 HHIP Carbohydrate metabolic process 
2q32.1 rs1682430 ZNF804A Transcriptional control 
5q31.3 rs10072382 PCDH1 Nervous system development 
13q32 rs9516067 GPC5 Carbohydrate metabolic process 
1p34.3 rs6425936 SFPQ DNA recombination and repair, RNA splicing 
6p21 rs810855 MDGA1 Neuron migration 
1p33-p32 rs55939932 ELTD1 Neuropeptide signaling pathway 
3q24 rs163757 PLSCR5 Unknown 
1q43 rs35428289 GREM2 Regulation of cytokine activity 
12p11.22 rs10771375 KLHL42 Regulation of microtubule-based process 
11q21 rs601711 VSTM5 Transmembrane protein 
1p34.2 rs4660191 FOXO6 Sequence-specific DNA binding transcription factor activity, glucose sensing 
6q16.1 rs7750013 EPHA7 Retinal ganglion cell axon guidance 
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Locus SNP Closest Gene Gene Function 
19q13.11 rs8113622 ZNF507 Regulation of transcription 
3p24.3 rs73033654 ZNF385D Regulation of transcription 
2q11.2 rs7579862 NPAS2 Cellular lipid metabolic process, central nervous system development 
5p14 rs72758936 CDH9 Cell-cell adhesion 
6q13 rs1338321 HTR1B Serotonin receptor activity 
8p22 rs2739683 ASAH1 Small molecule metabolic process 
1p35.3-p34.1 rs6699355 DLGAP3 Cell-cell signaling 
5q11.2 rs184989476 ANKRD55 Unknown 
8q24.21 rs10101440 MYC Cell cycle arrest 
2p12 rs72929232 IGK Unknown 
22q11.21 rs396130 THAP7-AS1 Non-coding RNA 
14q31 rs186178322 GALC Carbohydrate metabolic process 
4q13.3-q21.1 rs62323371 DCK Nucleotide biosynthetic process 
3q11.2 rs1118907 EPHA6 Ephrin receptor activity 
14q32.32 rs2494732 AKT1 Activation-induced cell death of T cells 
14q23-q24.2 rs8018785 SPTB Structural constituent of cytoskeleton 
8q24.1 rs2196051 ENPP2 Immune response 
5p15 rs139161838 SLC12A7 Cell volume homeostasis 
15q21.2 rs77245046 DMXL2 Cell junction 
2q14 rs11899778 GLI2 Cell proliferation 
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Locus SNP Closest Gene Gene Function 
2p11.2 rs145123753 DNAH6 Unknown 
13q31.1 rs17705805 SPRY2 Branching morphogenesis of an epithelial tube 
 
